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ABSTRACT
The plasma pentraxin proteins serum amyloid P component (SAP) and 
C-reactive protein (CRP) bind specifically to nuclear autoantigens. There is a 
blunted acute phase response of human CRP in systemic lupus erythematosus 
(SLE), and of mouse SAP in NZB/W murine SLE. SAP deficiency in 
(129/Svx C57BL/6)F2 mice is associated with spontaneous antinuclear 
autoimmunity. The pentraxins may thus function in preventing autoimmunity.
Pure line C57BL/6 SAP knockout mice, studied here for the first time, 
spontaneously developed broad spectrum anti-nuclear autoimmunity resembling 
human SLE, and, females in particular had proliferative immune complex 
glomerulonephritis but without proteinuria or renal failure. Mice hemizygous for 
the SAP gene deletion had an intermediate autoimmune phenotype. Injected 
apoptotic cells and isolated chromatin were more immunogenic in SAP-/- than in 
wild-type mice. Extrinsic chromatin was catabolised predominantly in 
hepatocytes, Kupffer’s cells and renal parenchymal cells. Plasma clearance of 
long chromatin and core particles was marginally slower in SAP-/- mice, with 
significantly greater splenic uptake of nucleosome core particles, which may 
have immunological significance. SAP bound to apoptotic cells but had no 
effect on their phagocytosis in mice in vivo, or by human macrophages in vitro. 
CRP also bound to apoptotic cells but did not compete with SAP, indicating 
recognition of different ligands.
In contrast, to the C57BL/6 strain, pure line 129/Sv SAP knockout mice did not 
produce autoantibodies. Formation of antinuclear autoantibodies is thus 
markedly strain dependent. Interestingly, transgenic expression of human SAP 
in the C57BL/6 SAP knockouts did not abrogate the autoimmune phenotype. 
Transgenic reconstitution of the knockouts with mouse SAP is currently in 
progress to confirm that autoimmunity is caused by SAP deficiency and not by 
129/Sv genes transferred into the C57BL/6 background during homologous 
recombination, or by disruption of loci associated with murine SLE that are close 
to the mouse SAP gene.
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ABBREVIATIONS
Abbreviations used in the text are listed alphabetically or are defined when 
first appear in the text
A Angstrom
ANA Antinuclear antibodies
APR Acute phase response
APMoS Acute phase mouse serum
bp Base pairs of nucleic acid
BSA Bovine serum albumin
°C Degrees Celsius
CFA Complete Freund’s adjuvant
CPM Counts per minute
CCPM Corrected counts per minute
CRP C-reactive protein
DNA Deoxyribonucleic acid
dsDNA Double-stranded DNA
EBV Epstein-Barr virus
EDTA Ethylene diaminotetra acetic acid
ENA Extractable nuclear antigens
EtBr Ethidium bromide
h Hours
hSAP Human SAP
125j Iodine 125
ICFA Incomplete Freund’s adjuvant
IgG Immunoglobulin G
IgM Immunoglobulin M
IL-1 Interleukin-1
IL-6 Interleukin-6
IP Intraperitoneal
IV Intravenous
kb Kilobases of DNA
kDa Kilodaltons
LPS Lipopolysaccharide
MBq Megabecquerel
min Minutes
mRNA Messenger RNA
mSAP Mouse SAP
NBS N-bromosuccinimide
OD Optical density
PBS Phosphate buffered saline
PCh Phosphocholine
PCR Polymerase chain reaction
PE Phosphoethanolamine
SAP Serum amyloid P component
SAP+/+ Wild-type mouse with regard to SAP genes
SAP+/- Mouse hemizygous for targeted deletion of SAP
gene
SAP-/- Mouse homozygous for targeted deletion of SAP
gene
SAP-/-, hSAP Tg “knock-out” SAP-deficient mouse transgenic for 
human SAP
SD Standard deviation
SDS Sodium dodecyl sulphate
SLE Systemic lupus erythematosus
ssDNA Single stranded DNA
TC Tyramine cellobiose
TCA Trichloroacetic acid
TGF-0 Transforming growth factor-/?
TNF-a Tumour necrosis factor-a
wk Week
WT Wild-type
w/v Weight for volume
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Chapter 1 - Introduction
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HISTORICAL BACKGROUND
Serum amyloid P component (SAP) and C-reactive protein (CRP), the classical 
acute phase reactant in humans, are normal plasma proteins of hepatic origin, which 
are members of the pentraxin family of proteins. Although much is known of their 
structure and properties, the physiological functions of these molecules have yet to 
be determined. They are, however, highly conserved throughout vertebrate 
evolution and no protein polymorphism or deficiency of human SAP or CRP have 
yet been described suggesting that they have important functions. The plasma 
pentraxins all exhibit calcium-dependent ligand binding that is likely to be of 
physiological and pathophysiological importance.
Amyloid P component (AP) is a glycoprotein derived from, and identical to, the 
normal circulating plasma glycoprotein, SAP [1-3]. AP is present in all amyloid 
deposits in all types of amyloidosis in which it has been sought, both in man and in 
animals [4,5]. The name P-component was coined by Cathcart et al when they 
discovered, using immunohistochemical techniques, that this protein constituent of 
amyloid deposits was related to a normal plasma protein [6-8]. Bladen et al 
independently discovered P-component in a negative staining electron microscopic 
study of amyloid extracts, but they interpreted the characteristic pentagonal 
molecular structure of SAP as the subunit of aggregated SAP rods which they
believed were the bulk of amyloid deposits [9]. In fact, amyloid deposits are 
composed largely of amyloid fibrils, derived from a range of different precursor 
proteins in different forms of the disease, whilst AP is a minor constituent associated 
with them by virtue of its capacity for calcium-dependent ligand binding to specific 
determinants shared by all types of amyloid fibrils [4]. SAP was independently 
isolated and characterised by Haupt et al [10] who named it 9.5S a-glycoprotein and 
Binnette et al [11,12] who subsequently demonstrated the identity of this molecule 
with the pentagonal unit of Bladen et al and the P-component of Cathcart et al 
Further confusion occurred however, when SAP contaminating isolates of the Cl 
component of complement was mistakenly identified as a fourth subcomponent of 
Cl and assigned the name C lt [13,14]. Although it was recognised that the putative 
C lt was SAP [15] and that its N-terminal amino acid sequence and electron 
microscopic appearance resembled the pentraxin CRP, it was only when the 
calcium-dependent binding of SAP to agarose was described that the mechanism 
underlying co-isolation of SAP with authentic Cl subcomponents was appreciated 
[16,17].
CRP was the first protein to be discovered which behaves as an acute phase reactant, 
displaying rapid and pronounced rise of its serum concentration in response to 
infection or tissue injury [18,19], CRP was initially discovered in 1930 by Tillett 
and Francis in the serum of patients with acute pneumococcal pneumonia [20]. It 
was so named because it bound to and precipitated the somatic C-polysaccharide of 
the pneumococcal cell wall. CRP was subsequently shown to have
calcium-dependent binding specificity for phosphocholine (PC), a constituent of 
many bacterial and fungal polysaccharides and of most biological cell membranes 
[21].
PENTRAXINS
SAP and CRP are members of the pentraxin family of proteins, a superfamily of 
calcium-dependent ligand binding and lectin (carbohydrate binding) proteins. The 
name pentraxin, coined by Osmand et al [22] and derived from the Greek words for 
five (penta) berries (ragos) reflects the arrangement of the globular subunits of SAP 
and CRP in a disc-like configuration with cyclic pentameric symmetry, as originally 
seen by electron microscopy.
Closely related plasma proteins sharing similar sequences, tertiary folds, subunit 
arrangement and functional properties are present in all vertebrates in which they 
have been sought, and even in some invertebrates, the most evolutionarily distant of 
which is the horseshoe crab, Limulus polyphemus [23,24]. Several more distantly 
related proteins with subunits comprising a pentraxin homology domain and an 
unrelated sequence have lately been identified. These so called “long” pentraxins 
include PTX3 [25,26], which is induced in hepatocytes, endothelial cells and 
fibroblasts by IL-lp and TNF-a; several neuronal pentraxins including neuronal 
activity-regulated pentraxin (NARP) which is the major protein expressed by rat 
cerebral neurons in relation to physiological neuronal stimulation [27,28]; apexin, a
450kDa calcium-dependent binding protein of the sperm acrosome [29,30] and a 
protein in the amphibian, Xenopus laevis, KL-PXN1 [31]. Neither the classical nor 
the long pentraxins show significant sequence homology with other proteins.
SAP AND CRP: GENE AND PROTEIN STRUCTURE
Gene Structure 
Pentraxin gene organisation
Human SAP and CRP have a high degree of homology at the amino acid and 
nucleotide levels. Both leader sequences are hydrophobic and share extensive amino 
acid sequence homology with a wide range of signal peptides reported for other 
secreted products. The overall amino acid identity of the mature product is 51%, 
and 66% when conservative substitutions are considered. The overall nucleotide 
identity is 59%. The level of homology between SAP and CRP however, is not 
constant throughout their sequences as a region of limited conservation is bound by 
two highly conserved regions. Although different levels of homology between 
different regions may reflect portions of the molecule having similar and dissimilar 
physiological functions, they do not correspond to separate exons as is often found 
in the gene structure of other proteins with distinct domains [32].
Human SAP and CRP
The human SAP gene has a relatively simple structure consisting of two exons 
separated by a 115 bp intron. The transcript is approximately 1.1 kb in size [33].
The first exon contains the mRNA 5’-untranslated region, a sequence encoding the 
leader peptide and the first two amino acids of the mature protein. The second exon 
contains the sequence encoding the remaining 202 amino acids and the 
3’-untranslated region. The CRP gene (2.5 kb) is similar, except that the intron is 
considerably larger (278 bp). It contains several interesting features including an 
unusually long 3’-untranslated region (1.2 kb), three heat-shock consensus 
sequences in the 5’-untranslated region and a (GT)n region in the intron that is, in 
theory, capable of adopting a Z-DNA form and may play a role in chromatin 
activation [34]. Recently, a G to C polymorphism at nucleotide 1059 within exon 2 
of the human CRP gene was reported, but this encodes a silent change at the amino 
acid level. The frequency of the 1059C allele was 0.109 in the Caucasian population 
[35].
Murine SAP and CRP
The gene structures of mouse SAP and CRP are similar to the human genes. The 
SAP transcript of 1065 nucleotides comprises a first exon of 206 nucleotides 
containing the 5’-untranslated region, the sequence encoding the leader peptide, the 
first two amino acid residues and the first base of the triplet encoding the third 
amino acid residue of the mature SAP protein [36-38]. A single 110 bp intron 
precedes a 749 nucleotide second exon that encodes the bulk of the mature protein 
and the 141 bp 3’-untranslated region. The 139 bp 5’-untranslated region is larger 
than its human counterpart (96 nucleotides). As with the human SAP gene, the 
murine SAP 5’-untranslated region lacks the heat-shock consensus sequences
described in the 5’-untranslated regions of the human and rabbit CRP mRNAs. The 
141 bp 3’-untranslated region of the mouse SAP mRNA is 14 residues shorter than 
that of human SAP. Both SAP 3’-untranslated regions are an order of magnitude 
shorter than those of the human and rabbit CRP 3’-untranslated regions. There has 
been less published work on the murine CRP gene but it has been shown to be 1.9 kb 
in length and have regions that are highly homologous to the human CRP gene 
including a heat-shock consensus element in the 5’-untranslated region [39].
Chromosomal mapping of pentraxin genes
The gross structural similarities and amino acid sequence homology between SAP 
and CRP suggest that they are the products of an ancestral gene-duplication event. 
This hypothesis is strengthened by the mapping of a single copy of the mouse SAP 
gene to the distal portion of chromosome 1, a region that is syntenic with the human 
portion of chromosome 1 containing band q2.1, to which both SAP and CRP have 
been mapped [40-42]. In both species this evolutionarily conserved part of the 
genome contains a considerable number of immunologically important loci, 
including genes encoding Fc receptors [43,44].
Protein Structure 
Subunit arrangement
Each molecule of human SAP consists of five globular subunits arranged in a 
disc-like configuration with cyclic pentameric symmetry, forming a ring 95 A in 
diameter with a substantial hole in the centre [2,22]. Each identical protomer of
SAP contains 204 amino acids in a single chain with an intrachain disulphide bond 
between Cys36 and Cys95 [32]. There is a single iV-glycosylation site at Asn32 and 
this bears a single typical complex biantennary oligosaccharide chain which does not 
show the microheterogeneity usually characteristic of glycoproteins [4]. 
Electrospray mass spectrophotometric analysis reveals a single protomer mass of 
25,462 Da, corresponding precisely to the mass predicted from the known amino 
acid sequence and the known glycan.
The structure of CRP is very similar to that of SAP and consists of five identical 
non-covalently associated 206 residue protomers arranged symmetrically around a 
central pore [45,46]. However, unlike SAP, CRP is not glycosylated. The overall 
dimensions of the CRP pentamer are about 102 A outside diameter with a central 
pore diameter of 30 A and a protomer diameter of 36 A.
Electron microscopic appearance
The appearances of negatively stained preparations of human CRP and SAP under 
the electron microscope as annular discs with cyclic pentameric symmetry are highly 
characteristic [9,22,47]. CRP and SAP from different species vary in the tendency 
of the basic pentameric discs to associate with each other to form two-disc, 10 
subunit structures and subsequently for these decameric molecules to stack up 
during preparation for electron microscopy [24,47]. Human CRP is almost always 
seen as single pentameric discs with only occasional pairs and no tendency to stack,
whereas human SAP is always seen as pairs of discs with a variable but always high 
propensity to stacking. Mouse SAP behaves very similarly to human SAP.
While electron microscopic appearances are important, they are susceptible to 
in vitro artefact in terms of disc pairing and stack formation which do not necessarily 
reflect the real structure of the native SAP and CRP molecules in vivo. For example, 
the decameric structure was assumed to be the normal physiological configuration of 
the SAP molecule but recently SAP was shown to exist as a pentamer in whole 
serum [48]. Electrostatic forces are clearly important in decamerisation of two 
pentamers, as rapid, complete and reversible decamer-pentamer transitions are 
achieved by transfer between different buffers [5,49].
Crystal structures of SAP and CRP
The crystal structures of both SAP and CRP have been determined at high resolution 
[32,45,46]. The SAP protomer is composed of a sandwich of two large antiparallel 
P-sheets, with a core of hydrophobic side chains and the single a-helix of SAP 
folding against one face of this sandwich. The fold of the SAP protomer is that of a 
jellyroll and is related to the folds of the other members of the lectin fold 
superfamily [50], such as concanavalin A and pea lectin. This relationship is not 
apparent at the sequence level and other features, such as the location of the metal 
binding sites, are not conserved. The calcium-dependent ligand binding site of SAP 
is situated on the opposite face to that of the a-helix and is formed mainly by polar 
residues from a long irregular loop, co-ordinating two calcium ions 4 A apart.
Extensive contacts are formed between the protomers and their P-sheets are roughly 
perpendicular to the five-fold symmetry axis of the pentamer, which has a polarity 
defined by 5 a-helices on one face (A face) and 5 calcium dependent ligand binding 
sites on the other (B) face. The pentamer is thus a strongly dipolar molecule, with a 
negative A face and a positive B face. The glycosylation site, Asn 32, is located on 
the A face at the periphery of the pentameric ring. The oligosaccharide chains are 
disordered in the crystals and although their orientation is unknown, it is likely that 
they are extended [51].
Like that of SAP, the CRP protomer is composed of a sandwich of two antiparallel 
P-sheets against which is folded a long a-helix. On the A face of each subunit there 
is a marked furrow which defines a region 24 A long, 7.5 A deep and 12.4 A wide. 
The furrows of the pentamer follow the curvature of the subunits and come close 
together as they enter the central pore. The outer part of the furrow is positively 
charged and the inner part, which terminates half way through the pentamer pore at 
residue Aspl 12, provides a ring of negative charge lining the pore. On the opposite 
face of the protomer to that of the a-helix is the calcium-dependent ligand binding 
site of CRP [45]. Thus the CRP molecule, like that of SAP, has two faces. 
However, unlike SAP, where all protomers are on the same plane, each subunit in 
CRP is rotated by 22° towards the pentameric fivefold axis. As a result of this 
rotation the a-helices lie closer to the fivefold axis while the bound calcium ions are 
carried away from it.
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SAP and CRP: LIGAND BINDING PROPERTIES 
SAP Ligands
SAP shows calcium-dependent binding to a wide variety of ligands. The capacity of 
SAP for specific calcium-dependent ligand binding was first described with respect 
to agarose, although the affinity of SAP for polyanions and metal ions, including 
barium, strontium, cobalt, zinc and nickel had already been observed by Haupt et al 
in their work on the 9.5S a  1-glycoprotein [10]. Since the original demonstration of 
calcium-dependent agarose binding [16], SAP has been reported to bind to 
glycosaminoglycans especially heparin, heparan sulphate and dermatan sulphate, to 
mannose terminated glycans and to glycans with preterminal galactose residues [52- 
55]. The best characterised carbohydrate ligand of SAP is the pyruvate acetal of 
galactose that occurs in agarose and a synthetic monosaccharide form methyl 
4,6-0-(l-carboxyethylidene)-p-D-galactopyranoside (MOPDG) used experimentally 
to determine ligand binding properties of SAP in vitro [56]. SAP binds even more 
avidly to phosphoethanolamine (PE) and calcium-dependent affinity 
chromatography on PE covalently immobilised via its amino group is the method of 
choice for isolation of SAP from serum or amyloid extracts. Unlike CRP, SAP does 
not bind to phosphocholine whereas both bind to PE and these differing interactions 
allow isolation of these pentraxins from whole serum [57-59].
SAP also binds avidly to DNA and chromatin and is the single protein from whole 
serum that shows calcium-dependent binding to these ligands at physiological pH
and ionic strength [60,61]. In addition to its avid binding to chromatin, SAP also 
binds in vitro to nucleoli in intact nuclei of cells permeabilised by fixation but not to 
any other nuclear or cytoplasmic structures [62]. SAP binds avidly to all types of 
amyloid fibrils in vivo [63-65] and to fibrils extracted ex vivo [66]. Although this 
interaction may involve the glycosaminoglycans (GAGs) that are universally 
associated with amyloid fibrils formed in vivo [67], SAP also binds to fibrils formed 
from pure proteins or peptides in vitro [68].
SAP binds to a variety of bacterial pathogens including Streptococcus pyogenes, 
Neisseria meningitidis and Escherichia coli although the specific ligand for SAP 
expressed by these organisms is unknown [69]. SAP binds to Gram-negative 
bacterial lipopolysaccharide (LPS) [70], although this is not the only ligand for SAP 
on Gram-negative bacteria since there is marked binding of SAP to an LPS-deficient 
mutant of Neisseria meningitides [69].
It has been shown that closely associated pairs of SAP molecules show specific 
calcium-dependent binding to fibronectin, C4-binding protein and to a lesser extent 
IgM [71]. Aggregated SAP shows calcium-independent binding to Clq and can 
activate the classical complement pathway in vitro [72], but non-aggregated SAP 
shows no significant interaction with any of these molecules. Despite conflicting 
reports, it has recently been shown very rigorously that SAP exists exclusively as 
single pentamers in whole undiluted normal serum and is not complexed with any 
macromolecular ligand within its physiological milieu [48].
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Binding of SAP to a wide range of ligands has been reported in the literature 
including CRP, phosphocholine, aggregated IgG, soluble immune complexes and 
type IV collagen [73-76]. Concerns have been expressed that these may not 
represent true physiological binding reactivities of SAP for several reasons. For 
example, the calcium-dependent autoaggregation of human SAP removed from 
serum has to be overcome by the addition of bovine or human serum albumin, at the 
physiological concentration of 4%, into all buffers in which isolated SAP is used for 
binding studies [5]. In other solvents, including those with lower concentrations of 
albumin, varying degrees of aggregation occur which modify the binding properties 
and ligand specificity of SAP [48]. Immobilisation of SAP or its ligands on 
microtitre plates may cause denaturation of the adherent protein [77] and have 
unpredictable effects on binding. Also, binding reactions and other biological 
properties of peptides from the SAP sequence may bear little relationship to the 
function of the whole molecule [78-82] and since SAP is markedly proteinase 
resistant in the universally calcium-containing extracellular milieu, it is unlikely that 
the generation of significant concentrations of such fragments will occur in vivo.
CRP Ligands
CRP, like SAP, shows binding to a wide variety of ligands. CRP was first identified 
by its reactivity with the C-polysaccharide of the pneumococcus [20]. This binding 
reaction, which is calcium-dependent, results from the specific capacity of CRP to 
recognise phosphocholine (PCh) residues [21] which are widely distributed in 
techoic acids, capsular carbohydrates and lipopolysaccharides of bacteria and other
micro-organisms. The presence of PCh has been reported in Streptococcus 
pneumoniae [83], Haemophilus influenzae [84], Pseudomonas aeruginosa, Neisseria 
meningitides, Neisseria gonorrhoeae [85], Proteus morganii [86] and Aspergillus 
fumigatus [87]. PCh is present in the outer leaflet of most biological membranes as 
the polar head group of lecithin and sphingomyelin. Initial evidence for binding of 
CRP to cell membranes was provided by experiments demonstrating the presence of 
CRP associated with cell membranes at sites of inflammation and tissue necrosis but 
not in normal cells [88]. It was subsequently shown that CRP could react with 
emulsions of the PCh-containing phospholipids lecithin and sphingomyelin [89]. 
Using lecithin liposomes and unilamellar vesicles the requirement of additional 
submicellar concentrations of lysolecithin for the binding of CRP to the PCh polar 
head group in lipid bilayers was demonstrated [90]. CRP, like SAP, also binds 
specifically to PE in a calcium-dependent manner.
CRP binds specifically to small nuclear ribonucleoprotein particles (snRNPs) in 
intact nuclei of cells permeabilised by fixation but not to any other nuclear structures 
[62].
Ligand-complexed CRP shows calcium-independent binding to Clq, the first 
component of the complement cascade, which results in activation of the classical 
pathway [89,91].
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The binding of CRP to FcyRI (CD64) [92] and FcyRIIa (CD32) [93] on phagocytes 
with low and high affinity has been reported, and more specifically binding of CRP 
to the R131 polymorphic form of the Fcylla receptor [94]. However, this was 
recently shown to be due to contamination of the CRP by IgG and pure CRP did not 
show any such binding [95]. The conclusion of the authors was that there was no 
evidence of a specific CRP receptor on human white blood cells.
Molecular Basis o f  Ligand Binding 
SAP
Co-crystallisation of SAP with MOpDG and PE and analysis of the complex with 
the nucleotide dAMP have shown that an acidic functional group of the ligand (the 
pyruvate carboxylate group of MOpDG or the phosphate ester moiety of PE and 
dAMP) bridges the two calcium ions in the ligand binding pocket of each SAP 
protomer [5,96]. The use of a series of synthetic MOpDG analogues to inhibit the 
binding of SAP to both amyloid fibrils and high pyruvate agarose demonstrated that 
the critical determinant of recognition by SAP is integrity of the carboxyethylidene 
ring [5,56,97].
The avid binding by SAP of macromolecular ligands such as nucleosomal DNA, 
glycosaminoglycans (GAGs) and amyloid fibrils is likely to be the result of a 
multi-site interaction involving the B face (bearing the calcium-dependent binding 
sites) of the SAP pentamer. However, the five fold symmetry of SAP does not 
match any of its macromolecular ligands, and since co-crystallisation of SAP with
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larger biological ligands has yet to be achieved, it is difficult to extrapolate from the 
few available structures with small synthetic ligands. The binding of SAP to DNA 
and heparin is calcium-dependent but these ligands may not bind directly to SAP 
through the two calcium ions and it is impossible to construct a model complex 
between SAP and dsDNA that involves a direct interaction of the phosphate 
backbone and the two resident calcium ions [5]. DNA may, therefore, bind in the 
basic grooves between the protomers of the pentamer, which are of the right size to 
accommodate a DNA double helix, and the calcium may have an allosteric effect. 
Although SAP may bind to the GAGs found on amyloid fibrils in vivo [67,98], it 
does interact directly with fibrils formed from pure proteins or peptides in vitro 
[5,68]. SAP may recognise certain features of the amyloid fibrils such as turns 
between the strands [99], and the spacing between these turns may accommodate the 
SAP pentamer.
CRP
Ligand binding by CRP, like SAP, is calcium-dependent and on the B face of the 
protomer, two calcium ions are ligated to side chains and main chain carbonyls of 
the polypeptide chain at a distance of 4 A from each other. Crystallographic 
analysis of CRP and PCh and analysis of the CRP-PCh complex [46] have 
demonstrated that two of the oxygens of the phosphate group directly co-ordinate 
with the two CRP-bound calcium ions while the choline group rests within the 
hydrophobic pocket of the CRP protomer. Mutational studies have confirmed the 
importance of the hydrophobic pocket of CRP for PCh-binding [100].
The structure and topology of the Clq-binding site have also been investigated by 
site-directed mutagenesis [101,102]. The mutational data combined with the known 
structure of the molecule indicate that the Clq-binding site is located on the A face 
of each protomer at the shallow end of a cleft which extends from the centre of the 
protomer to its edge at the central pore of the pentamer. The cleft is formed on one 
side by the a-helix and on the other by parts of the amino and carboxyl termini of the 
protomer. Residues Asp112 and Tyr175 are considered to be the Clq contact residues 
as their substitution with Ala results in significantly reduced avidity for C lq and 
diminished complement activating ability.
SAP AND CRP: BIOLOGICAL FEATURES
SAP Serum Concentration 
Human SAP
Messenger RNA for SAP was initially reported to be exclusively found in 
hepatocytes [103] although McGeer’s group reported recently that SAP mRNA is 
present in pyramidal neurons of the brain as well as the lungs, heart, arteries, 
kidneys and spleen [104]. However, adequate tissue and antibody controls were not 
used in this latter study. The human SAP promoter has been shown to direct 
expression of linked transgenes exclusively to the liver and this is thought to be 
under control of elements in the 5’ region of the gene [105,106]. Human SAP 
mRNA can be induced in vitro in hepatoma cells by IL-6 but can be down-regulated 
with IL-ip, an effect that predominates when both cytokines are present [107].
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The plasma concentration of human SAP is tightly regulated, being slightly lower in 
women {mean (SD), 24 (8) mg/1} than men {32 (7) mg/1} [108]. The value remains 
normal even during massive deposition of SAP into amyloid indicating that although 
human SAP is not an acute phase reactant, the rate of synthesis and secretion can be 
upregulated [65,109], the plasma pool of SAP being in equilibrium with the large 
amyloid-associated pool of SAP. The concentration of SAP in cord sera is much 
lower at approximately 4 mg/1 but rises rapidly during the first weeks of life to reach 
the lower part of the adult range [110]. In conditions characterised by an acute 
phase response, the SAP concentration does rise but tends to remain close to the 
normal range and does not exceed 100 mg/1 [110], although patients with 
macroglobulinaemia may be exceptional in having high levels of SAP in the absence 
of an acute phase response [111,112]. Among patients with renal insufficiency, SAP 
concentration is significantly elevated although there is no correlation with serum 
creatinine or duration of disease [108]. Significantly low concentrations of SAP 
have only been seen in patients with hepatocellular impairment of sufficient severity 
to reduce plasma protein synthesis [110,113].
Murine SAP
Murine experiments in the early 1980s suggested that SAP was synthesized, possibly 
exclusively, in the liver. It was shown that in mice undergoing a vigorous acute 
phase response the hepatic cytoplasm stained immunospecifically with anti-SAP, 
particularly in the periportal zone. Administration of colchicine to mice receiving an 
acute phase stimulus reduced or abolished the rise in SAP. At the same time, the
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staining of hepatocytes with anti-SAP became more intense suggesting that the liver 
was the site of synthesis and that colchicine, by inhibiting secretion of SAP, caused 
it to be retained within the cells [114,115]. Immuno-electron microscopy showed 
that SAP was associated with the rough endoplasmic reticulum of hepatocytes.
Murine SAP has several specific characteristics. Firstly, there are marked
genetically determined differences in normal serum concentration between different 
inbred strains. C57BL mice and lines with the same background have
concentrations of up to 10 mg/1, whilst DBA/2 mice may have levels as high as 
100 mg/1. Other strains such as C3H, BALB/c, CBA, and A/J have intermediate 
serum concentrations of 20-80 mg/1, but crosses with C57BL mice always produce 
progeny with low levels [116,117].
Secondly, SAP is a major acute phase reactant in all mouse strains. Hepatic SAP 
mRNA levels massively increase within two to four hours and the concentration of 
SAP in the serum starts to rise by about eight hours after an acute physical or 
chemical injury or inflammatory stimulus and reaches a peak at about 24-48 hours. 
Background levels of both hepatic mRNA and plasma protein are re-established by 
72 hours after a single transient stimulus. There are no differences between male 
and female mice and acute phase levels are derived from de novo synthesis of the 
protein rather than release of preformed stocks. Mice depleted of T- and B-cells, 
rendered agranulocytopaenic by irradiation or hypocomplementaemic by cobra 
venom factor all respond to injections of casein or croton oil with the same SAP
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concentration as controls [116]. In vitro studies of SAP synthesis in mouse 
hepatocyte cultures show that SAP mRNA and protein levels increase in response to 
stimulation with a variety of cytokines such as IL-1, IL-6, TNF-a and TGF-P [118]. 
The addition of IL-1 a caused a tenfold increase and the addition of IL-6 a sevenfold 
increase; the addition of both cytokines together had an additive effect [107],
Finally, elevation of SAP concentration following stimulation of the acute phase 
response correlates with amyloid deposition in murine models of this disease [119]. 
Repeated subcutaneous injections of casein can induce AA amyloidosis in mice 
[120]. Strains that are more susceptible to this, such as C57BL and CBA, develop 
persistent elevation of SAP concentration (10-100 times baseline) during 
administration of casein, which subsequently fall to normal when the injections 
cease. Strains such as A/J mice that are relatively resistant to amyloid deposition 
develop only transient elevation of SAP concentration during casein treatment. All 
strains develop similar elevations in serum amyloid A (SAA) concentration, the 
precursor protein of the amyloid fibrils, during casein administration. Mice given 
bovine serum albumin, which also induces elevation of SAA, do not develop 
amyloidosis and produce only small, transient increases in SAP concentration [119].
SAP Metabolism
The plasma half life of human SAP is 24 hours and is remarkably constant in all 
individuals who have been studied and in all diseases except amyloidosis [63-65]. 
In mice the half life of SAP is about 7.5-9.5 hours in all strains studied, regardless of
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their state of health and whether they are mounting an acute phase response or have 
established amyloidosis [63,115,121]. Studies in mice indicate that hepatocytes are 
the sole site of clearance and catabolism [122]. Persistence of SAP in the circulation 
is absolutely dependent on the intactness of its oligosaccharide with loss of the 
terminal sialic acid residues resulting in extremely rapid uptake via the hepatocyte 
asialoglycoprotein receptor and swift catabolism. Blockade of the
asialoglycoprotein receptor in mice, however, does not affect the clearance of SAP 
indicating that physiological SAP turnover may involve protein rather than 
carbohydrate recognition [4].
Tissue Amyloid P  Component (TAP)
Human
Although SAP had already been extensively investigated in amyloidotic tissue, its 
presence as a normal constituent of the extracellular matrix in human spleen, liver 
and kidney was first recognised immunohistochemically in 1978 by Schneider and 
Loos [123]. Dyck etal then characterised the normal tissue AP (TAP) of human 
glomerular basement membrane and showed that it is confined to the lamina rara 
interna where it is covalently associated with collagen and possibly other matrix 
constituents [124]. It was found that SAP is also associated with the microfibrillar 
mantle of elastic fibres throughout the body and that in the skin at least, TAP is 
non-covalently bound, suggesting that it is not an integral constituent of elastic fibre 
microfibrils [125-128]. TAP is absent or abnormally distributed in a range of 
glomerular and elastic tissue disorders although its functional significance remains
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unknown [127,129]. Although TAP has not been fully characterised, it is 
immunochemically identical to SAP and may be derived from circulating SAP, 
originally produced in the liver. This is consistent with the age-dependent 
appearance of TAP in the tissues, being undetectable until the third year of life and 
increasing to approximately adult concentrations by five years [130].
It is possible that the roles of TAP include modulation of the biological properties of 
the matrix GAGs and/or protection of proteinase sensitive structures (basement 
membrane, elastic fibres). The density of TAP molecules suggest that they are 
likely to achieve the close pairing required for recognition and binding of fibronectin 
and C4-binding protein. There is no evidence however, that C4-binding protein is a 
normal matrix protein and the distribution of TAP and fibronectin in the tissues is 
only partly overlapping. The physiological function of TAP therefore remains 
elusive.
Other species
The existence of TAP in species other than man remains controversial. 
Leblond etal have published a variety of immunohistochemical reports showing 
TAP in mice and also isolated mouse SAP from the EHS sarcoma, a transplantable 
tumour with an exceptionally rich connective tissue matrix [131-133]. Pepys’ group 
however has been unable to demonstrate TAP in any species other than man and 
question the interpretation of the electron micrograph images [5]. It is possible that
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the SAP obtained from EHS tissue was derived from the serum acute phase response 
and not from the tumour matrix.
CRP Serum Concentration 
Human CRP
Although messenger RNA for CRP has been reported in extrahepatic tissues such as 
alveolar macrophages, the hepatocyte is the major source of CRP [134-136]. The 
principal cytokine mediator of human CRP induction in vitro in hepatoma cell lines 
is IL-6, but some models show a requirement for both IL-6 and either IL-1 or TNF-a 
[137].
The speed of change and incremental range of CRP concentration are exceptional 
among all acute phase proteins, apart from SAA. With the ability to increase 
synthesis by up to 10,000 fold, the distribution of CRP is clearly non-Gaussian and 
among healthy subjects the median concentration of CRP is only 0.8 mg/1, with an 
interquartile range of 0.3-1.7 mg/1. Ninety percent of apparently healthy subjects 
have levels of less than 3 mg/1 and 99% of them less than 10 mg/1 [138-140]. Serial 
studies of normal subjects and of monozygotic and dizygotic twins demonstrate that 
each individual’s baseline serum CRP concentration is remarkably constant and is 
substantially genetically determined [141]. The concentration of CRP in cord sera is 
extremely low with a median of 0.04 mg/1 (range 0.01-0.49) but rises to adult values 
within a few days [142,143].
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Most significant microbial infections are associated with elevated CRP 
concentration [20,144,145] although uncomplicated viral infections such as the 
common cold, are frequently associated with a modest CRP response or none at all 
[146]. Whilst individual infections elicit a variable rise in CRP concentration, the 
response perse  exists in all hosts regardless of age [142,143], immune status, or 
therapeutic intervention [147,148]. Normalisation of the CRP concentration usually 
corresponds to clinical cure whilst persistently elevated concentration often indicates 
recurrence or persistence of infection.
With a few exceptions, most inflammatory diseases are associated with elevated 
CRP concentration which, when monitored serially, reflect the extent and activity of 
the condition. For example, in rheumatoid arthritis CRP concentration is predictive 
of future progression of bone erosion and joint damage [149,150], and in Crohn’s 
disease or systemic vasculitis elevated CRP concentration frequently indicates active 
pathology that may be difficult to detect clinically [151-153]. Many malignancies 
are associated with an elevated CRP concentration and it has been suggested that in 
certain conditions such as myeloma [154] and non-Hodgkins lymphoma [155] the 
degree correlates with tumour burden and prognosis.
There are a few conditions in which there is characteristically, an inappropriate CRP 
response to autologous tissue damage despite unequivocal evidence of active 
inflammation. These include the prototypic systemic autoimmune disease systemic 
lupus erythematosus (SLE) [156,157], ulcerative colitis [151,152] and
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dermatomyositis [158]. The mechanism behind this phenomenon is not known, but 
in vivo turnover studies with I-labelled CRP have shown no increased catabolism 
or consumption of CRP in patients with SLE compared to normal controls, 
indicating a reduced rate of synthesis [159]. Interestingly, patients with these 
conditions appear to mount an appropriate CRP response to intercurrent infection 
[156,160,161].
It has been recognised for some time that CRP concentration rises following a 
myocardial infarction [162,163], and that complications and survival correlate 
strongly with CRP concentration [164-166]. In recent years however, attention has 
focused on the importance of CRP concentration as a predictor of future 
cardiovascular events in normal healthy individuals [167-171]. Large case 
controlled studies have confirmed that in both men and women the finding of a CRP 
concentration of greater than 3 mg/1 is associated with a two to fivefold increase in 
risk of future myocardial infarction, cerebrovascular accident or peripheral vascular 
disease [172].
Murine CRP
In mice, CRP is present in serum at concentrations of less than 2 pg/ml and does not 
increase markedly during the acute phase response [173,174]. Despite attempts to 
stimulate CRP production by subcutaneous or intraperitoneal injection of different 
doses of LPS, croton oil in liquid paraffin, and Freund’s complete adjuvant into 
CBA, C57/BL and BALB/c mice, the serum concentration did not exceed 2 pg/ml.
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CRP Metabolism
The plasma half life of human CRP is 19 hours, and is remarkably constant in all 
individuals in which it has been studied including those with a wide range of 
inflammatory and neoplastic diseases [159]. The identical turnover profiles of CRP 
among patients with SLE compared to healthy controls and patients with acute 
infections indicate that the failure of patients with SLE to mount a marked serum 
acute phase response of CRP to autologous inflammation and tissue damage is due 
to failure of CRP production rather than accelerated clearance. The in vivo turnover 
of serum CRP in rabbits is remarkably constant and is unaffected by the 
intravascular presence of even macromolecular ligands to which CRP binds, such as 
apoB-containing lipoproteins [175]. Thus, formation of CRP-ligand complexes in 
the circulation does not accelerate CRP clearance, which apparently proceeds at a 
constant maximum rate via a mechanism which is not saturable.
Although there are many reports of the variable presence of immunohistochemically 
detectable CRP in inflammatory and/or necrotic tissue lesions [88,176,177], it has 
not been clear whether significant CRP is generally deposited at sites of 
inflammation. More recent studies have found that CRP is deposited in most human 
atherosclerotic lesions [178,179], and in all human acute myocardial infarcts [180].
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SAP AND CRP; PHYSIOLOGICAL AND PATHOLOGICAL 
ROLES
Pentraxins and Host Defence 
Host Defence against infection
The mammalian body is susceptible to a wide variety of pathogens which differ 
greatly in their lifestyles and host specificity, requiring a diverse set of defensive 
responses from the host immune system. The immune system of vertebrates has 
been conceptually divided into two parts, innate and acquired immunity. There are 
many distinguishing features of the two systems but the essential difference is 
genetic. The recognition proteins of the innate system are encoded in the germline, 
having evolved in invertebrates for the purpose of host defence against infection. 
Innate immunity exhibits rapid response kinetics but lacks memory. It also has the 
drawbacks of being able to recognise only the relatively few microbial structures 
that are highly conserved and being unable to evolve as rapidly as do 
micro-organisms. The receptors of acquired immunity, which are the antigen 
receptors of T and B lymphocytes, have overcome these problems by not being 
encoded in the germline. Rather, they are the products of somatically rearranged 
elements, the V, D and J segments of T-cell receptor and antibody genes. This 
remarkable capability occurred suddenly with the evolution of vertebrates 
approximately 400 million years ago [181] and created an enormous repertoire of 
antigen binding structures. Acquired immunity has slow response kinetics but the 
ability to remember.
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Innate immunity
The first phase of host defence is innate immunity, which is responsible for detecting 
and destroying most of the micro-organisms that are encountered by a healthy 
individual. Organisms that penetrate the epithelial surfaces of the body are faced 
with two immediate lines of defence. First, they are subject to humoral attack by the 
alternative pathway of complement activation, which is spontaneously active in 
plasma and can opsonise or destroy many organisms whilst sparing host cells which 
are protected by complement regulatory proteins. Second, they may be recognised 
directly and engulfed by phagocytic macrophages and neutrophils, primarily situated 
in subepithelial connective tissues, that have receptors for common pathogenic 
components. The other effects of the interaction of phagocytes with pathogens 
include the secretion of cytokines by phagocytes and the expression of 
co-stimulatory molecules on the surface of macrophages that allow them to function 
as professional antigen-presenting cells in the adaptive immune response.
If the micro-organism evades or overwhelms innate defences a subsequent wave of 
responses involving the activation of a variety of humoral and cell-mediated effector 
mechanisms are initiated that form the early induced (non-adaptive) response. These 
responses are triggered by receptors that are non-clonal or of limited diversity and 
are distinguished from adaptive immunity by their failure to provide immunological 
memory. Certain such responses are induced by cytokines released by phagocytes in 
response to microbial infection; for example, induction of production of acute phase 
proteins which can bind to bacterial surface molecules and activate complement.
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Interferons are produced by cells infected with viruses; they slow viral replication, 
enhance presentation of viral peptides to cytotoxic T cells and activate natural killer 
(NK) cells. NK cells, CD5 B cells and y/8 T cells are lymphocytes with receptors of 
limited diversity that provide early protection from a limited range of pathogens but 
do not generate lasting immunity. All these mechanisms play an important role in 
holding infection in control during its early phases while the adaptive response is 
being generated.
Adaptive immunity to infection
Adaptive immunity occurs when pathogens have evaded non-adaptive mechanisms 
of host defence and established a focus of infection. Antigens of the pathogen are 
transported to local lymphoid organ by migrating antigen presenting cells or trapped 
there by resident cells. Such antigens are processed and each is presented to 
antigen-specific naive T cells, the end result of which is production of effector T 
cells that either leave the lymphoid organ to effect cell-mediated immunity in sites 
of infection in the tissues or remain in the lymphoid organ and participate in humoral 
immunity by activating B cells. The type of response that occurs is determined by 
the differentiation of CD4 T cells into TH1 or TH2 cells, which in turn, is 
determined in part by the cytokines produced in the early non-adaptive phase. 
Ideally, the adaptive immune response eliminates the pathogen and provides the host 
with a state of protective immunity against re-infection with the same pathogen by 
developing immunological memory.
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The role of acute phase proteins in host defence
Since the beginning of the 20th century many studies have demonstrated non-specific 
resistance to infection that can be enhanced by administration of killed 
micro-organisms or preparations derived from micro-organisms, such as bacterial 
endotoxin. In 1967, Raskova demonstrated protection against the adverse effects of 
LPS by irritation of tissue by phenol or procaine, thereby mimicking 
‘endotoxin-induced tolerance’ [182]. This effect was transient and could be 
passively transferred with serum. Evidence has since accumulated that acute phase 
proteins can mediate such non-specific protection against endotoxin as well as 
against Gram negative bacterial sepsis. Human CRP was reported to opsonise 
bacteria in vitro [183,184] and in vivo inhibition of hepatic synthesis of acute phase 
proteins was shown to increase sensitivity to LPS-induced lethality [185], an effect 
that was abrogated by pre-activation of acute phase protein synthesis [186].
Acute phase proteins have a wide range of activities that contribute to host defence. 
They can directly neutralise inflammatory agents, help to minimise the extent of 
local tissue damage and participate in tissue repair and regeneration. The changes in 
plasma concentration of individual acute phase reactants are variable. Most are 
induced between 50% and several fold over normal concentration. In contrast, the 
concentration of so-called major acute phase proteins, which include SAA and either 
CRP in humans or SAP in mice, can increase 1000-fold or more. The magnitude 
and rapidity of their induction following an acute phase stimulus, together with their
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short half-lives, suggest an important role for these proteins early in the 
establishment of host defence.
SAP and host defence
SAP binds to certain bacteria including the important human pathogens 
Streptococcus pyogenes [187], Neisseria meningitides and rough variants of 
Escherichia coli [69], suggesting a possible role in host defence. However, 
Noursadeghi et al showed that this binding had a powerful anti-opsonic effect both 
in vitro and in vivo, and enabled bacteria to evade neutrophil phagocytosis and 
display enhanced virulence. They demonstrated that SAP knockout mice survive 
lethal infection with Streptococcus pyogenes and Escherichia coli J5, organisms to 
which SAP binds, and that the susceptibility of SAP deficient animals was fully 
restored by injection of isolated human SAP. They suggested that the anti-opsonic 
properties of SAP are critical for its physiological function in handling chromatin 
and nucleosomes in vivo and that bacteria have evolved a meclianism of using this to 
their advantage.
In contrast to the effects of SAP binding that are harmful to the host, Noursadeghi 
et al also showed that SAP contributes to survival during infections with organisms 
to which it does not bind, such as Salmonella typhimurium. The mechanisms 
underlying this effect remain unclear.
Lipopolysaccharide (LPS), or endotoxin, is the major component of the outer 
membrane of Gram-negative bacteria and is a major distinguishing factor between 
Gram-negative and Gram-positive bacteria. LPS consists of three main structural 
elements: the O-specific polysaccharide chain, the core region and the lipid A 
moiety. Although SAP binds to LPS in vitro [70,188] and prevents LPS-mediated 
classical pathway complement activation [189], SAP deficient mice were only 
marginally more susceptible to lethal LPS challenge than their wild-type 
counterparts. Furthermore, injection of large amounts of SAP into wild-type mice 
did not affect sensitivity to LPS, indicating that SAP is not a significant modulator 
of LPS toxicity in vivo [69].
As well as binding to bacteria, SAP also binds to the influenza virus haemagglutinin 
and inhibits invasion of cells in vitro [190]. Horvath et al recently reported that 
preincubation of the influenza A virus with human SAP in vitro or intra-nasal 
administration of human SAP to mice prevents infection in vivo [191], suggesting 
that SAP might play a role in innate immunity to influenza infection. Studies from 
our laboratory however, in which we compared SAP deficient and wild-type mice 
following intra-nasal infection with adapted human influenza virus, did not show 
any consistent difference with respect to the clinical course or outcome, viral 
replication and anti-viral response. It was concluded that binding of SAP to 
influenza virus in vivo has no significant functional consequences [192].
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CRP and host defence
Activation of the classical complement pathway by binding of CRP to 
phosphocholine and other phosphate ester-containing compounds [91], together with 
reports that CRP binds to monocytes [92,193] and neutrophils [194] imply a 
significant role for CRP in host defence. CRP was first shown to effectively prevent 
mortality from pneumococcal challenges in 1981 by Du Clos’ group [195]. They 
demonstrated that a bolus injection of CRP protected mice from infection with 
serotypes 3 and 4 of Streptococcus pneumoniae, a finding which was later repeated 
by Volanakis’ group [196]. Similar results were obtained by Szalai et al with 
transgenic mice expressing human CRP [197], and the conclusion from these studies 
was that the opsonic properties of CRP were responsible for its protective effect. 
Xia et al showed that transgenic mice expressing high levels of rabbit CRP were 
partially protected from a lethal challenge of bacterial LPS compared to littermates 
in which CRP expression had been suppressed [198]. However, the authors also 
observed similar protection with challenges from platelet-activating factor (PAF) 
and a combination of TNF-a and interleukin-ip (ILlp), and showed that the 
mechanism by which CRP provides protection probably does not involve 
sequestration of PAF, consistent with the view that CRP plays a significant role in 
host defence other than by direct opsonisation.
Serum Amyloid P  Component in Amyloidosis
SAP is present in all amyloid deposits in all tissues, where its concentration relative 
to that in the plasma is remarkably high, reflecting the avid calcium-dependent
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binding of SAP to amyloid fibrils [66,199,200]. These observations suggested that 
the association of SAP with amyloid may be related to the pathophysiology of 
amyloidosis, evidence for which was initially obtained by comparisons of 
susceptibility, in different mouse strains, to casein induced AA amyloidosis [201]. 
Whilst there was no difference between these strains in the acute phase response of 
serum amyloid A protein (SAA) (the amyloid fibril precursor in casein induced AA 
amyloidosis), there was a marked difference in the SAP response between 
susceptible and resistant mouse strains, with sustained high levels of SAP in 
susceptible strains and temporary and modest SAP levels in resistant strains [119]. 
Similar findings have been reported in other studies [202,203].
The demonstration of a very long half life of SAP in human amyloid deposits of 30 
days compared to 24 hours in the circulation [65], coupled with the completely 
unaltered nature of AP in amyloid deposits compared to plasma SAP [4] and the 
extreme proteinase resistance of SAP [68,204] was further support for a 
pathophysiological role of SAP in amyloidosis. The binding of SAP to amyloid 
fibrils in vitro protects them against proteolytic degradation [68] and it is probable 
that AP serves the same function in vivo.
Investigation of effects of human SAP on in vitro amyloid fibril formation from 
soluble precursor proteins is complicated by the inevitable calcium-dependent 
self-aggregation of SAP. Various authors have suggested that SAP promotes 
fibrillogenesis, however, these experiments were usually carried out in conditions in
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which the SAP autoaggregates [205,206] or in the absence of calcium [207] which is 
entirely un-physiological. There is thus no compelling, physiologically relevant 
evidence of any effect of SAP on fibrillogenesis per se.
In order to explore further the role of SAP in amyloidogenesis, mice totally lacking 
SAP by targeted deletion of the SAP gene were created at Hammersmith Hospital 
[208]. The mice grew, developed and survived apparently normally in standard 
animal house conditions, were anatomically normal and fertile. However, the 
induction of AA amyloidosis by repeated casein injection was highly significantly 
delayed in comparison with SAP-sufficient controls, providing the first unequivocal 
evidence of a contributory role for SAP in amyloid pathogenesis [208].
Extensive clinical studies with radiolabelled SAP as a specific quantitative in vivo 
tracer for amyloid have demonstrated that amyloid deposits are in a state of dynamic 
turnover and that reducing or abolishing new amyloid deposition is associated with 
regression of existing amyloid deposits and frequent clinical benefit [209-211]. Any 
contribution to accelerated clearance of existing amyloid and/or to retarded 
deposition would therefore be beneficial and could have a major impact on the 
morbidity and mortality of the systemic amyloidosis syndromes. In view of the 
protective effect of human SAP against proteolysis of amyloid fibrils in vitro, and 
delayed amyloidogenesis in SAP deficient mice, inhibition of binding of SAP to 
amyloid fibrils in vivo is a rational and attractive therapeutic target in all forms of 
amyloid-related disease.
With this objective in mind, a drug discovery program was recently embarked upon.
A drug, (R)-1 -[6[(R)-2-Carboxy-pyrrolidin-1 -yl]-6-hexanoyl]pyrrolidine-2-
carboxylic acid, was designed which is a competitive inhibitor of SAP binding to 
amyloid fibrils. It is a palindromic compound which cross links and dimerises SAP 
molecules leading to their very rapid clearance from the circulation by the liver. It 
produces remarkable depletion of circulating SAP and is currently being clinically 
evaluated in patients with systemic amyloidosis [212].
Pentraxins and Systemic Lupus Erythematosus 
Pathogenesis of systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is the prototypic systemic autoimmune disease 
with clinical features that include glomerulonephritis, rashes, serositis, haemolytic 
anaemia, thrombocytopaenia, and central nervous system involvement. The 
characteristic immunological abnormality is the presence of high affinity, somatically 
mutated IgG autoantibodies directed against ubiquitous intracellular, cell-surface and 
extracellular autoantigens [213]. The spectrum of intracellular autoantigens includes 
the proteins and DNA that form chromatin, proteins of the spliceosome complex and 
the Ro/La small cytoplasmic ribonucleoprotein particle. Autoantibodies to cell-surface 
antigens include anti-phospholipid antibodies and autoantibodies to red and white 
blood cells and platelets.
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Pathogenesis of SLE - Genetic and environmental factors
Human lupus has an important genetic component as illustrated by 24% concordance 
of disease between monozygotic twins compared with 2% between dizygotic twins 
[214]. However, the observation that the second twin does not develop lupus in three- 
quarters of monozygotic twin pairs also indicates an important role for environmental 
or stochastic factors.
Genetic factors
A number of linkage studies have mapped genetic loci (each containing multiple 
genes) that influence the development and expression of SLE in both humans and 
mice. There are a number of mouse strains in which SLE reproducibly develops in all 
members of colonies held in standard animal houses worldwide. Thus far, linkage 
analyses in multiple murine models have detected 31 susceptibility loci distributed 
among 21 non-overlapping 20 cM genomic intervals, illustrating the complexity of the 
genetic basis for susceptibility to systemic autoimmunity [215]. However, genomic 
segments on murine chromosomes 1 {Slel), 4 (Sle2) and 7 (Sle3) are associated with 
disease susceptibility in multiple strain combinations, suggesting that these intervals 
may contain genes or gene clusters that strongly influence autoimmunity. Further 
analyses of congenic mouse strains carrying genomic intervals with Slel, Sle2 and Sle3 
have provided a detailed characterisation of the component autoimmune phenotype 
produced by each of these susceptibility genes. Slel mediates the loss of immune 
tolerance to chromatin and leads to the appearance of high titres of antinuclear 
autoantibodies (ANAs) and initiation of autoimmunity, and both Sle2 and Sle3 mediate
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polyclonal activation affecting the B cell lineage. In addition Sle3 mediates the 
production of ANAs and, in contrast to Slel, can cause the development of severe 
lupus nephritis [216-218]. A bicongenic strain bearing both Slel and Sle3 was 
subsequently shown to exhibit splenomegaly, expanded populations of activated T and 
B cells, an IgG autoantibody response targeting multiple components of chromatin, 
and highly penetrant glomerulonephritis [219]. Fine mapping analysis of the genetic 
location of Slel has demonstrated that three loci within this congenic interval, termed 
Slel a, Slelb and Slelc, can independently cause loss of tolerance to chromatin [220].
In humans, both genetic linkage studies and association studies analysing the 
contribution of numerous candidate genes have been performed [221]. The first 
human linkage studies in SLE were done by Bias et al, and suggested an autosomal 
dominant mode of inheritance [222]. However, poorly informative markers were 
used and there was a paucity of pedigree material available for study. More recent 
approaches have identified particularly strong linkage with the syntenic equivalent 
of Slel in the mouse, lq21-44 [223-226]. This region of chromosome 1 contains 
several interesting candidate genes including the Fc receptors at lq21-23 which have 
previously been linked to SLE susceptibility by association and case control studies 
[227,228]. The Fc receptors for IgG -  FcyRI, FcyRII, and FcyRIII are all encoded 
within this region and bind IgG-containing immune complexes with distinct 
affinities [229]. Furthermore, FcyRII, and FcyRIII allele distribution has been 
reported to differ between SLE patients and the normal population [228,230,231]. 
Other genes of interest within this region of chromosome 1 include SAP and CRP
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[232], PARP, TGFp2 and ADPRT, a gene that is involved in apoptosis and cellular 
proliferation [233].
The genetic basis for SLE is unknown in the vast majority of patients with the 
condition. However, in a tiny minority of humans with SLE and in certain mouse 
strains, single gene abnormalities are responsible for determining disease 
susceptibility. In humans, as well as the Fc receptor genes mentioned above, certain 
inherited deficiencies of proteins of the classical pathway of complement, are almost 
invariably associated with the development of SLE [234-236]. Recently, ablation of 
the Dnase 1 gene in mice was reported to result in a lupus-like syndrome, and the 
activity of Dnase 1, the major serum nuclease, was reduced in patients with SLE 
compared to normal controls [237]. The MRL mouse strain is prone to spontaneous 
development of lupus; however susceptibility to SLE is dramatically enhanced by 
the presence of the Ipr gene, which encodes a mutated fas protein, a cell surface 
receptor which regulates apoptosis in several cell types including lymphocytes 
[238]. The gld gene, associated with a similar phenotype in mice to Ipr, was 
subsequently discovered to encode a mutated fas-ligand [239]. There is strong 
evidence in both humans and mice with SLE for the participation of the products of 
genes of the major histocompatibility complex (MHC). Certain polymorphic 
products of MHC class II genes, influencing the selection of peptides to be presented 
to T cells, are strong candidates for modifying disease susceptibility [240]. 
However, there is also evidence that other genes encoded in the region of the MHC
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may be important, such as the C2 and C4 genes, and the genes for the cytokines 
TNF-a and lymphotoxin-a [241].
Environmental factors
The very low prevalence of SLE in rural black populations in West Africa compared 
with a prevalence of up to 1:250 in female African Americans suggests a role for 
important environmental influences in protection against development of lupus in 
Africa. It has been speculated that the high incidence of infectious disease, 
especially malaria, in Africa may protect against development of SLE [242].
The best characterised environmental agent predisposing to the development of SLE 
is intake of certain drugs, such as hydrallazine and procainamide. However the 
phenotype of drug-induced lupus is different from the idiopathic disease, with a low 
prevalence of glomerulonephritis and predominance of anti-histone rather than 
anti-dsDNA antibodies [243]. Dietary factors have been shown to predispose to 
development of SLE in animals; cynomolgus macaques that were fed alfalfa sprouts 
developed an SLE-like illness [244]. The key constituent of alfalfa to induce this 
effect appeared to be the amino acid L-canavanine [245].
Viral infections have been implicated in the pathogenesis of several autoimmune 
diseases, including diabetes mellitus and SLE, and an association was reported 
between Epstein-Barr virus (EBV) infection and SLE in children and young adults 
[246]. There is some evidence for the involvement of a transmissible agent in
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canine lupus; cell-free spleen extracts from dogs with lupus resulted in the 
generation of ANAs when given to newborn puppies [247]. This led to the 
suggestion that human SLE might be a zoonosis transmitted from dog to man. 
However, despite suggestions of immunological abnormalities in dogs belonging to 
humans with lupus [248,249], this was not confirmed in other large, well-controlled 
studies [250-252].
Despite evidence that environmental factors influence susceptibility to SLE in 
humans, no single environmental agent responsible for SLE has consistently been 
identified, with the exception of the rare cases of drug-induced disease.
Pathogenesis of SLE -  Mechanisms responsible for the autoimmune response
Early studies demonstrated that a tendency to produce autoantibodies and develop 
glomerulonephritis could be transferred from NZB mice to normal mice by bone 
marrow cells [253]. These experiments did not address the specific cell types 
involved and it is likely that both myeloid and lymphoid cells were transferred.
The importance of B lymphocytes in murine lupus was shown by abrogation of 
disease in MRL/lpr mice that were genetically manipulated to be deficient in B cells 
[254]. Evidence for the pathogenicity of autoantibodies in mice and humans, in 
particular anti-DNA antibodies, comes from several observations; tolerisation to 
DNA abrogates disease in NZB/W mice [255], injection into normal mice of 
anti-DNA antibodies from lupus-prone mice results in renal inflammation [256], and
41
anti-DNA antibodies can be eluted from human renal tissue and are concentrated 
compared to their titre in serum [257,258].
There is extremely strong evidence that the mature autoantibody response in SLE is 
driven by antigen, which is explored in more detail below. However, there is also 
evidence from mouse and human studies of polyclonal B cell activation which is 
likely to reflect abnormalities in the threshold for activation of lymphocytes and may 
play a role in disease susceptibility. The earliest immunological abnormality that 
can be identified in young NZB/W mice is polyclonal B cell activation [259]. The 
idea that polyclonal B cell defects may contribute to the pathogenesis of SLE is 
suggested by the fact that mutant mice with defects of B cell negative regulation 
develop a lupus-like disease. These include mice deficient in Lyn, CD22, SHP-1 
and FcyRIEB. Environmental polyclonal activators such as pristane and endotoxin 
have also been shown in animal models to accelerate or augment lupus-like disease, 
although in the case of endotoxin which has wide ranging effects, it is difficult to 
attribute this to polyclonal activation alone.
Two important observations in humans suggest a role for T cells in the pathogenesis 
of SLE. Firstly, the association of disease with MHC class II [260] and secondly, 
the nature of the autoantibodies found in SLE which show features associated with T 
cell responses including isotype-switching and somatic mutation [261,262]. Several 
experimental approaches have subsequently demonstrated the T cell requirement 
more directly. Antibodies against CD4 abrogate disease in both MRL/lpr and
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NZB/W mice, illustrating the role of T helper cells in both models [263]. 
Furthermore, MRL/lpr mice deficient in MHC class II have decreased susceptibility 
to disease compared to unmanipulated MRL/lpr mice [264], and manipulations to 
inhibit B and T cell interaction with CTLA4-Ig or anti-CD40 ligand reduce 
expression of disease in NZB/W mice [265-267]. These data show that the IgG 
anti-dsDNA autoantibodies in SLE bear the characteristics of an antigen-driven, T 
cell-dependent immune response, and that T helper cells are important in the 
provision of help required to generate such autoantibodies.
Native DNA is poorly immunogenic [268] and deliberate immunisation with DNA 
does not lead to SLE suggesting that DNA is only a target antigen and not the 
primary immunogen in SLE. The isolation of autoreactive T cells from SLE patients 
recognising cationic DNA-binding proteins, and the finding that nucleosome-primed 
T cells emerged spontaneously in lupus-prone mice before the serologic 
manifestations of autoimmunity, thus predicting the development of lupus nephritis 
well in advance, led to the hypothesis that DNA-protein complexes are the major 
immunogen in SLE [269-272]. In addition, Datta et al found that immunisation of 
pre-autoimmune lupus mice with pure mononucleosomes accelerated development 
of severe lupus nephritis [273]. This hypothesis was further strengthened by 
Burlingame et al who demonstrated, using serial serum samples from MRL/lpr and 
BXSB mice, that early autoantibodies recognised discontinuous epitopes on native 
chromatin and the (H2A-H2B)-DNA subnucleosome and that as the immune 
response progressed, native DNA and other chromatin constituents generally became
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antigenic [274]. The same group compared the antigenicity of whole chromatin, 
DNA, denatured individual histones, and histone-histone and histone-DNA 
subnucleosome complexes and found that sera from patients with SLE reacted most 
frequently with whole chromatin, and that adsorption with chromatin removed the 
majority of reactivity with subnucleosome complexes and native DNA [275].
The source o f autoantigens
As discussed above, there is much evidence that the autoimmune response in SLE is 
driven by antigen and that the initial immunogen consists of DNA-protein 
complexes. What is the source of these autoantigens which are ubiquitous and 
abundant intracellular components of all healthy tissues in the body?
Growth, development and repair all depend on the ability to remodel tissues. Cell 
death is a key feature of each of these processes and this normally occurs by the 
mechanism of apoptosis, or programmed cell death. Under normal circumstances, 
apoptotic cells are efficiently removed from tissues by uptake by phagocytosis by 
other cells by means of a variety of specific receptors [276].
A breakthrough in the recognition of the possible source of the autoantigens of SLE 
came with the observation by Casciola-Rosen et al that many of the most 
characteristic “intracellular” autoantigens of SLE were present in surface blebs of 
cells undergoing apoptosis [277]. This led to the hypothesis that it might be 
apoptotic cells and bodies that are the source of the autoantigens that drive the
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autoimmune response in SLE. This hypothesis is further supported by the fact that 
several of the mouse models of SLE result from mutated genes encoding proteins 
which regulate development of apoptosis [238,239]. For example, the presence of 
the Ipr gene, which encodes a mutated fas  gene, dramatically enhances susceptibility 
to lupus in the MRL strain of mouse [238]. Furthermore, Elkon’s group 
demonstrated that intravenous administration into normal mice of syngeneic 
apoptotic thymocytes induces autoantibody production [278], and defective in vivo 
clearance of injected apoptotic thymocytes was demonstrated in lupus-prone 
Clq-deficient mice [279]. Increased lymphocyte apoptosis was reported some time 
ago in humans with SLE [280]; more recently however, defective clearance of 
apoptotic cells has been suggested as an important event in the aetiopathogenesis of 
human SLE [281].
During apoptosis, various potential autoantigens in SLE become modified, which 
may result in enhancement of their immunogenicity [282]. In particular, apoptosis 
induced by the action of granzyme B was shown to modify many of the targets of 
systemic immune responses [283], and it is proposed that apoptosis might thus 
render cryptic epitopes immunodominant and lead to antigen presentation of 
epitopes to which the immune system has not achieved tolerance [284].
Immune complex-mediated inflammation in SLE
Anti-DNA and anti-nucleosome antibodies are thought to be a major cause of tissue 
damage in SLE and many studies have addressed how they may cause
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glomerulonephritis. Anti-DNA antibodies have been eluted from kidneys of both 
humans [258] and mice [285] with lupus. However, anti-DNA antibodies are neither 
necessary nor sufficient for disease and humans, as well as certain strains of mice, 
may have high titres of anti-DNA antibodies without evidence of nephritis. In 
addition nephritis may be present in the absence of circulating anti-DNA antibodies. 
The mechanism by which autoantibodies bind to the glomeruli of patients with SLE 
is debated. The glomerular basement membrane is negatively charged and it has 
been suggested that positively charged antibodies with an alkaline pi may 
preferentially locate there [286]. However, other studies have not confirmed this 
[287].
Patients with SLE have a high incidence of DNA [258,288] and histones [289] 
present in the glomeruli compared to controls. The presence of increased nuclear 
material within lupus kidneys is consistent with several different proposed models of 
immune complex localisation in glomeruli, and there is evidence from rodent 
perfusion studies for each of them. They include complexes of antibody and DNA 
binding to histones planted in glomeruli [290], complexes of antibody and intact 
nucleosomes binding to glomeruli [291,292], and binding of free antibody to planted 
nuclear material such as DNA or nucleosomes [293].
There is evidence from mouse studies that antibodies located in the glomeruli are of 
pathogenetic significance. In one such study, NZB/W mice were made deficient for 
Fey receptors I and III and did not develop glomerulonephritis despite deposition of
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immune complexes [294]. However, simultaneous studies have shown that 
complement activation by immune complexes in experimental models is not 
necessary for the development of glomerulonephritis [295].
Interaction of pentraxins with nuclear constituents
Despite the potential importance of exposure of the immune system to nucleosomes 
and chromatin, little is known about the mechanisms of clearance and processing of 
nucleosomes and chromatin. Recent evidence suggests that the pentraxin family of 
proteins may have an important in vivo role in the clearance of nucleosomes and 
chromatin.
The first indication that the pentraxins could interact with nuclear antigens came 
from a study by Gitlin et al in which they detected CRP localised to cell nuclei in 
synovial tissues from patients with rheumatoid arthritis [296]. The pattern of 
staining was not clearly defined, although the authors showed that the CRP was not 
produced in situ. The first direct evidence that pentraxins could interact with nuclear 
antigens came from the work of Robey et al [297]. They demonstrated that rabbit 
CRP bound in a spotty pattern to the nuclei of rabbit skin and lung fibroblasts treated 
with bradykinin, phospholipase A2 or lysolecithin to permeabilise them. They 
attributed this binding to chromatin and showed that binding to isolated chromatin 
from rabbit nuclei was inhibited by excess CRP or by phosphocholine, therefore 
implying that CRP may have a role in handling chromatin.
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In 1987, Pepys’ group demonstrated that SAP is the major calcium-dependent 
specific DNA binding protein in the serum, by demonstrating that human SAP was 
the only protein in normal or acute phase (containing high levels of CRP) serum that 
underwent binding under physiological conditions of pH and ionic strength to either 
single-stranded or double-stranded DNA immobilised on cellulose, on agarose beads 
or covalently coupled to Sepharose [60]. No specific binding of CRP from acute 
phase serum was detected and when the same experiments were repeated using sera 
from various other animals (mouse, rat, guinea pig, cow and plaice), all 
demonstrated specific calcium-dependent binding of SAP to DNA. In contrast, CRP 
from the rat, rabbit, plaice and horse-shoe crab, as well as hamster female protein, a 
homologue of CRP [298], did not bind to DNA, thus resembling the behaviour of 
human CRP. Isolated purified human SAP also showed major calcium-dependent 
binding to native long chromatin, HI-stripped chromatin and native DNA at 
physiological ionic strength, and when immobilised on Sepharose, to core particles 
in solution, whereas CRP only bound in trace amounts. Binding of SAP to 
extracellular chromatin in the skin lesions of two patients with SLE [299] and to 
dermal keratin bodies, that is apoptotic cells, in normal skin [300] has been 
demonstrated.
There has been considerable controversy over the ability of CRP to bind to 
chromatin. Such binding was demonstrated by DuClos’ group using chromatin 
from calf thymus rather than from chicken erythrocytes. Avian chromatin contains 
histone H5 instead of histone HI, and the amino acid sequences are very different.
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Du Clos’ group have shown that the binding of CRP to chromatin is entirely 
dependent on the presence of histone HI [301] and CRP therefore cannot bind to 
avian chromatin. These binding studies [301-304], however, were carried out using 
isolated, purified nuclear constituents immobilised under conditions that could lead 
to denaturation [77] or performed in unphysiological buffers [297], and although the 
results may be interesting with regard to the potential for interaction of different 
molecules, they may not reflect the interactions that occur in vivo. Du Clos’ group 
has also examined CRP binding to chromatin subunits and shown that CRP can bind 
to the H2A-H2B dimer and the (H3-H4)2 tetramer and to HI, all interactions being 
inhibited by DNA. CRP preferentially bound to histones HI and H2A and a short 8 
amino acid sequence was defined on histone H2A which bound CRP in a 
calcium-dependent manner. Hamster female protein was shown to bind to HI, H2A, 
chromatin and DNA, all interactions being inhibited by phosphocholine [305].
Solubilisation of chromatin by pentraxins
The first report of pentraxins solubilising chromatin was from Robey et al who 
showed that CRP-chromatin complexes could consume complement at physiological 
concentrations of CRP and that this reaction was strictly complement dependent 
through the classical complement pathway [306]. However all these studies were 
conducted at sub-physiological ionic strength and are not likely to reflect meaningful 
interactions in vivo. Indeed Pepys and colleagues showed that SAP rather than CRP 
could solubilise native long chromatin under physiological conditions [61]. Unlike 
the earlier reports from Robey, there was no requirement for complement and no
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cleavage of chromatin during these experiments. The binding of SAP to chromatin 
resulted in the displacement of HI-type histones (H5) essential for condensation and 
higher order folding of chromatin. This binding is remarkable as displacement of 
HI and H5 by salt alone requires 0.5M NaCl. SAP also bound to nucleosome core 
particles forming soluble complexes with an apparent stoichiometry of 1:2, a result 
that is compatible with the attachment of SAP at the nucleosome dyad, the site of HI 
in intact chromatin. CRP did not bind significantly to chromatin or core particles at 
physiological ionic strength. SAP may thus undergo a specific, avid interaction with 
chromatin and nucleosome core particles in vivo, and promote their solubilisation 
and normal handling when released from dying cells.
Binding of pentraxins to extractable nuclear antigens
The spotty fluorescence reported by Robey was recognised as being similar to that 
observed by the binding of autoantibodies to extractable nuclear antigens and in 
1989 Du Clos demonstrated that CRP bound to nuclei of tissue culture cells that had 
been fixed and permeabilised with an identical pattern to that seen with anti-RNP 
binding, suggesting recognition of the same nuclear particles [307]. Using 
immunoprecipitation, CRP was shown to precipitate the U1 RNA species and the 
U4-U6 species characteristic of autoantibodies to the small nuclear ribonuclear 
protein complex, Sm/RNP. By blotting analysis, CRP reacted with the D protein of 
Sm and the 70 kDa protein of RNP.
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These studies were confirmed by Pepys etal in 1994 using confocal microscopy, 
monoclonal antibodies and whole acute phase serum to show that CRP bound 
exclusively to small nuclear ribonucleoprotein particles and SAP bound only to 
chromatin and, for the first time, to nucleoli [62]. Together with the evidence that 
SAP is deposited in vivo in extracellular accumulations of chromatin from dead cells 
[299], this was further evidence of a possible functional role of pentraxins in 
handling nuclear material.
Binding of pentraxins to Fc-gamma receptors
Salmon etal noted in 1996 that the Fc-gamma receptor IIA (FcyRIIA) gene has 2 
codominantly expressed alleles, R131 and H131, which differ in their ability to 
ligate human IgG2. They hypothesised that the FcyRIIA genes are important disease 
susceptibility factors for SLE, and subsequently demonstrated a reduced frequency 
of H131 homozygotes among African-American lupus patients compared to 
African-American non-SLE controls [227], a finding which has been repeated in 
other studies [308].
The binding of CRP to intact human cells via a specific receptor has been the subject 
of considerable controversy. As binding was found on predominantly FcyR 
expressing cells, FcyR was suggested to be the CRP receptor [92,309,310]. 
However, several authors presented data arguing against this hypothesis [193,311- 
313]. More recently, low and high affinity binding of CRP to human FcyRI and 
FcyRII has been reported by Du Clos’ laboratory [92,93]. They also reported
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decreased CRP binding to cells from FcyRIIA H I31 homozygotes, and postulated 
that the reciprocal relationship between CRP and IgG binding avidities on 
leukocytes might explain the contribution of FcyRIIA alleles to SLE susceptibility 
[314]. In all these studies however, binding to FcyR was demonstrated by using 
human CRP preparations that had not been rigorously shown to be absolutely pure 
and also by IgG antibody-dependent detection methods. More recently, Hundt et al 
demonstrated that highly purified natural CRP and recombinant human CRP did not 
bind to white blood cells, but that even trace contamination of the CRP with IgG 
reproducibly gave the apparent binding of CRP to leukocytes observed by Du Clos 
[95]. These results are consistent with earlier work from our laboratory in which we 
were unable to detect any significant binding or association of purified CRP with the 
surface of intact peripheral blood leukocytes (M.B. Pepys, unpublished 
observations).
Defective CRP response in SLE
In a number of autoimmune and inflammatory diseases, such as rheumatoid arthritis, 
Crohn’s disease and rheumatic fever, CRP concentration is the single most sensitive 
objective criterion of activity of disease [151,152,315,316]. When clinical 
symptoms and laboratory indices of disease activity are reduced, either 
spontaneously or following therapy, CRP levels tend to fall. CRP concentration 
rises and falls rapidly, over 24 to 48 hours, in response to acute changes in disease 
activity, covers a wide incremental range, and is not affected by the action of any of
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the commonly used cytotoxic or anti-inflammatory drugs per se, unless these drugs 
reduce the activity or extent of tissue damage and inflammation [317].
In marked contrast to most autoimmune disorders, disease activity in SLE with 
severe symptoms and continuing tissue damage is associated with CRP levels which 
are raised only modestly, despite other tests for active inflammation being positive 
[110]. Honig et al found that definitive positive tests for CRP were rare in patients 
with SLE alone, regardless of its activity, but that if patients had evidence of an 
intercurrent microbial infection then the CRP test became strongly positive [318]. 
Subsequent studies have confirmed that although patients with SLE have 
significantly higher serum concentrations of CRP when their disease is active than 
when it is inactive, the maximum concentrations obtained are relatively modest, 
even in patients with extremely severe disease [156,160]. In contrast, patients with 
unequivocal evidence of intercurrent microbial infection, whether bacterial, viral or 
fungal, appear to mount an “appropriate” response of CRP to their infection, and 
CRP concentration is now frequently applied clinically to differentiate between 
inflammation associated with lupus activity itself and intercurrent infection in 
patients with SLE.
The mechanism for the poor CRP response in SLE is not known. However, in vivo 
turnover studies with 125I-labelled CRP did not provide evidence of increased 
catabolism or consumption of CRP in SLE [159] and there is therefore, by 
definition, a reduced rate of synthesis. There may be failure of the disease process
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in the tissues to generate the particular cytokine mediators which signal hepatocytes 
to synthesise and secrete CRP. However, an intriguing possibility is that the 
capacity to respond to particular forms of inflammation, tissue injury or other stimuli 
by production of CRP is genetically determined. There is evidence for such genetic 
control in inbred mice in which resting and acute phase levels of CRP [173] and 
SAP [116] are significantly different in different strains. In particular, the acute 
phase plasma protein response of SAP to autologous tissue damage in the NZB x W 
mouse strain which spontaneously develops a lupus-like phenotype was deficient 
when compared to the MRL Ipr/lpr mouse which develops a phenotype resembling 
rheumatoid arthritis [319]. If this were true in man, it would raise the possibility that 
CRP-responder status could contribute to hereditary predisposition to SLE.
Biological significance of pentraxin interaction with nuclear antigens
Few studies have investigated the role of pentraxin binding to nuclear antigens 
in vivo. The effect of CRP on the course of autoimmune disease in the 
(NZB x NZW)Fi female hybrid mouse was examined by Du Clos’ group [320]. 
Mice were treated with intraperitoneal injections of chromatin immobilised on a 
solid phase matrix in the presence or absence of CRP. Injection of chromatin in the 
absence of CRP decreased the survival of 26-week old mice, from a median survival 
age of 37 weeks for controls to 29 weeks. CRP prevented this accelerated 
phenotype and mice injected with CRP-chromatin had a median survival age of 40 
weeks. Mice treated with CRP alone did not survive longer than controls and
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pretreatment with CRP did not affect the clearance of nucleosome core particles in 
normal BALB/c mice.
The effect of the acute phase response on clearance of HI-stripped chromatin and 
nucleosome core particles was examined in different mouse strains, chosen due to 
their different basal concentrations of SAP [321]. Core particle clearance was found 
to be slow whereas chromatin clearance was rapid and varied in the different mouse 
strains. Induction of the acute phase response in C57BL/10 mice led to a decrease in 
chromatin clearance, as did co-injection with human SAP or human CRP. The acute 
phase response also caused a higher percentage of chromatin to localise to the liver 
compared to the spleen and less to localise to the kidney, suggesting a protective role 
of the acute phase response against renal deposition of chromatin. However, small 
numbers of animals were used in this study and the conclusions reached were not 
convincingly demonstrated by the actual observations.
The spontaneous phenotype of mice with targeted deletion of the SAP gene was first 
reported from our laboratory [232]. A cohort of (129/Svx C57BL/6)F2 SAP 
deficient mice was noted to spontaneously develop antinuclear autoimmunity, 
including anti-chromatin, anti-histone and anti-DNA antibodies, with 41% of 
deficient female mice developing immune complex glomerulonephritis. The 
clearance of administered chromatin was also reported to be faster in SAP deficient 
animals compared to their wild-type counterparts. However, these studies were
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performed in a heterogeneous group of mice and whether SAP deficiency in pure 
line mice is sufficient to cause autoimmunity has not been tested.
SCOPE AND HYPOTHESIS OF THIS THESIS
The pentraxin proteins are highly conserved through evolution suggesting an 
important physiological function in vivo. SAP is the single normal circulating 
protein that shows specific calcium-dependent binding to DNA and chromatin 
[60,299,300] and CRP binds specifically to small nuclear ribonucleoproteins 
[62,307]. Furthermore, a cohort of [C57BL/6 x 129/Sv]F2 mice with targeted 
deletion of the SAP gene were recently discovered to develop spontaneous 
antinuclear autoimmunity and immune complex glomerulonephritis, a phenotype 
resembling human lupus [232]. Accompanied by the deficient CRP response to 
autologous tissue damage in patients with SLE [156,157], these results suggested 
that an important function of both SAP and CRP may be to facilitate the safe and 
non-immunogenic disposal of autologous ligands.
In this thesis the hypothesis that one of the physiological functions of SAP and CRP 
is to protect against autoimmunity is tested and attempts are made to elucidate the 
mechanisms involved. In particular, we determine for the first time the detailed 
spontaneous phenotype of pure-line C57BL/6 and 129/sv SAP deficient mice, 
testing the hypothesis that SAP deficiency in mice causes a lupus-like phenotype.
As highlighted earlier in the chapter, several lines of evidence suggest a role for 
apoptotic cells in the induction of autoimmunity [238,239,277-279]. Pentraxins
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specifically bind nuclear autoantigens and in this thesis we confirm the binding of 
pentraxins to apoptotic cells in vitro.
One possible mechanism by which pentraxins may prevent systemic autoimmunity 
in vivo is by facilitating the non-immunogenic clearance of apoptotic cells by 
macrophages [276,322]. In order to test this hypothesis we compared the following: 
the immune response to administration of syngeneic apoptotic thymocytes between 
wild-type and SAP deficient mice in vivo; the phagocytosis of apoptotic thymocytes 
between SAP deficient and wild-type C57BL/6 pure-line mice in vivo; the 
phagocytosis of primary human apoptotic lymphocytes by macrophages in vitro, in 
the presence and absence of SAP.
Another possible mechanism by which pentraxins may prevent systemic 
autoimmunity is by enhancement of the non-immunogenic handling and disposal of 
nucleosome core particles that are known to be released into the circulation from 
cells dying by apoptosis [323,324]. In order to test this hypothesis we compared the 
following: the in vivo plasma clearance kinetics of administered long-chromatin and 
nucleosome core particles in SAP-/- and wild-type C57BL/6 mice; the sites of 
catabolism of nucleosome core particles in SAP-/- and wild-type mice.
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Chapter 2 - Materials and Methods
MATERIALS
General Reagents
All reagents were obtained from BDH (Leicestershire, UK), Sigma-Aldrich (Poole, 
Dorset, UK), or Pharmacia Biotech (St Albans, UK) except for:
Agar Difco Laboratories Ltd, West Molesey, UK
Indubiose A37 agarose IBF/Uniscience Gennevilliers, France
Tween 20 Biorad Labs, Herts, UK
Cellulose DE52 Whatman International Ltd, Maidstone, UK
Enzymes
N-bromosuccinimide British Drug Houses, Poole, UK
Staphylococcal nuclease S7 F. Hoffinann-La Roche Ltd, Basel,
Switzerland
Kit Reagents
Nucleon DNA extraction kit 
QIAampR DNA extraction kit 
Annexin V apoptosis detection kit 
FragEl™ apoptosis detection kit 
Phycolinl^ phycoerythrin (RPE)
Life Sciences, UK 
Qiagen Ltd, Crawley, UK 
Immunotech, Marseilles, France 
Oncogene, Boston, USA 
ProZyme Inc, San Leandro, USA
Radiolabelled Isotopes and Autoradiography Reagents
The radiolabelled (125I)sheep anti-mouse whole immunoglobulin and Na125I isotope 
were supplied by Amersham Biosciences, Little Chalfont, UK.
Nuclear Emulsion solution 38 ml K5 nuclear emulsion (Ilford Ltd, Knutsford,
UK) in 12 ml dH20  
Ilford Ltd, Knutsford, UK 
Kodak, Hemel Hempstead, UK 
Amersham Biosciences, Little Chalfont, UK 
Amersham Biosciences, Little Chalfont, UK
Rapid Fixer 
LX24 Developer 
Hyperfilm™ 
Hypercassette™
Cell Culture Media and Cell Lines
All cell culture reagents were obtained from Invitrogen Ltd, Paisley, UK except for:
Jurkhat cell line 
Hep-2 cell line 
Fetal Calf serum (FCS) 
DMEM
Serum replacement
Trypsin
Lymphoprep™
Cell Culture Flasks
From Dr M Botto, Hammersmith Hospital
From Dr M Botto, Hammersmith Hospital
Bio Whittaker Ltd, Venders, Belgium
Dulbecco’s Modified Eagles Medium, Bio Whittaker
Ltd, Venders, Belgium
ICN Biomedicals, Aurora, USA
0.25% in HBSS, ICN Biomedicals, Aurora, USA
Nycomed Pharma, Oslo, Norway
Coming Costar Corp., Cambridge, USA
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Common Buffers
Barbitone-EDTA (BE)
EDTA
PBS
PEBT
SDS-PAGE reducing buffer
Sodium carbonate buffer
TBE
TC
TCB
TE
0.07 M Barbitone (0.0603 M Na Barbitone, 0.0097 M 
Barbitone), 0.01 M di-tetra EDTA, 0.1% Na azide 
(pH 8.6)
Equimolar mixture, pH 7.5, of disodium and 
tetrasodium ethylene diamine tetra-acetate 
Phosphate buffered saline, 0.2 g potassium phosphate 
monobasic, 0.2 g KC1, 8 g  NaCl and 1.15 g sodium 
phosphate dibasic dissolved in 1 litre of (IH2 O 
(supplied as a powder mix by Sigma-Aldrich)
PBS containing 10 mM EDTA, 1% BSA, 0.2% Tween
20 and 0.1% sodium azide, pH 7.4
0.01 M Tris, pH 8, 1 mM di-tetra EDTA, 2.5% v/w
SDS, 0.025% v/w Bromophenol Blue and 0.7 M
mercaptoethanol, 1% v/w glycerol
0.5 M mixture of disodium salt, pH, and monosodium
salt, pH achieving final pH 9.5
Tris borate, 0.09 M Tris-borate, 0.02 M EDTA
Tris calcium, 0.01 M Tris, 0.138 M NaCl, 0.002 M
CaCl2, pH 8.0
TC containing 1-4% w/v BSA (Sigma-Aldrich)
Tris EDTA, 0.01 M Tris, 0.138 M NaCl, 0.01 M 
EDTA, pH 8.0
TEB
TN
Tris-HCl
TE containing 1% w/v BSA (Sigma-Aldrich) 
Tris NaCl, 0.01 M Tris, 0.138 M NaCl, pH 7.4 
0.01 M Tris, pH 8.0
Antibodies and Antigens
All antibodies, antigens and microtitre plates were purchased from Sigma-Aldrich 
(Poole, Dorset) except for:
Lyophilised calf thymus histones Calbiochem Novabiochem, La Jolla, USA
Avian long chromatin
MRLfMp-lpr/lpr serum 
FITC-goat anti-mouse C3 
Crithidia luciliae slides 
Hep-2 slides 
Nunc plates 
Sheep anti-human SAP
Sheep anti-mouse SAP
Prepared by Dr WL Hutchinson, CAAPP, 
Dept, of Medicine, Royal Free and University 
College Medical School, London [325,326]
Dr M Botto, Hammersmith Hospital, London 
Cappell-Worthington, Durham, NC 
The Binding Site, Birmingham, UK 
The Binding Site, Birmingham, UK 
Nunc, Roskilde, Denmark 
Monospecific antiserum raised by
immunisation with the respective pure protein 
[66]
Monospecific antiserum raised by
immunisation with the respective pure protein
Goat anti-human CRP
Rabbit anti-mouse albumin 
Mouse anti-human Fas
Histological Compounds
10% buffered formalin 
10% Giemsa stain 
Haematoxylin and eosin stain 
Periodic acid Setoffs (PAS) stain 
OCT compound 
DPX mountant
Histological Buffers
Bouin’s solution
Electron microscopy fixative
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Monospecific antiserum raised by 
immunisation with the respective pure protein 
Biogenesis Ltd, Poole, UK 
Immunotech, Marseilles, France
Histopathology Dept., Royal Free Hospital 
Haematology Dept., Royal Free Hospital 
Histopathology Dept., Royal Free Hospital 
Histopathology Dept., Hammersmith Hospital 
Sakura Finitek, Torrance, Ca 
Raymond Lamb, Eastbourne, UK
75 ml saturated 1.2% picric acid, 25 ml 
formaldehyde 40% w/v, 5 ml acetic acid, 
added before use
1 ml 25% gluteraldehyde, added before use to 
11.5 ml PBS
Animals
Pure line SAP-deficient mice were obtained by back crossing the original SAP 
knockouts [208] through at least 6 generations onto the background strain in a
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specific pathogen free (SPF) environment. Other strains of inbred mice (C57/BL6 
and 129/sv) were purchased from Harlan Olac, Bicester, Oxon, UK. All 
experiments involving the use of animals were conducted in accordance with local 
ethical guidelines and Home Office regulations.
METHODS
Gel Electrophoresis 
Agarose gel electrophoresis
Electrophoresis grade agarose was dissolved in lxTBE to a final concentration of 
0.8-2% depending on the size range of the DNA fragments to be resolved 
(Sambrook et al 1989). The agarose solutions were cooled to 50°C and ethidium 
bromide (EtBr) was added to a final concentration of 0.5 pg/ml before the gels were 
set in horizontal gel trays. Sample loading buffer was added to all samples prior to 
loading. A “1 Kb ladder” was added to marker lanes for size estimation. 
Electrophoresis was carried out in 1 x TBE under a constant voltage of between 2.5 
and 5.0 V/cm.
Gels were visualised using a short-range UV transilluminator (312 nm) (Ultraviolet 
Products Ltd, Cambridge, UK), electronically captured using the Visionworks Image 
Acquisition Software (Ultraviolet Products Ltd, Cambridge, UK) and recorded on 
thermosensitive paper using a digital graphic printer (Sony Corporation, Tokyo, 
Japan).
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Electroimmunoassay
Electroimmunoassay was performed by the standard method [327], using 1% 
indubiose agarose containing the relevant monospecific antiserum at a concentration 
of 1-2%. Serum samples (2 pi) were placed in 2 mm diameter wells on a 1 mm 
thick gel and a constant voltage of 200 V was applied for 8 h across the gel, in an 
electrophoresis tank with cooled plates containing barbitone-EDTA and using 
double thickness 3 MM™ chromatography paper as a contact wick between buffer 
and gel. The gel was washed overnight at 37°C with 5% NaCl, 0.02% NaN3 to 
remove unprecipitated protein, and then pressed and dried. The gel was stained with 
0.2% Coomassie blue and destained (45% ethanol, 10% glacial acetic acid) until the 
background of the gel was clear. Rocket shaped curves occur with the precipitation 
of the antigen-antibody complex at a critical antigen-antibody ratio (equivalence). 
The heights of the “rockets” are proportional to the concentration of antigen in each 
sample and are compared to known concentrations of the antigen in standards of 
serum, calibrated against the pure antigen.
Denaturing polyacrylamide gel electrophoresis
Samples for protein analysis were diluted in SDS-PAGE reducing sample buffer and 
heated at 95°C for 5 min. The electrophoresis unit was cooled to 15°C by connecting 
to a thermostatic circulator. The electrophoresis gel (ExcelGel, Pharmacia Biotech, 
St Albans, UK) was positioned on the cooling plate using silicone fluid (BDH), and 
the SDS buffer strips were applied to the appropriate side of the gel. Samples 
estimated to contain 200-500 ng of each protein and appropriate low molecular
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weight (LMW) calibration standards (Pharmacia Biotech, UK) were applied to the 
gel through application pieces, and run at 600 V with a current of 50 mA and power 
of 30 W for 1-2 h. The gels were subsequently placed directly into Coomassie 
Staining solution (0.1% Coomassie Blue in 30% methanol, and 10% acetic acid) at 
56°C for 30 min and washed once with distilled water before destaining. Silver 
staining was performed where necessary according to the method of Heukeshoven 
and Demick [328].
Phenotypic Analysis o f  SAP-deficient Mice 
Serological analysis
Blood was collected by tail bleeding (200 pi per bleed) or at bleed out into 1.5 ml 
vials (Eppendorf, Hamburg, Germany) and allowed to clot for 6 h  at room 
temperature. Serum was separated by centrifugation at 14000 rpm in a microfuge 
(Sigma-Aldrich, Poole, UK) for 5 min, and stored in aliquots at -70°C prior to 
analysis.
Immunoradiometric assays (IRMAs) were developed and optimised with the help of 
Dr WL Hutchinson [329], Centre for Amyloidosis and Acute Phase Proteins, Royal 
Free and University College Medical School, London. All such assays used 
immobilised pure antigen as an initial capture phase for specific murine antibodies. 
Detection was achieved using radiolabelled sheep anti-mouse IgG which was 
estimated by counting individual reaction wells in a gamma counter (Cobra™ II, 
Packard, Pangboume, UK).
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The dilutions chosen for IRMAs were chosen to accommodate the volume of serum 
available and produce values throughout the range of detection. For each assay the 
intra-assay coefficient of variation was assessed by comparison of 2 samples 
measured 6 times per assay and the inter-assay coefficient of variation was assessed 
on the same samples measured on each occasion.
All samples were assayed in triplicate and results were expressed relative to those 
produced by a standard of pooled, high titre MRL/Mp-lpr/lpr serum which was 
assigned an arbitrary value of 100 units. Samples were considered positive when 
> 3 SD above the lower limit of detection.
Anti-nuclear antibodies (ANA) -  by indirect immunofluorescence
HEp-2 cells were grown to confluence at 37°C in RPMI medium containing 10% 
heat inactivated fetal calf serum, penicillin G sodium 250u/ml, streptomycin 
sulphate 200 pg/ml, amphotericin B 2 pg/ml and glutamate. Once confluent, cells 
were released from the cell culture flask by incubation at 37°C with 0.25% trypsin 
for 2-4 min, and gentle tapping. The cell suspension was diluted 1:5 with RPMI 
medium, centrifuged (Sorvall RT6000B) at 350 g for 5 min, the supernatant was 
discarded and cells resuspended in fresh RPMI medium. One ml of cell suspension 
per slide was then pipetted onto sterile multi-well slides in individual petri dishes 
and cultured at 37°C for a further 24-48 h. Once confluence had been attained, 
slides were removed, washed twice in sterile PBS, fixed with acetone for 5 min and 
stored at -70°C until use.
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Samples were diluted 1/80 with sterile PBS. MRL/Mp-//?r/7pr serum was used as a 
positive control and pooled serum from normal mice as a negative control. Multi 
well slides, bearing HEp-2 cells, were preincubated with 15 pi samples in a wet box 
and left for 1 h at room temperature. The slides were washed twice in PBS for 5 min 
and incubated in the dark for 30 min with 400 pi of FITC-conjugated goat IgG 
anti-mouse Fc secondary antibody, diluted 1/120 [330,331]. The slides were washed 
in PBS, a coverslip applied with Permafluor (Immunon, UK) and the samples 
viewed in a fluorescence microscope (Olympus BH/2). Positive samples were then 
serially diluted and titrated to end-point (i.e. the last dilution at which a positive 
result was demonstrated). Results were expressed as titration units. Each assay was 
standardised using positive pooled MKLfMp-lpr/lpr serum which was serially 
diluted from 1/80 to 1/2560. Values of 1/80 or above were considered positive.
Anti-dsDNA antibodies - by indirect immunofluorescence (Crithidia luciliae) 
Samples were diluted 1/20 with sterile PBS. Pooled MRLfMp-lpr/lpr serum was 
used as a positive control and pooled serum from normal mice as a negative control 
on every slide. The assay was standardised using a further sample of positive pooled 
serum and serially diluting from 1/20 to 1/160. The sample was positive at 1/160. 
Sample dilutions were placed into each well of commercially prepared slides bearing 
Crithidia luciliae and incubated in a humid chamber for 1 h. The slides were 
washed twice with PBS and 40 pi of FITC-conjugate at a dilution of 1/50 was added 
to each well (goat anti-mouse polyvalent immunoglobulins -  IgG, IgA, IgM) and 
incubated again for 30 min in the dark at room temperature. The slides were washed
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with PBS, a coverslip mounted with Permafluor and the slides visualised in a 
fluorescence microscope. Positive samples were titrated to end-point. Values of 
1/20 or above were considered positive [332].
Anti-histone antibodies -  by immunoradiometric assay (IRMA)
Microtitre plates with N-oxysuccinimide activated surfaces (Coming Costar, Bucks, 
UK) were coated with calf thymus histones by incubation with 100 pi per well of the 
antigen at 100 pg/ml in PBS, pH 9.0, for 1 h at 21°C. After decanting, the wells 
were each washed twice with 200 pi of PBS, pH 7.4, containing 0.05% Tween 20, 
before blocking for 30 min with 100 pi per well of 20g/l bovine serum albumin 
(BSA) in PBS, pH 7.4. After finally rinsing each well three times with 200 pi 
volumes of PBS, the plates were used for assays within 7 days. Stability of coated 
plates was confirmed by repeating assays 7 days apart.
Calibrators were constructed containing dilutions at 1/50, 1/100, 1/200, 1/500, 
1/1000, 1/2000, 1/4000 and 1/8000 of pooled MRLfM$-lpr/lpr serum in PEBT 
buffer. Serum samples for the assay were each diluted 1/200 in PEBT buffer (1/200 
dilution of the standard corresponded to the top of the linear region of the sigmoid 
curve). The standards and diluted samples, together with PEBT buffer alone, were 
loaded in triplicate into the histone coated plates at 100 pi per well. After incubation 
at 37°C for 1 h, the plates were decanted and each well was washed three times with 
200 pi of PEBT buffer before finally being blotted dry and counted individually in 
the y-counter. The calibration curve was constructed using a four parameter logistic
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curve fit program (figure 2.1a), and values for samples and controls were determined 
by interpolation.
The calibrators yielded a response proportional to the dilution used between 1/2000 
and 1/200. Readings reached a plateau for calibrators at dilutions lower than 1/200, 
and higher than 1/2000. Intra-assay coefficients of variation were between 1.77% 
and 7.6% and inter-assay coefficients of variation ranged from 1% to 8.4%.
Anti-chromatin antibodies -  by immunoradiometric assay (IRMA)
Microtitre plates with N-oxysuccinimide activated surfaces (Coming Costar, Bucks, 
UK) were coated with avian long chromatin by incubation with 100 pi per well of 
the antigen at 100 pg/ml in PBS, pH 9.0, for 1 h at 21°C. After decanting, the wells 
were each washed twice with 200 pi of PBS, pH 7.4, containing 0.05% Tween 20, 
before blocking for 30 min with 100 pi per well of 20 g/1 bovine serum albumin 
(BSA) in PBS, pH 7.4. After finally rinsing each well three times with 200 pi 
volumes of PBS, the plates were used for assays within 7 days. Stability of coated 
plates was confirmed by repeating assays 7 days apart.
Calibrators were constructed containing dilutions at 1/200, 1/400, 1/800, 1/1000, 
1/2000 and 1/4000, 1/8000 and 1/16000 of pooled MRL/Mp-//?r/7pr serum in PEBT 
buffer. Serum samples for the assay were each diluted 1/1000 in PEBT buffer 
(1/1000 dilution of the standard corresponded to the top of the linear region of the 
sigmoid curve). The standards and diluted samples, together with PEBT buffer
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alone, were loaded in triplicate into the chromatin coated plates at 100 pi per well. 
After incubation at 37°C for 1 h, the plates were decanted and each well was washed 
three times with 200 pi of PEBT buffer before finally being blotted dry and counted 
individually in the y-counter. The calibration curve was constructed using a four 
parameter logistic curve fit program (figure 2.1b), and values for samples and 
controls were determined by interpolation.
The calibrators yielded a response proportional to the dilution used between 1/1000 
and 1/4000. Readings reached a plateau for calibrators at dilutions lower than 
1/1000, and higher than 1/4000. Intra-assay coefficients of variation were between 
1.2% and 5.7% and inter-assay coefficients of variation ranged from 3.3% to 11.7%.
Anti-ssDNA antibodies -  by immunoradiometric assay (IRMA)
Calf thymus single-stranded DNA (ssDNA) (Sigma, Poole, UK) was dissolved at 
100 pg/ml in PBS, pH 9.0 by heating to 70°C for 30 min. Microtitre plates with 
N-oxysuccinimide activated surfaces (Coming Costar, Bucks, UK) were coated by 
incubation with 100 pi per well of the antigen for 1 h at 21°C. After decanting, the 
wells were washed, blocked and washed further, before use within 7 days as before. 
Stability of coated plates was confirmed by repeating assays 7 days apart.
Calibrators were constructed containing dilutions at 1/200, 1/400, 1/800, 1/1000, 
1/2000 and 1/4000, 1/8000 and 1/16000 of pooled MRL/Wp-lpr/lpr serum in PEBT 
buffer. Serum samples for the assay were each diluted 1/1000 in PEBT buffer
CP
M
70
A)
7000-
B)
7500-
S  5000-
2500-
R2=0.993
0.0625 0.25 1 5
Dilution (log) Dilution (log)
C)
10000 -
7500-
2500-
R2=0.998
0.0625 0.25 51
Dilution (log)
Figure 2.1 Calibration curves for immunoradiometric assays (IRMAs) 
using serial dilutions of pooled MRL/Mp-lpr/lpr serum. A) Anti-histone 
antibody assay calibration curve B) Anti-chromatin antibody assay 
calibration curve C) Anti-ssDNA antibody assay calibration curve.
Correlation coefficients (R2) are shown for individual curves.
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(1/1000 dilution of the standard corresponded to the top of the linear region of the 
sigmoid curve). The standards and diluted samples, together with PEBT buffer 
alone, were loaded in triplicate into the ssDNA coated plates at 100 pi per well. 
After incubation at 37°C for 1 h, the plates were decanted and each well was washed 
three times with 200 pi of PEBT buffer before finally being blotted dry and counted 
individually in the y-counter. The calibration curve was constructed (figure 2.1c), 
and values for samples and controls were determined by interpolation, as before.
The calibrators yielded a response proportional to the dilution used between 1/1000 
and 1/4000. Readings reached a plateau for calibrators at dilutions lower than 
1/1000, and higher than 1/4000. Intra-assay coefficients of variation were between 
0.1% and 2.5% and inter-assay coefficients of variation ranged from 0.5% to 5.8%.
Urinary analysis
Urine was collected from each C57BL/6 mouse over a 24 h period prior to 
exsanguination using a modified cage (Dr M Robson, Department of Rheumatology, 
Imperial College School of Medicine). The total volume of urine was measured and 
serum and urine creatinine concentrations were determined using a standard 
Olympus AU600 instrument. Creatinine clearance was calculated for each mouse 
using the standard formula GFR = [UCr x V]/PCr, where UCr and PCr are the urine 
and plasma creatinine concentrations respectively, and V is the volume of urine in 
24 h. Creatinine clearance was expressed in ml per minute.
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Urinary albumin concentration was determined by single radial immunodiffusion 
[333] using a 1.2% agarose gel containing rabbit anti-mouse albumin (Biogenesis) at 
a concentration of 1.5%. The assays were calibrated with standards of murine 
albumin in solution in mouse urine. Inter-assay variation was determined by 
comparison of the same two samples on each gel and was < 6%. Albuminuria was 
expressed in pg/ml with a lower cut off point of 50 pg/ml.
Histological analysis
Preparation of samples
Blocks of mouse liver, spleen, kidney, heart, lung, large intestine, small intestine, 
stomach salivary gland, aorta and skin were obtained and prepared in several ways 
(as required):
a. Fixed in 10% buffered formalin, prior to processing in paraffin, sectioning 
and staining with haematoxylin and eosin.
b. Snap frozen -  from 0.9% saline on cork boards with OCT compound, by 
immersion in isopentane, cooled in liquid nitrogen. All tissues were stored at 
-70°C.
c. Fixed in Bouin’s solution -  blocks of mouse kidney were immediately 
immersed in Bouin’s solution and left for 4 h and then stored in 70% ethanol, 
prior to processing in paraffin, sectioning and staining with haematoxylin 
and eosin or Periodic Acid Schiff (PAS).
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d. Fixed in glutaraldeyde - blocks of mouse kidney were cut into 1 mm cubes 
and fixed in 2% glutaraldehyde in PBS at 4°C for 2-3 h, before storage in 
PBS. These were used for electron microscopy.
Analysis of samples
Light microscopy
Sections fixed with Bouin’s solution or 10% buffered formalin were coded and read 
blind by Professor HT Cook, Department of Histopathology, Hammersmith 
Hospital. Kidney sections were scored for glomerulonephritis by grading 
glomerular hypercellularity in the following way: 0 = <25%, 1 = 25-50%, 11 = 51- 
90% and III = >90% abnormal glomeruli (Jevnikar 1992). Other tissues were 
evaluated for lymphocytic infiltration and scored according to the proportion of 
tissue infiltrated.
Splenic samples were coded and read blind by Dr RP Hasseijian, Department of 
Histopathology, Hammersmith Hospital, and were given a “spleen lymphocyte 
score” as follows: white pulp volume scored from 0 (none) to 3 (very abundant); 
white pulp coalescence scored from 0 (completely separated white pulp nodules) to 
3 (totally coalescent white pulp); red pulp lymphocytes scored as 0 (very rare) to 3 
(numerous). The spleen lymphocyte score was the sum of all parameters, ranging 
from 0-9, and > 4 was considered abnormal.
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Direct Immunofluorescence Staining for IgG and C3
The presence of IgG and C3 deposits in renal tissue from mice with varying degrees 
of glomerulonephritis, was sought by direct immunofluorescence on 5 pm thick 
cryostat sections of unfixed renal tissue (Bright Instruments Ltd, Huntingdon, UK). 
Sections were left to air dry for at least 1 h at room temperature, fixed in acetone and 
allowed to dry. Sections were then blocked with 20% normal goat serum in PBS for 
30 min at room temperature, prior to incubation for 1 h at room temperature with 
50 pi antibody conjugate used at 1/40 (FITC-polyclonal goat anti-mouse IgG, Fc 
specific) or 1/50 (FITC-polyclonal goat anti-mouse C3). Sections were washed 
twice in PBS for 3 min each, mounted in permafluor and viewed under fluorescent 
light. Specificity of staining was established by fluid-phase absorption of the 
fluorescent antibody conjugate with an equal volume of the respective antigen in 
slight, 1.2:1, antigen excess. The mixture was incubated at 37°C for 1 h and then 
rotated overnight at 4°C, centrifuged and the SN was removed and diluted to the 
same dilution as the unabsorbed labelled antibody for staining.
Serum from SAP-deficient and wild-type mice, that were strongly ANA positive and 
negative respectively, were incubated with snap-frozen cryostat sections of unfixed 
normal mouse tissues (liver, kidney, spleen) from C57BL/6 mice. After washing, 
these composite blocks were incubated with FITC-labelled sheep anti-mouse IgG 
and viewed under fluorescent light to detect the presence of tissue specific 
autoantibodies in the serum.
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Immunisation with avian native long chromatin
Groups of age-matched male and female SAP deficient (SAP-/-) and wild-type 
129/sv mice were injected with 100 pg chicken erythrocyte native long chromatin in 
50 pi lOmM Tris, pH 8.0, emulsified in an equal volume of complete Freund’s 
adjuvant, intramuscularly into the right thigh on day 0. All mice were bled on day 
-1, +14, +28 and +41. They were boosted with the same dose of chromatin 
suspended in incomplete Freund’s adjuvant on day +32 and bled out on day +56.
Plasma Clearance and Organ Localisation o f  Radiolabelled Chicken 
Erythrocyte Chromatin and Nucleosome Core Particles 
Obtaining long chromatin and nucleosome core particles
Chicken erythrocyte long chromatin was prepared by Dr WL Hutchinson by limited 
digestion with exogenous staphylococcal nuclease according to the protocol of Dr 
S Searles (LMB, Cambridge), and stored at a concentration of 4.6 mg/ml in 10 mM 
Tris-HCl, pH 8.0 with glycerol to 50% v/v at -30°C. Aliquots were taken as 
necessary and chromatin was dialysed out of glycerol and into 10 mM Tris-HCl at 
4°C using benzoylated dialysis tubing (Sigma-Aldrich, Poole, UK).
Nucleosomes were obtained from native long chromatin as follows; calcium chloride 
in Tris-HCl was added to the dialysed chromatin to a final concentration of 1 mM. 
After vortex mixing, the intact long chromatin was allowed to precipitate at room 
temperature for 30 min. EDTA was added to a final concentration of 2 mM, the
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sample was microcentrifuged at 14000 rpm, and the supernatant (containing 
nucleosomes) was removed.
The DNA content of the supernatant was estimated by diluting 1:20 in 0.1 M NaOH 
and reading the optical density at A2 6 0  and A3 2 0  using the Beckmann DU650 
spectrophotometer. In order to determine the size range of the DNA fragments in 
the supernatant, approximately 50 pg of DNA was extracted from an appropriate 
aliquot using the BACC2 DNA extraction kit (Life Sciences, UK). The DNA 
fragments were analysed by agarose gel electrophoresis alongside a “1 Kb ladder.” 
The presence of HI-type histones in the nucleosome preparations was confirmed by 
SDS-PAGE.
Direct radioiodination of long chromatin and mononucleosomes
Long chromatin was directly radioiodinated as follows: following dialysis into 
lOmM Tris, pH 8, 1 mg aliquots of chromatin were reacted with 5 pi Na125I 
(neutralised with 1 M Tris, pH 8) (Amersham International pic) and 5 pi 
N-bromosuccinimide (NBS) at 1 mg/ml for 20 sec before dilution to a final volume 
of 4.4 ml with 10 mM Tris, pH 8. Extensive dialysis was then carried out in Tris 
buffer in the presence of Amberlite IRA-420 anion exchange resin (100 ml in 5 litres 
buffer). Dialysis was undertaken for 96 h with 30 litres of buffer. The final 5 litre 
dialysis was carried out in the absence of resin. The proportion of radioactivity 
associated with protein in the final material was determined by precipitation with 
30% trichloroacetic acid (TCA) and counting of the precipitate.
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Nucleosomes were directly radioiodinated as follows; a Sephadex G-25 pre-packed 
10 ml mini-column (PD10, Amersham Pharmacia Biotech, Uppsala, Sweden) was 
equilibrated in TN buffer, blocked with 20% BSA and re-equilibrated in TN buffer. 
Twelve pi of cold KI at 10 pg/ml in (IH2O was added to 200 pi (200 pg) of 
nucleosome solution. Three pi of Na125I (activity of 100 mCi/ml) (Amersham 
International pic) was added followed by 12 pi of N-bromosuccinimide (NBS). The 
reaction was allowed to proceed for 15 sec and was halted by addition of the 
solution to the equilibrated PD10 column. The PD10 column was eluted with TN 
and 0.5 ml aliquots were collected in separate fractions. The activity of each 
fraction was determined using a gamma counter and the two samples containing 
maximum activity were pooled. The final material was tested for TCA 
precipitability.
Synthesis of tyramine-cellobiose
This was performed according to the method of Pittman et al [334] and involved 
reductive amination of cellobiose by tyramine, using sodium cyanoborohydride as 
the reducing agent. Tyramine (100 mmol) in 1 litre CIH2 O (0.1 M) was dissolved by 
stirring in 20 ml acetic acid. Sodium cyanoborohydride (100 mmol) and cellobiose 
(40 mmol) were added and the pH was adjusted to 5.4 with glacial acetic acid. The 
mixture was refluxed with stirring for 96 h with readjustment of the pH to 5.4 at 24 
hourly intervals. The solution was cooled, adjusted to pH 3.5 and refluxed for a 
further 24 h to destroy any remaining sodium cyanoborohydride. The volume of the 
solution was reduced to approximately 100 ml by rotary evaporation. Following
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centrifugation to remove any particulate matter, the concentrate was applied to a 
120 ml column of AG 50W-X8 cation exchange resin (Biorad, Herts, UK), 
equilibrated with H2 O. The column was eluted with a minimum of 2.5 litres of 
water to remove unreacted cellobiose, and then with a linear gradient of H2 O and 
1 M NH4 OH which elutes the tyramine-cellobiose ahead of unreacted tyramine. The 
elution pattern was monitored by thin layer chromatography on silica gel developed 
in butanol: acetic acid: H2 O (7:1:2). Tyramine-cellobiose was identified by staining 
with a mixture containing equal volumes of 2  mg/ml naphthoresorcinal in ethanol 
and 20% H2 SO4 . Fractions containing tyramine-cellobiose were pooled, rotary 
evaporated to about 60 ml and lyophilised to yield a powder and stored in a 
dessicator.
Radioiodination of the tyramine cellobiose ligand
To a 300 pi microreaction glass vessel, 400 ng of l,3,4,6-tetrachloro-3a,6a- 
dipthenylglycouril (Iodogen, Pierce Chemical Co.) in 10 pi methylene chloride was 
added. The solvent was evaporated by hand warming to leave a thin coating of 
iodogen on the vessel walls. Five nmol of tyramine-cellobiose (in 20 pi of 0.15 M 
sodium phosphate buffer, pH 7.4) was added and gently mixed. Carrier-free Na125I 
at approximately 500 mCi/ml (Amersham International pic) was added, and 
iodination was allowed to proceed for 30 min. The reaction was stopped by addition 
of a mixture of 10 pi 0.1 M Nal and 20 pi 0.1 M Na2 S2 0 s in H2 O.
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Activation and protein binding of radioiodinated tyramine-cellobiose
To the solution of 125I-tyramine cellobiose (125I-TC) prepared above, 5 nmol of 
cyanuric chloride was added in 40 pi of acetone. The reaction was allowed to 
proceed for 30 sec before addition of the protein for binding. Prior to binding, 
nucleosomes were dialysed out of lOmM Tris-HCl and into 0.15 M sodium 
phosphate buffer, pH 7.4 at 4°C using benzoylated dialysis tubing (Sigma-Aldrich, 
Poole, Dorset). Five hundred pg (70 pi) of nucleosomes were added to the solution 
of 125I-TC activated with cyanuric chloride. Binding was carried out for 3 h at room 
temperature before separation from unbound label by gel filtration on a Sephadex 
G25 column (PD10, Pharmacia, Milton Keynes, UK) which was equilibrated with 
TN buffer.
Autoradiography
In order to confirm direct radioiodination of chromatin and nucleosomes and 
radioiodination of tyramine-cellobiose labelled nucleosome core particles, 
autoradiography was performed on an 8-18% SDS-PAGE gel onto which the 
different preparations had been loaded. Three dilutions of each preparation were 
added, equivalent to approximately 0.3, 0.9 and 1.8 pg of protein. The gel was
'TlV/f rT \y fautoradiographed using Hyperfilm in a Hypercassette (Amersham International 
pic) for 8 h before being developed.
Following counting in the gamma counter, dipping film autoradiography was 
performed on selected samples of mouse liver, spleen and kidney which had been
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injected with TC-labelled nucleosomes 24 h previously. Composite blocks of liver, 
spleen and kidney were created from each of 6 mice (3 SAP-/- and 3 wild-type) and 
5 pm sections were cut onto clean slides using a microtome. The slides were dried 
at 37°C for 24 h, dewaxed, and dipped in K5 nuclear emulsion solution. They were 
carefully drained and placed onto a cold plate, section uppermost. After 10 min the 
slides were removed from the cold surface and dried for 3 h. After drying, the slides 
were placed in a sealed black box, with a small amount of dessicant, and stored at 
4°C for 2 wk before development. The slides were developed as follows; in 1:4 
solution of LX24 developer in dt^O for 5 min with constant movement of the slides, 
washed for 20 sec in cfflhO, fixed for 3 min in a 1:4 solution of Ilford Rapid Fixer in 
tap water and washed in tap water for a further 5 min. The slides were stained with 
Mayers Haematoxylin for 5 min before washing in tap water. They were blued in 
Scott’s tap water for 3 min and washed again in tap water. The slides were allowed 
to dry at 37°C and mounted using DPX mountant. The slides were viewed by light 
microscopy and labelling was seen as black dots laying over the relevant cell types.
Experimental Protocols
Directly-labelled long chromatin, of which 96% of the activity was TCA 
precipitable, was injected intra-peritoneally (IP) into 13 female, age-matched 
C57BL/6 mice from each of 3 genotypes, wild-type, SAP-/- and SAP-/-, hSAP Tg. 
Each mouse received 2 x 106 counts in 100 pi, equivalent to approximately 10 pg of 
chromatin. Mice were counted twice in a gamma counter immediately after IP 
injection and again after 4 h and 7 h.
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Preliminary studies of plasma clearance of directly radioiodinated chromatin were 
performed in 4 wild-type C57BL/6 female mice in which thyroid blockade had been 
achieved by addition of 60 mg/1 potassium iodide to the drinking water for 48 h prior 
to injection. These studies were undertaken in order to roughly determine the rate of 
clearance of long chromatin from the blood, so that relevant time points could be 
selected for comparison of rates of clearance between SAP-/- and wild-type 
C57BL/6 mice. All mice were injected with 100 pi (100000 counts per min (CPM) 
corresponding to approximately 1 pg of chromatin) of radioiodinated chromatin into 
the tail vein. Prior to injection two aliquots of the material were precipitated by 
addition of trichloroacetic acid (TCA) to a final concentration of 10% or 2mM 
calcium chloride, and the percentage of total counts in each pellet was determined. 
TCA and calcium precipitability were 98% and 80%, respectively. Approximately 
50 pi of blood was obtained from the tail vein 2 min after injection and each mouse 
was serially bled after a further 15 min, 30 min, and 1, 2, 4 and 5 h. The turnover of 
chromatin was expressed at each time point as counts per gram of blood as a 
percentage of counts per gram of blood 2 min after injection (i.e., the counts per 
gram of blood after 2 min was 100% for each mouse). A single curve was 
constructed by pooling the information from each mouse at each time point.
Comparison of plasma clearance of long chromatin between SAP-/- and wild-type 
C57BL/6 mice was performed as follows: for each experiment six female SAP-/- 
and 6 female, age and weight-matched 6-8 week old wild-type C57BL/6 mice were 
given potassium iodide for 48 h prior to injection of chromatin in order to provide
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thyroid blockade. Each mouse was injected with 100 jul radioiodinated long 
chromatin and approximately 50 pi of blood was taken exactly 2 min after injection 
and after a further 15 min, 30 min and 90 min. In order to prevent clotting, all blood 
was taken directly into tubes which had been left uncapped in a 37°C incubator 
overnight following addition of 10 pi of 0.2 M EDTA. The blood was 
microcentrifuged for 5 min and the supernatant (plasma) and pellet were counted 
separately, confirming that over 96% of the radioactivity was in the plasma. 
Twenty-five pi of plasma was removed into a 100 pi tube containing 13 pi of 30% 
TCA. The tubes were microcentrifuged for 5 min and the supernatant was 
discarded. Each pellet (TCA precipitate) was counted in a gamma counter. 
Identical experiments, apart from a difference in chromatin dose injected, were 
performed twice. In the initial experiment approximately 1 pg of chromatin 
equivalent to 100000 CPM was injected per mouse and for the repeat experiment 
approximately 5 pg of chromatin per mouse was given (500000 CPM). The same 
batch of chromatin (also used for the preliminary experiment) was used in both 
experiments.
Comparison of plasma clearance of nucleosomes between SAP-/- and wild-type 
C57BL/6 mice was performed as follows: six female SAP-/- and 6 female, age and 
weight-matched 6-8 week old wild-type C57BL/6 mice were given potassium iodide 
for 48 h prior to injection of chromatin in order to provide thyroid blockade. Each 
mouse was injected with 100 pi of directly radioiodinated nucleosome preparation 
(approximately 1 pg of nucleosomes, 400000 CPM) into the tail vein and was
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serially bled after 2 min and a further 15, 30 and 90 min. The blood was collected 
into EDTA coated tubes, centrifuged and 25 pi aliquots of plasma were precipitated 
with TCA, prior to counting of the pellet alone.
In order to prove that the observed difference in plasma clearance rate of 
nucleosomes between SAP-/- and wild-type mice was due specifically to SAP, 
clearance experiments were repeated comparing 4 groups of mice. There were 5 
weight-matched female mice per group and the groups were as follows: wild-type, 
SAP-/-, SAP-/- after administration of mouse SAP, and SAP-/- after administration 
of human SAP. One ml of TN buffer alone (as a control) was given intraperitoneally 
to each mouse from the first two groups 30 min prior to injection of nucleosomes. 
The latter two groups received 300 pg of mouse SAP in 1 ml of TN buffer and 
300 pg of human SAP in 1 ml of TN buffer respectively, given intraperitoneally to 
each mouse 30 min prior to injection of nucleosomes. As before, mice were bled 
into EDTA-coated tubes 2 min after injection of nucleosomes and 15 min later, and 
TCA precipitates were counted.
In order to determine whether the trapped catabolism method was biologically 
applicable, plasma clearance of TC-labelled nucleosomes was compared with 
directly radioiodinated nucleosomes by injection of 6 female wild-type mice, 
following thyroid blockade. Three mice received 100 pi TC-labelled nucleosomes 
(TCA precipitability 74%) and three age and weight-matched mice received 100 pi 
directly radioiodinated nucleosomes (TCA precipitability 91%). The plasma decay
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kinetics were compared in the two groups by serial bleeds as before. Since only 
74% of the tracer in the TC-labelled nucleosome preparation was associated with 
protein, counting was performed on TCA precipitated material alone.
In order to compare nucleosome catabolism between SAP-/- and wild-type C57BL/6 
mice, organ localisation was examined at two different time points. Organ 
localisation of TC-labelled nucleosomes was examined 24 h after injection in both 
mouse genotypes in order to determine whether SAP has an effect on overall 
contribution to catabolism by each organ. In addition, organ localisation of 
TC-labelled nucleosomes was compared in SAP-/- and wild-type mice 15 min after 
injection, to determine whether SAP influenced the site of catabolism at the time 
point at which it influenced clearance of nucleosomes from the plasma.
Several separate experiments were performed. In each experiment, 100 pi 
TC-labelled nucleosomes (400000 CPM per mouse, as before) were injected into the 
tail veins of 8 female wild-type and 8 female age and weight-matched SAP-/- mice 
that had received thyroid blockade, as before. In the initial experiment the mice 
were anaesthetised 24 h after injection and bled out completely. In two subsequent 
experiments (performed identically), the mice were anaesthetised and bled out 
15 min after injection. In each experiment, the following organs were dissected out 
in their entirety and transferred into individual tubes containing 1 ml of 10% 
buffered formalin; liver, spleen, kidneys, heart, lungs, stomach, intestines and 
adrenal glands. All organs were drained of blood as completely as possible and
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stomach and intestines were cleared of food/debris prior to collection. Each organ as 
well as the blood and carcass of each animal was counted in a gamma counter. The 
counts per organ were expressed as a percentage of the total number of counts 
retrieved per animal.
Binding o f  Pentraxins to Apoptotic Cells 
Cell culture and induction of apoptosis
Jurkhat cells were obtained from Dr MBotto, Department of Rheumatology, 
Hammersmith Hospital and cultured at a cell density of between 2 x 105 and 1 x 106 
cells/ml in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS), 
L-glutamine, penicillin and streptomycin. Apoptosis was induced in different 
experiments, either by ultraviolet (UV) irradiation or by addition of an anti-Fas 
monoclonal antibody. The time course of development of apoptosis was determined 
for each method.
UV irradiation was performed as follows; a Petri dish containing 10 ml of cell 
suspension was placed 2 cm above a UV (312 nm) transilluminator (Ultraviolet 
Products Ltd, Cambridge, UK) for lOmin at 37°C, before being returned to a 
standard incubator. In all cases, a control “non-apoptotic” population of cells were 
placed alongside the UV irradiated cells on a UV shield and subsequently treated 
identically to the apoptotic cells. Cell viability was determined by trypan blue 
exclusion at different time points after UV irradiation and binding experiments were 
performed only on suspensions in which > 95% of cells excluded trypan blue. UV
86
irradiation of Jurkhat cells for > 20 min resulted in < 95% trypan blue exclusion 
within 2 h of irradiation and for < 10 min was insufficient for apoptosis induction. 
Induction of apoptosis with anti-Fas monoclonal antibody, CH11 (Immunotech, 
Marseilles, France), was by incubation with 50 ng/ml of antibody. In all cases, a 
control “non-apoptotic” population of cells was incubated in the absence of anti-Fas 
monoclonal antibody and subsequently treated identically to the apoptotic cells.
Detection of apoptosis and distinction between apoptosis and necrosis
Apoptosis was detected by several methods including DNA laddering, annexin V 
binding, TdT-mediated uridine nick-end labelling (TUNEL staining) and light 
microscopy. Once the different methods had been compared, annexin V staining 
was used most frequently to determine populations of cells undergoing “early” 
apoptosis. Early apoptotic cells were distinguished from late apoptotic or necrotic 
cells by trypan blue or propidium iodide exclusion.
Annexin V staining was performed as follows: 1 x 105 cells were removed from the 
cell culture flask, centrifuged at 150 g and washed in cold HBSS. The cells were 
centrifuged at 150 g, the supernatant was discarded, and they were resuspended in 
100 pi of cold “binding buffer.” Cells were then incubated for 10 min in the dark 
with 1 pi of FITC-annexin V +/- 5 pi propidium iodide. After 10 min, a further 
400 pi of binding buffer was added to the cell suspension and apoptosis determined 
by reading on a flow cytometer (Beckman-Coulter). In cases where annexin V 
staining was not accompanied by incubation of cells with propidium iodide, cells
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were stained with trypan blue and the percentage of cells excluding trypan blue was 
determined.
TUNEL staining was performed using the FragEL apoptosis detection kit. 
Following incubation with the source of SAP or CRP and staining with 
fluorochrome-labelled anti-SAP or anti-CRP antibody, cells were cytospun onto a 
PLL coated slide using a Shandon Cytospin 3, allowed to dry, and fixed in 100% 
ethanol for 2 min. Slides were immersed in TBS buffer for 15 min at room 
temperature and then dried. The cells were permeabilised with 100 pi of proteinase 
K at 20 pg/ml in 10 mM Tris, pH 8 for 5 min and washed in TBS. Each slide was 
incubated for 20 min with 100 pi of TdT equilibration buffer, blotted, and the cells 
were coated in 3 pi of TdT enzyme diluted in 57 pi of fluorescein-TdT labelling 
reaction mix. The cells were covered with parafilm and incubated at 37°C for 
90 min, before being washed 3 times in TBS at RT and counterstained with 2 pi of 
DAPI-containing mounting medium. A coverslip was applied before viewing by 
confocal microscopy. For each experiment, a positive and negative control was 
included which consisted of a slide containing known apoptotic cells (HL-60 cells) 
and a slide to which the TdT enzyme was not applied, respectively.
For detection of apoptotic cells by simple light microscopy, cells were washed in 
fresh RPMI medium and 100 pi of cell suspension was cytospun onto a slide at 
500 rpm for 5 min. The slide was air dried for 30 min before fixation in 100% 
ethanol and staining with filtered haematoxylin for 30 sec, washing in water for
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5 min, and staining in 1% eosin for 2 min. The slides were washed for a further 
2 min in tap water, dehydrated and mounted in the usual fashion, before viewing by 
light microscopy. Small cells with condensed, multi-lobed nuclei were identified as 
apoptotic.
Pentraxin binding to apoptotic Jurkhat cells in suspension
Jurkhat cells that had been UV irradiated were allowed to proceed for 6 h before 
binding studies were performed, since exclusion of trypan blue (confirming 
viability) and presence of apoptosis were present in over 95% and 80% of cells 
respectively, at this time point. Similarly, 6 h after incubation with a monoclonal 
anti-Fas antibody, 95% of Jurkhat cells excluded trypan blue and 88% were 
annexin V positive. Following confirmation of apoptosis, cells were maintained at 
4°C to prevent progression to cell necrosis. Cells (3 x 106) were washed twice in 
cold HBSS, were resuspended and incubated for 30 min at 4°C in either normal 
human serum (NHS) containing a CRP concentration of 0.5 mg/1 and SAP 
concentration of 26 mg/1, acute phase human serum (APHS) containing a CRP 
concentration of 92 mg/1 and SAP concentration of 51 mg/1, or pure SAP at 150 mg/1 
in TCB buffer containing 4% BSA and pure CRP at 1000 mg/1 in TC. In all binding 
experiments, 3 x 106 control cells were simultaneously incubated with the 
appropriate source of SAP and/or CRP in the presence of 10 mM EDTA in order to 
chelate calcium. Specific ligand-binding by pentraxins is calcium dependent, and 
this property was used as a specificity control. After incubation for 30 min, cells 
were washed 3 times in 400 pi of TCB buffer containing 1% BSA (cells incubated in
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the presence of EDTA were washed in TEB buffer containing 1% BSA) before 
staining with fluorescently labelled anti-human SAP or anti-human CRP antibodies.
Staining with fluorochrome labelled anti-human SAP and anti-human CRP
The IgGl fraction of a sheep anti-human SAP antiserum, raised by immunisation 
with isolated, pure human SAP was fluorescently labelled with 
tetramethylrhodamine isothiocyanate (RITC) as follows. The IgG at 40 mg/ml in 
PBS was dialysed overnight at 4°C into 0.5 M sodium carbonate buffer (CB), 
pH 9.5. RITC (mixed isomers) was diluted to 2 mg/ml in CB and added dropwise to 
the IgG while gently stirring at a ratio of 40 pig: 1 mg IgG and stirred overnight at 
4°C. The free fluorochrome was separated from coupled IgG by gel filtration on a 
Sephadex G25 column (PD10, Pharmacia, Milton Keynes, UK) which was 
equilibrated with CB. The IgG conjugate was dialysed overnight at 4°C into 
0.0175 M phosphate buffer (PB), pH 6.3, and was fractionated by ion exchange 
chromatography using DE52 cellulose (Whatman International Ltd, Maidstone, UK) 
which had been equilibrated for pH and conductivity with PB. Fractions were eluted 
stepwise with PB containing 0.125 M, 0.25 M and 0.5 M NaCl. The 
fluorochrome:protein (F:P) ratio and protein concentration were determined for each 
fraction by reading the optical density at A280 and A 51 5 using the Beckmann DU650 
spectrophotometer, and a suitable fraction was selected. The F:P ratio and protein 
concentration of the selected fraction were 2.2:1 and 0.46 mg/ml, respectively. 
Before use, the conjugated rhodamine-anti-human SAP was dialysed against PBS 
containing 0 .1 % sodium azide.
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Specific binding of the RITC-anti-human SAP to CNBr-Sepharose beads to which 
isolated human SAP or CRP had been covalently coupled at 1 mg protein per ml 
beads was used to test the antibody conjugate and determine the appropriate dilution 
for use, with Sepharose beads bearing CRP as the negative control. This was 
performed as follows: sedimented human SAP and CRP beads were diluted 1:10 in 
TC buffer. The RITC-anti-human SAP was diluted 1:2, 1:5, 1:10, 1:20, 1:50, 1:100 
and 1:200 in TC buffer and 50 pi aliquots of each dilution were mixed separately, 
with 50 pi of SAP and CRP bead suspensions, and incubated in the dark for 30 min 
at 37°C with occasional agitation. After 30 min, the mixtures were centrifuged for 
5 min and the supernatants were discarded. The beads were washed 3 times in 1 ml 
of TC buffer, resuspended in 20 pi of TC buffer, and viewed under a fluorescence 
microscope. There was no staining of the beads bearing CRP at any dilution. The 
beads bearing SAP were stained at antibody dilutions of 1:2, 1:5 and 1:10 but 
staining disappeared at dilutions above 1:10. Since there was little background at 
1:5 but excellent fluorescence of the beads, this dilution was selected for optimal 
staining of apoptotic cells.
Fluorescein-labelled sheep anti-human SAP (FITC-anti-human SAP), that had been 
prepared and tested by the same methods, was available in the laboratory.
The IgG fraction of a goat anti-human CRP antiserum, raised by immunisation with 
isolated pure human CRP, was fluorescently labelled with fluorescein (FITC) as 
follows. The IgG was dialysed overnight at 4°C into 0.1 M sodium phosphate
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buffer, pH 9.5. Fluorescein isothiocyanate (isomer 1) was diluted to 2 mg/ml in 
0.1 M phosphate buffer and added dropwise to the IgG while gently stirring at a ratio 
of 50 pig: 1 mg IgG and stirred overnight at 4°C. The free fluorochrome was 
separated from coupled IgG by gel filtration on a Sephadex G25 column (PD10, 
Pharmacia, Milton Keynes, UK) which was equilibrated with 0.1 M phosphate 
buffer. The FITC-IgG conjugate was dialysed overnight at 4°C into 0.01 M 
phosphate buffer, pH 7.6, and was fractionated by ion exchange chromatography 
using DE52 cellulose (Whatman International Ltd, Maidstone, UK) which had been 
equilibrated for pH and conductivity with 0.01 M phosphate buffer. Fractions were 
eluted stepwise with 0.01 M phosphate buffer containing 0.2%, 0.4%, 0.8%, 1%, 
2%, 5% and 0.4 M phosphate buffer. The fluorochromeiprotein (F:P) ratio and 
protein concentration were determined for each fraction by reading the optical 
density at A 2 8 0  and A 4 9 5  using the Beckmann DU650 spectrophotometer, and a 
suitable fraction was selected. The F:P ratio and protein concentration of the 
selected fraction were 3.5:1 and 2.73 mg/ml, respectively. Before use, the 
conjugated FITC-anti-human CRP was dialysed against PBS containing 0.1% 
sodium azide.
Specific binding of the FITC-anti-human CRP to Sepharose beads bearing human 
CRP was used to test the antibody conjugate and determine the appropriate dilution 
for use, with Sepharose beads bearing SAP as the negative control. The method was 
identical to that for the RITC-anti-human SAP. Staining of the beads bearing SAP 
was absent at all dilutions but staining of beads bearing CRP was present at 1:2, 1:5,
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1:10 and 1:20 but staining disappeared at dilutions above 1:20. Since there was little 
background at 1:10 but excellent fluorescence of the beads, this dilution was 
selected for optimal staining of apoptotic cells.
Suspensions of apoptotic cells (3 x 106 cells per sample) on ice were stained by 
incubation in the dark for 30 min in 25 pi per sample of a 1:5 dilution in TC buffer 
of RITC-anti-human SAP, or a 1:10 dilution in TC buffer of FITC-anti-human CRP, 
or a 1:50 dilution in TC buffer of FITC-anti-human SAP. After 30 min, the cells 
were washed 3 times in 400 pi of TC buffer before being examined and counted by 
microscopy and/or flow cytometry. In all experiments, a separate control sample of 
apoptotic cells was simultaneously incubated with antibody which had previously 
been absorbed with the respective immobilised pure antigen. This was performed as 
follows: sedimented beads bearing the pure antigen were incubated with the 
fluorescent antibody at an antigen:antibody ratio of > 10:1 for 30 min at 37°C and 
then overnight at 4°C with constant rotation. The beads were centrifuged and the 
supernatant was removed and diluted to the required dilution in TC. Cells were 
incubated with 25 pi of the appropriately diluted supernatant as a negative control in 
order to demonstrate specificity of the fluorochrome-labelled antibody for the 
desired antigen.
Competition between SAP and CRP for ligands on the surface of apoptotic cells
In order to determine whether there is competition between SAP and CRP for ligands 
on the surface of apoptotic cells, SAP binding was determined in the presence of
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increasing concentrations of CRP, and CRP binding was determined in the presence 
of increasing concentrations of SAP. Apoptosis was induced in Jurkhat cells by 
incubation for 6 h  with anti-Fas monoclonal antibody, as before. For each 
experiment a total of seven samples each containing 3 x 106 apoptotic cells, were 
incubated at 4°C for 30 min with different concentrations of SAP and CRP, and SAP 
and/or CRP binding was determined, as before.
When examining SAP binding, a single sample of 3 x 106 cells was incubated with 
SAP (at a concentration of 150 mg/1 in TCB containing 4% BSA) in the absence of 
CRP. Each of five further samples of cells (3 x 106 cells per sample) were incubated 
with NHS containing SAP at a concentration of 26 mg/1 and the following 
concentrations of CRP respectively; 0.5 mg/1, 1 mg/1, 10 mg/1, 100 mg/1 and 
1000 mg/1. As a negative control, SAP binding was determined after incubation of 
apoptotic cells with CRP alone in TC at 1000 mg/1 (in the absence of SAP).
When examining CRP binding, several separate samples each containing 3 x 106 
apoptotic Jurkhat cells were incubated for 30 min in 50 pi of human serum containing 
CRP at a concentration of 50 mg/1 and the following concentrations of SAP 
respectively; 0.5 mg/1, 1 mg/1, 10 mg/1, 100 mg/1 and 150 mg/1. As a negative control, 
CRP binding was determined after incubation of apoptotic cells with SAP alone in 
TCB at 150 mg/1 (in the absence of CRP).
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Immune Response to Administration o f  Syngeneic Apoptotic 
Thymocytes in vivo
Thymocyte extraction and apoptosis induction
Thymocytes were obtained from 6-8 week old SAP-/- mice of the inbred strain to be 
injected. Mice were killed by CO2 inhalation and the thymus gland was immediately 
exposed, excised whole and transferred into 5 ml of serum-free RPMI medium on
Q
ice. Assuming a yield of 1 x 10 thymocytes per mouse, the required number of 
thymus glands were then transferred into 10 ml per thymus of fresh ice cold 
serum-free medium in a class II flow cabinet (Envair Ltd, Rossendale, UK). Each 
thymus gland was gently crushed with as little shearing as possible, and the cell 
suspension was pipetted through a tea strainer into a sterile tube. The cell density 
was determined using a cytometer and the cells were centrifuged at 150 g at 4°C for 
5 min. The supernatant was discarded and the cells were resuspended in fresh 
serum-free RPMI medium at a density of 1 x 107 cells/ml and transferred to a cell 
culture flask. The thymocytes were then cultured in an incubator at 37°C containing 
10% CO2 for 6-12 h (until detection of apoptosis). Apoptosis was initially 
determined by several methods, as before (figure 2.2). Once these had been 
compared, annexin V staining alone was used since this was found to be an early 
indicator of apoptosis, particularly in the absence of coexistent staining with 
propidium iodide or trypan blue. Annexin V staining was performed as before.
Intravenous administration of apoptotic cells
Apoptotic thymocytes were centrifuged at 150 g for 5 min at 4°C, the supernatant 
was discarded and the cells resuspended at a density of 1 x 108 cells/ml in cold,
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Figure 2.2 Confirmation of thymocyte apoptosis by A) flow cytometry and
B) agarose gel electrophoresis A) Annexin V (green) and propidium iodide 
(red) staining at T=0 (left) T=4 hours (middle) and T=8 hours (right) after 
removal from the animal and culture in serum-free medium. B) 
Characteristic DNA laddering associated with apoptosis after ex vivo culture 
of thymocytes for 4 and 8 hours. There was no laddering at T=0 hours. The 
lane on the left (M) is a control sample containing DNA fragments of 
repeating lengths of 1 kb to a maximum of 12 kb.
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sterile PBS buffer. A 100 j j ,1 aliquot of the cell suspension (1 x 108 cells/ml) was 
injected into the tail vein of each mouse weekly for 4 weeks. Non-apoptotic 
thymocytes were obtained for intravenous injection using the same method, but were 
re-suspended in cold PBS for injection without prior incubation. Mice were bled 
prior to the first injection and 2, 4, 6 and 8 weeks later, at which time they were 
sacrificed and the kidneys obtained for renal histology.
All sera were tested for ANAs, and sera from day 28 were additionally screened for 
antibodies to dsDNA, chromatin and ssDNA. Kidneys were fixed in Bourn’s 
solution, stained with PAS and viewed blind by Professor HT Cook, as before.
For comparison of the autoimmune response between SAP-/- and wild-type C57BL/6 
mice, results from 2 identical experiments were pooled. Importantly, the mice in both 
experiments were the same age at the time they received their first intravenous 
injection (Day 0), and the experimental protocol was identical in each experiment. In 
total, 26 female and 9 male SAP-/- C57BL/6 mice and 20 female and 10 male age and 
weight-matched wild-type C57BL/6 mice were injected.
For comparison of the autoimmune response between SAP-/-, wild-type and 
SAP-/-, human SAP transgenic C57BL/6 mice, each of 16 female SAP-/- mice, 10 
female wild-type and 16 female SAP-/-, human SAP transgenic mice were injected 
with apoptotic thymocytes, as before.
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For comparison of the immune response between SAP-/- and wild-type 129/Sv mice, 
each of 17 (9 males and 8 females) SAP-/- mice and 17 (9 males and 8 females) 
wild-type mice, were injected with apoptotic thymocytes, as before.
Macrophage Ingestion o f Apoptotic Mouse Thymocytes in vivo
Thymocytes were obtained from SAP-/- or wild-type 6-8 week old C57BL/6 mice as 
before. In order to speed development of apoptosis, 2 pM dexamethasone was 
added to the serum-free RPMI culture medium containing the thymocytes. 
Apoptosis was detected by flow cytometry after 4 h by staining with annexin V and 
propidium iodide, as before (figure 2.3).
For each experiment, 6 female SAP-/- and 6 female age- and weight-matched 
wild-type mice were injected intraperitoneally with 1 ml of sterile 3% thioglycollate 
to induce sterile peritonitis. Three days later, mice were injected intraperitoneally 
with 2 x 1 0  apoptotic murine thymocytes in 200 pi of PBS buffer. In all 
experiments, mice were killed after 30 min and peritoneal cells were recovered by 
lavage with 6 ml of ice cold HBSS. The 30 min time point was based on 
comparable experiments reported by Taylor and colleagues in which the full time 
course was studied [279]. The cells were washed in serum-free RPMI medium and 
further diluted to a final concentration of 1 x 105 cells/ml, before being cytospun 
onto a slide and air dried for 30 min. The specimens were fixed in 100% methanol 
for 10 min before immersion in May-Griinwald stain 0.3% w/v for 10 min. They 
were then stained in 10% Giemsa in Sorensens buffer for 15 min and washed in
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Figure 2.3 Time course of apoptosis induction in mouse thymocytes after incubation 
with 2 |iM dexam ethasone. Staining with annexin V and propidium iodide are shown on 
the x and y axis, respectively. A-E) Staining of late apoptotic cells demonstrating flow 
cytometer settings A) Absence of signal in the absence of staining B) Annexin V signal 
alone and C) PI signal alone, when stained with each reagent, respectively D) Staining 
of late apoptotic cells and E) Staining of cells exposed to formaldehyde, with both 
Annexin V and PI F-l) Time course of apoptosis showing that after 4 hours of 
incubation with 2 pM dexam ethasone, 38% of cells were annexin V positive and PI 
negative (early apoptotic) and 27% were positive for both (late apoptotic).
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Sorensens buffer, pH 6.8 for 4 min before being air dried and mounted in DPX 
mountant. Slides were viewed by brightfield light microscopy using the Leica 
CTRMic. Macrophages were easily recognisable and distinguishable from 
lymphocytes. Phagocytosis was scored on coded cytospins of stained cells, and was 
expressed as the percentage of macrophages ingesting apoptotic cells. Apoptotic 
cells were considered phagocytosed when > 50% of the cell volume was contained 
within the border of the macrophage, although this may underestimate the level of 
phagocytosis [335]. Between 200 and 300 macrophages were scored in each 
sample. Three identical replicate experiments were performed with injection of 
SAP-/- apoptotic thymocytes and wild-type apoptotic thymocytes injected into each 
genotype, respectively.
Macrophage Ingestion o f  Apoptotic Human Lymphocytes in vitro
Peripheral blood mononuclear cells were isolated from healthy donors as follows. 
Venous blood (30 ml) was taken into citrated tubes, and 5 ml volumes were gently 
layered onto 4 ml volumes of Lymphoprep™ (Nycomed Pharma, Oslo, Norway) in 
15 ml plastic centrifuge tubes. The tubes were centrifuged at 800 g for 20 min at 
4°C and the interface containing lymphocytes and monocytes was removed and 
inserted into a single 50 ml tube. Cold, sterile PBS was added to a final volume of 
50 ml and the cells were centrifuged at 350 g for 10 min. The supernatant was 
discarded and the cells were washed with 25 ml fresh PBS before centrifugation and 
removal of the supernatant. Cells were re-suspended in 5 ml of cold DMEM 
medium, counted and diluted in further DMEM to a final concentration of
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4 x 106 cells/ml. A sterile 13 mm glass coverslip was added to the base of each well 
of a 24-well plate and 200 pi of the cell suspension was pipetted onto each coverslip. 
The cells were incubated for 2 h at 37°C and washed 3 times with 1 ml per well of 
fresh, warm DMEM medium to remove any non-adherent cells. Differentiated, 
elongated macrophages were ready for use after 7 days of culture in DMEM 
medium.
Jurkhat cell apoptosis was induced by culturing cells in the presence of anti-Fas 
monoclonal antibody as described earlier. Apoptosis was confirmed by annexin V 
binding and cells were incubated with human serum as a source of SAP as described 
earlier. For comparison, cells were incubated with SAP in the presence of 10 mM 
EDTA. Binding of SAP (and absence of SAP binding in the samples incubated in 
the presence of EDTA) was confirmed by incubation of cells with anti-human SAP 
and microscopy as described earlier.
SAP-coated apoptotic Jurkhat cells (and apoptotic cells not coated in SAP for 
comparison) were re-suspended in serum-free DMEM containing 2mM calcium 
chloride at 1.5 x 107 cells/ml, and 200 pi of the cell suspension was incubated for 1 h 
at 37°C with each well of washed macrophages. After 1 h the coverslips were 
removed from each well into a histology cassette, washed 3 times in cold PBS, and 
stained with Giemsa overnight before dehydration and mounting, cell side down, 
onto a slide.
Slides were viewed blind and results were expressed as the percentage of 
macrophages ingesting apoptotic cells. In each sample between 200 and 300 
macrophages were counted. Apoptotic cells were considered phagocytosed when 
more than 50% was contained within the border of the macrophage. Three identical 
replicate experiments were performed, although an additional negative control 
consisting of incubation of macrophages with non-apoptotic Jurkhat cells was 
performed in a single experiment, as well as the standard negative control of 
incubation of macrophages in the absence of Jurkhat cells.
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Chapter 3 -  Spontaneous Phenotype Of 
SAP Knockout Mice
INTRODUCTION
Chromatin and other nucleic acid-protein complexes are primary targets of 
pathogenic autoantibodies in the prototypic systemic autoimmune disease systemic 
lupus erythematosus (SLE). There are several lines of evidence to suggest that the 
autoimmune response in SLE is antigen driven which include association of disease 
with particular MHC class II alleles [260,264], the nature of the autoantibodies in 
SLE [261,262], and the abrogation of disease in mouse models with a variety of 
antibodies that interfere with T cell interactions [263,265-267]. Native DNA is 
poorly immunogenic and DNA-proteins complexes are now believed to be the major 
immunogen in SLE [269-272,274].
Nucleosomes and chromatin are released into the circulation by apoptotic cell death; 
however, little is known about the mechanisms of their clearance. Recent evidence 
suggests that the pentraxin family of plasma proteins may have an important in vivo 
role in clearance of nucleosomes and chromatin.
Serum amyloid P component (SAP) is the major calcium-dependent specific DNA 
binding protein in the serum [60], and, under physiological conditions, solubilises 
native long chromatin by binding to DNA and displacing histone HI [61]. SAP also
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binds to exposed chromatin in vivo, for example in skin lesions of patients with SLE 
[299], and to dermal keratin bodies, which are apoptotic keratinocytes, in normal 
skin [300]. It has been claimed that CRP also binds to chromatin, but as originally 
reported by DuClos [307], CRP from whole serum binds exclusively to small 
nuclear ribonucleoprotein particles under physiological conditions in vitro, and 
presumably also in vivo [62].
In a number of autoimmune diseases, such a rheumatoid arthritis, Crohn’s disease 
and rheumatic fever, CRP concentration is the single most sensitive objective 
criterion of activity of disease [151,152,315,316]. In marked contrast to most 
autoimmune disorders, disease activity in SLE with severe symptoms and continuing 
tissue damage, is associated with CRP levels which are raised only modestly, despite 
other tests for active inflammation being positive [110,156]. The mechanism for this 
apparently inappropriate failure of production in SLE is not known. An intriguing 
possibility is that the capacity to respond to particular forms of inflammation, tissue 
injury or other stimuli by production of CRP is genetically determined, and that 
CRP-responder status could contribute to hereditary predisposition to SLE.
Few studies have investigated the role of pentraxin binding to nuclear antigens 
in vivo. In the (NZB x NZW)Fi female hybrid mouse model of SLE, the 
autoimmune phenotype was reportedly accelerated by intraperitoneal injections of 
chromatin, and the effect was abrogated by co-injection of CRP [320]. However the 
results in this paper do not robustly support the authors’ conclusions. The
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spontaneous phenotype of mice with targeted deletion of the SAP gene was first 
reported from our laboratory [232]. A cohort of (129/Svx C57BL/6)F2 SAP 
deficient mice were noted to spontaneously develop antinuclear autoimmunity, 
including anti-chromatin, anti-histone and anti-DNA antibodies, with 41% of 
deficient females mice developing immune complex glomerulonephritis. The 
clearance of administered chromatin was also reported to be faster in SAP deficient 
animals compared to their wild-type counterparts. However, these studies were 
performed in an inevitably genetically heterogeneous group of mice, and whether 
SAP deficiency in pure-line mice is associated with autoimmunity has not been 
previously reported.
The present results demonstrate that SAP deficiency is indeed importantly associated 
with development of autoimmunity, but highlight simultaneously, the complexity of 
the genotype-phenotype relationship in SLE, and its dependence upon the interaction 
of multiple genetic loci. Pure-line C57BL/6 mice with targeted deletion of the SAP 
gene spontaneously developed antinuclear autoimmunity and glomerulonephritis, a 
phenotype closely resembling human SLE. However, SAP deficiency in the 129/Sv, 
“non-autoimmune” strain of mouse was insufficient to cause the lupus-like 
phenotype.
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SPONTANEOUS DEVELOPMENT OF AUTOIMMUNITY IN 
PURE-LINE C57BL/6 SAP DEFICIENT MICE
The deleted SAP gene was backcrossed for 6 generations onto the inbred C57BL/6 
mouse strain by Dr M Botto, Department of Rheumatology, Imperial College School 
of Medicine to produce “pure-line” C57BL/6 SAP deficient mice. A cohort of 312 
C57BL/6 mice, 154 males (49.4%) and 158 females (50.6%) were followed for 12 
months, all housed under identical conditions. One hundred and three (33%) of the 
mice were wild-type (WT), of which 50 were female and 53 were male; 104 (33.3%) 
were heterozygous for deletion of the SAP gene (SAP+/-), of which 53 were female 
and 51 were male; and 105 (33.7%) were homozygous for the SAP gene deletion 
(SAP-/- or SAP deficient), of which 55 were female and 50 were male.
During the course of follow up 3 wild-type mice were lost, one at < 3 months of age, 
one between 6 and 9 months and one between 9 and 12 months of age. One wild- 
type mouse was killed at 10 months due to rectal prolapse. One heterozygous mouse 
was lost between 6 and 9 months of age, and one was killed at 3 months due to an 
ear infection. Three SAP-/- mice were lost, one between 3 and 6 months of age, one 
between 6 and 9 months, and one between 9 and 12 months of age. Two further 
SAP-/- mice were found dead, one at less than 3 months of age, and one at 7months. 
Two SAP-/- mice were killed due to skin injuries at 6 and 10 months, and one at 11 
months because of an ear infection. All other mice were healthy until they were 
killed by exsanguination at 12 months of age. Mice killed between 9 and 12 months 
of age were included in the 12 month analysis.
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All available mice were bled from the tail vein at 6 months of age and a 
representative sample of 215 and 219 mice were bled at 3 and 9 months respectively. 
All mice were killed by bleed out from the axillary artery at 12 months of age before 
harvesting the following organs in each case: liver, spleen, kidneys, heart, lungs, 
salivary gland, aorta, stomach, small intestine, large intestine.
Serological Analysis
Serum obtained at 3, 6, 9 and 12 months was tested for the presence of anti-nuclear 
antibodies (ANAs). Samples were screened at a dilution of 1/80 and titrated to 
end-point. ANA staining was always homogeneous. At 3 months of age ANAs 
were present in 7.6% SAP-/- mice (5 of 66) at a titre of 1/80, and none of 57 SAP+/- 
mice and 91 wild-type mice (P = 0.004, Chi-squared test). Presence and titre of 
ANAs increased over time in the majority of mice, but particularly in SAP deficient 
animals (figure 3.1). Information on ANA titres at both 3 months and 12 months 
was available in 211 mice. In this subgroup, titres increased in 127 (60.2%) and 
remained the same in 74 (39.8%); no mouse showed a drop in titre over this period 
(P = 0.0001, Sign rank test). By six months of age ANAs were present in 5.9% of 
wild-type mice (median = 0; range = 0-1/320), 30.1% of SAP+/- mice (median = 0; 
range = 0-1/640) and 82.8% of SAP-/- mice (median = 0; range = 0-1/640) 
(P = 0.001, Chi squared test) and by 9 months of age 8.6% (median = 0; 
range = 0-1/1280), 37.5% (median = 0; range = 0-1/640) and 95.7%
(median = 1/160; range = 0-1/1280) of wild-type, SAP+/- and SAP-/- mice, 
respectively (P = 0.001).
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Figure 3.1 Time course of development of anti-nuclear autoantibodies 
(ANAs) in C57BL/6 mice according to genotype. Presence and titre of 
ANAs increased over time in the majority of mice, but particularly in SAP 
deficient animals. Among 211 mice in which ANA titres were determined at 
both 3 and 12 months of age, titres increased in 127 (60.2%) and 
remained the same in 74 (39.8%); no mouse experienced a drop in titre 
over this period (P = 0.0001, Sign rank test).
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At 12 months of age ANAs were found in 31% of wild-type mice (median = 0; 
range = 0-1/1280), 56.9% of SAP+/- mice (median = 1/80; range = 0-1/1280) and 
92% of SAP-/- mice (median = 1/640; range = 0-1/2560) (P = 0.001, Chi-squared 
test) with significantly higher titres among SAP-/- compared to SAP+/- mice, and, in 
turn, SAP+/- compared to wild-type animals (P = 0.0001, Mann-Whitney U test) 
(figure 3.2).
At 12 months of age ANAs were detected in 40% (20/50) of female wild-type mice 
(median = 0; range = 0-1/1280), 64.2% (34/53) of female SAP+/- mice
(median = 1/80; range = 0-1/1280) and 88.2% (45/51) of female SAP-/- mice 
(median = 1/640; range = 0-1/2560) (P = 0.001, Chi-squared test; P = 0.0001, 
Mann-Whitney U test). ANAs were detected in 22% (11/50) of male wild-type mice 
(median = 0; range = 0-1/640), 49% (24/49) of male SAP+/- mice (median = 0; 
range = 0-1/1280) and 97.9% (47/48) of male SAP-/- mice (median = 1/640; 
range = 0-1/2560) (P = 0.001, Chi-squared test; P = 0.0001, Mann-Whitney U test) 
(figure 3.3).
The remaining serological analyses were carried out only on serum obtained at 12 
months of age.
Anti-dsDNA antibodies were analysed by indirect immunofluorescence using slides 
coated with Crithidia luciliae as a substrate. Samples were screened at a dilution of 
1/20 and titrated to end point. Titres of 1/20 or above were considered positive. At
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Figure 3.2 Anti-nuclear antibody (ANA) titres at 12 months of age in 
wild-type (WT) C57BL/6 mice compared to mice heterozygous 
(SAP+/-) and mice homozygous (SAP-/-) for deletion of the SAP gene. 
There were more SAP-/- mice with ANAs compared to WT mice, with 
SAP+/- mice intermediate between them (Chi-squared test, P<0.001), 
and there was a progressive increase in ANA titres from wild-type to 
SAP+/- to SAP-/- mice (Mann-Whitney U test, P<0.0001).
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Figure 3.3 Anti-nuclear antibody (ANA) titres at 12 months of age in female 
and male wild-type (WT) C57BL/6 mice compared to mice heterozygous 
(SAP+/-) and homozygous (SAP-/-) for deletion of the SAP gene. There 
were more SAP-/- mice of both sexes with ANAs compared to wild-type mice, 
with SAP+/- mice intermediate between them (Chi-squared test, P=0.001), 
and there were higher ANA titres in SAP deficient mice of both sexes 
compared to SAP+/- and wild-type mice (Mann-Whitney U test, P=0.0001).
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12 months of age significantly increased anti-dsDNA antibody titres were seen in 
64.7% (33/51) of female SAP-/- mice (median = 1/20; range = 0-1/80), compared to 
26.4% (14/53) of female SAP+/- mice (median = 0, range = 0-1/80) and 6% (3/50) 
of female wild-type mice (median = 0, range = 0-1/80) (P = 0.001, Chi-squared test). 
Anti-dsDNA antibodies were present in 39.6% (19/48) of male SAP-/- mice 
(median = 0; range = 0-1/80), compared to 18.4% (9/49) of male SAP+/- mice 
(median = 0, range = 0-1/80) and 12% (6/50) of male wild-type mice (median = 0, 
range = 0-1/80) (P = 0.001, Chi-squared test) (figure 3.4).
Antibodies to histones, chromatin and ssDNA were all measured by 
immunoradiometric assay (IRMA) and results expressed in arbitrary units based on a 
standard of pooled serum from MRL/Mp-lpr/lpr mice, as described in Materials and 
Methods. The dilutions used in each assay are outlined in Materials and Methods.
Significantly higher titres of anti-histone antibodies were seen in male SAP-/- mice 
(median =13.5 units) (figure 3.5) compared to their SAP+/- (median = 8 units) and 
wild-type (median = 8 units) counterparts (P = 0.01, and P = 0.009 respectively, 
Mann-Whitney U test). There were no significant differences in anti-histone 
antibody titres between the three groups of female mice (P = 0.1, Mann-Whitney U 
test).
Significantly higher titres of anti-chromatin antibodies were seen in male and female 
SAP-/- mice (males: median = 39 units, range = 0-169; females:
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Figure 3.4 Anti-dsDNA antibody titres in female and male wild-type (WT) 
C57BL/6 mice compared to mice heterozygous for deletion of the SAP gene 
(SAP+/-) and mice homozygous for the SAP gene deletion (SAP-/-). There 
were significantly more female and male SAP-/- mice with anti-dsDNA 
antibodies compared to wild-type mice, with SAP+/- mice intermediate 
between them (Chi-squared test, P=0.003 for males and 0.001 for females).
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Figure 3.5 Anti-histone antibody titres at 12 months of age in wild-type (WT) 
C57BL/6 mice compared to mice heterozygous (SAP+/-) and mice 
homozygous (SAP-/-) for the SAP gene deletion. Significantly higher titres of 
anti-histone antibodies were seen in male SAP-/- mice compared to their 
wild-type (Mann-Whitney U test, P=0.0009) and SAP+/- (Mann-Whitney U 
test, P=0.01) counterparts. However, there was no significant difference in 
anti-histone antibody titres between female SAP-/- and wild-type mice 
(Mann-Whitney U test, P=0.1).
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median = 36.5 units, range = 0-365) compared to SAP+/- mice (males: 
median = 5 units, range = 0-49; females: median =12 units, range = 0-98)
(P < 0.0001 for both sexes, Mann-Whitney U test), and in male and female SAP+/- 
mice compared to wild-type mice (males: median = 2.5 units, range = 0-49; females: 
median = 3 units, range = 0-240) (females, P <  0.0001; males, P <  0.005) 
(figure 3.6).
Significantly higher titres of anti-ssDNA antibodies were seen in male and female 
SAP-/- mice (males: median = 2.4 units, range = 0-22; females: median = 3.8 units, 
range = 0-26) compared to wild-type mice (males: median = 0 units, range = 0-7; 
females: median =1.1 units, range = 0-9.8) (females, P < 0.0001; males, P < 0.003, 
Mann-Whitney U test). Interestingly, there were no significant differences in 
anti-ssDNA antibody titres between SAP-/- and SAP+/- mice of either sex (males, 
P = 0.6 and females, P = 0.2) (figure 3.7).
In order to analyse the relationship between the different autoantibodies detected, the 
presence and titres of antibodies from the cohort of SAP-/- mice were compared. 
The most significant correlation was between presence of ANAs and anti-chromatin 
antibodies (males: rsp = 0.77; females: rsp = 0.85).
In order to exclude the possibility of direct competition between SAP and 
autoantibodies for their respective nuclear antigens as an artefactual cause of 
apparently increased autoantibody titres in SAP-/- mice, autoantibody titres were
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Figure 3.6 Anti-chromatin antibody titres at 12 months of age in wild-type (WT) 
C57BL/6 mice compared to SAP+/- and SAP-/- mice. Significantly higher titres 
were seen in both male and female SAP-/- mice compared to SAP+/- mice 
(Mann-Whitney U test, P<0.0001), and in SAP+/- mice compared to wild-type 
mice (females, P<0.0001; males, P<0.005).
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Figure 3.7 Anti-ssDNA antibody titres at 12 months of age in wild-type (WT) 
mice compared to SAP+/- and SAP-/- mice. Significantly higher titres were 
seen in both male and female SAP-/- mice compared to their wild-type 
counterparts (Mann-Whitney U test; females, P<0.0001 and males, P<0.003).
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compared in SAP-/- serum before and after addition of pure mouse SAP at 
concentrations of 8.7 pg/ml and 87 pg/ml. There was no significant changes in 
anti-nuclear, anti-dsDNA, anti-histone, or anti-chromatin antibody titres following 
addition of mouse SAP (table 3.1), thus excluding direct competition between SAP 
and autoantibodies for antigen.
Urinary Analysis
At 12 months of age, urine was collected from each mouse over the 24 hours prior to 
exsanguination. There was no significant difference in creatinine clearance between 
wild-type mice (males: median = 0.10 mls/min, range = 0.03-0.18; females: 
median = 0.08 mls/min, range = 0.03-0.16), SAP+/- mice (males: 
median = 0.11 mls/min, range = 0.03-0.26; females: median = 0.10 mls/min,
range = 0.04-0.17) or SAP-/- mice (males: median = 0.10 mls/min,
range = 0.02-0.21; females: median = 0.09 mls/min, range = 0.04-0.14) of either sex 
(P = 0.1, Mann-Whitney U test) (figure 3.8).
Albuminuria was determined by radial immunodiffusion, and was not significantly 
different between WT mice, SAP+/- mice and SAP-/- mice of either sex. The vast 
majority of mice had albuminuria of < 50 pg/ml (the lower limit of detection of the 
assay), which is considered normal for mice [336].
Autoantibody Coded serum 
number
No mouse SAP + 8.7 pg/ml mouse SAP + 87 pg/ml mouse SAP Change
Immunofluorescent assay Titre Titre Titre
ANA 160 1/2560 1/2560 1/2560 Nil
165 1/320 1/320 1/320 Nil
Anti-dsDNA 160 1/80 1/80 1/80 Nil
165 1/20 1/20 1/20 Nil
Immunoradiometric assay Counts per minute Counts per minute Counts per minute
Anti-histone 160 4418 4151 4040 <-10%
165 1389 1259 1541 <+/-10%
Anti-chromatin 160 9440 9493 9595 < +2%
165 1445 1409 1417 < -3%
Table 3.1 Comparison of autoantibody titres in serum from two SAP-/- mice before and after addition of 87 pg/ml or 
8.7 pg/ml of pure mouse SAP. There was no significant change in antibody titres in the presence of SAP, thus excluding 
direct competition by SAP for antigen as an artefactual cause of apparently increased autoantibody titres in SAP deficient 
mice compared to wild-type animals.
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Figure 3.8 Creatinine clearance at 12 months of age according to genotype 
in female (A) and male (B) C57BL/6 mice. There was no significant 
difference between the creatinine clearance values in any of the genotypes in 
either sex.
Histology
In human SLE, anti-dsDNA and other antibodies are responsible for the immune 
complex vasculitis which underlies the pathology of the disease in the kidney and 
other organs.
Renal histology
Renal histology was examined in all mice. Coded sections of renal tissue were 
examined by Professor HT Cook, Department of Histopathology, Hammersmith 
Hospital, for the presence of glomerulonephritis as described in Materials and 
Methods.
At 12 months of age, glomerulonephritis was present in 75% of female SAP-/- mice, 
compared to 43% of female SAP+/- mice (P < 0.0001, Chi-squared test) and 16% of 
female wild-type mice (wild-type vs SAP+/- mice: P <  0.0001, Chi-squared test). 
Glomerulonephritis was less common and less severe in male mice, being present in 
28% of SAP-/- mice, compared to 20% of SAP+/- mice and none of the wild-type 
SAP+/+ mice (wild-type vs SAP-/- mice: P < 0.0001 Fisher’s exact test). Moderate 
or severe glomerulonephritis (grade II or III) was present in 38% of female SAP-/- 
mice compared to 9% of SAP+/- and 2% of wild-type females (P < 0.0001, Mann- 
Whitney U test), and in 6% of male SAP-/- mice, compared to none of the SAP+/- or 
SAP+/+ males (figure 3.9 and 3.10a).
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Figure 3.9 Glomerulonephritis at 12 months of age in female (A) and male 
(B) C57BL/6 mice. There was a highly significant increase in presence 
and severity of glomerulonephritis in SAP-/- mice compared to SAP+/- 
mice, and in SAP+/- mice compared to wild-type mice, with increased 
presence and severity of glomerulonephritis in females compared to 
males.
On univariate analysis, moderate/severe glomerulonephritis in female mice was 
associated with the presence (P = 0.001) and titre (P < 0.0005) of ANAs from 6 to 
12 months of age. Moderate/severe glomerulonephritis in female mice was also 
significantly associated with presence of anti-dsDNA antibodies (P = 0.001) and 
higher titres of anti-chromatin (P = 0.0001, median 26.8 vs 4.7 units) and 
anti-histone antibodies (P = 0.05, median 15.6 vs 12.6 units). Similarly, among male 
mice, moderate/severe glomerulonephritis was significantly associated with presence 
(P < 0.005) and titre (P < 0.01) of ANAs from 6 to 12 months of age, presence of 
anti-dsDNA antibodies (P = 0.005), and higher titres of anti-chromatin antibodies 
(P = 0.002, median 16.1 vs 4.7 units) and anti-histone antibodies (P = 0.004, median 
15.1 vs 8.7 units). In addition, among males there was an association between high 
anti-ssDNA antibody titre and moderate/severe glomerulonephritis (P = 0.01, 
median 2.7 vs 1.9 units). Interestingly, there was no significant 
correlation/association between creatinine clearance or albuminuria and the presence 
of moderate/severe glomerulonephritis histologically.
Using a multivariate logistic regression model to assess relationships between all 
variables and moderate/severe glomerulonephritis, SAP-/- and SAP+/- mice were 
11.5 (P = 0.0001) and 4 (P = 0.006) times more likely respectively, to have 
glomerulonephritis than wild-type mice. Similarly, females were 12 times more 
likely to have moderate/severe glomerulonephritis than males (P = 0.0001).
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Representative samples of mouse kidney with and without glomerulonephritis were 
chosen, and the presence of immune complexes in the glomeruli was sought by 
direct immunofluorescence using sheep anti-mouse total IgG and goat anti-mouse 
C3. There was deposition of both IgG and C3 in the glomeruli of all mice with 
glomerulonephritis on light microscopy, but interestingly, IgG and C3 were also 
present in the glomeruli of mice with normal light microscopy. Staining was 
completely abolished by prior absorption of each antibody with pure antigen, 
confirming the specificity of fluorescent staining (figure 3.10b).
Electron micrographs of selected mouse kidneys in which there was severe 
glomerulonephritis on light microscopy showed markedly increased mesangial 
matrix accompanied by immune complex deposition (figure 3.10c).
Extra-renal histology
Histological abnormalities were sought in coded sections of skin, heart, lungs, liver, 
aorta, stomach, small and large intestine and salivary gland in all mice by Professor 
HT Cook, Department of Histopathology, Hammersmith Hospital and coded 
sections of spleen were examined by Dr R Hasseqian, Department of 
Histopathology, Hammersmith Hospital as described in Materials and Methods.
The skin, heart, stomach, aorta and small and large intestines were all histologically 
normal in over 99% mice, regardless of SAP genotype. Lymphoid infiltrates were 
present in the livers of 19.3% male and 28.1% female mice, in the lungs of 4.1%
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Figure 3.10 Glomerulonephritis in SAP-/- C57BL/6 mice.
A) Glomerulus with normal morphology (left) from a wild-type mouse. 
Haematoxylin and eosin staining, x250. Enlarged glomerulus from 
SAP-/- mouse (right), showing proliferative glomerulonephritis with 
increased mesangial matrix and marked hypercellularity with mononuclear 
cells in capillary loops. x250 B) Immunofluorescence staining with 
anti-mouse IgG (left) showing the granular appearance typical of immune 
complex deposition. Absence of immunofluorescence staining (right) 
following fluid-phase absorption of the fluorescent antibody conjugate, 
confirming specificity of staining. C) Electron micrograph of normal kidney 
(left) from a wild-type mouse. Electron micrograph of a kidney with 
proliferative glomerulonephritis (right) showing mesangial expansion and 
immune complex deposition.
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males and 7.2% females, and in the salivary glands of 57.9% males and 66% 
females. However, there was no significant association between SAP genotype and 
abnormality of any of these organs.
Spleens were abnormal, as determined by “spleen lymphocyte score”, in 62.5% 
(30/48) of SAP-/- female mice compared to 30.6% (15/49) of wild-type female mice 
(P = 0.002, Fisher’s exact test) and in 48.9% of SAP-/- male mice compared to 
20.4% of wild-type males (P = 0.007, Fisher’s exact test). Spleens were abnormal in 
58% and 38.8% of female and male SAP+/- mice respectively, not significantly 
different from SAP-/- mice. The spleen lymphocyte score is described in detail in 
Materials and Methods, but ranged from 0-9 (> 4 is abnormal) and was the sum of 
white pulp volume, white pulp coalescence, and red pulp lymphocytosis, each scored 
from 0-3.
The autoantibodies and histological abnormalities discovered in wild-type, SAP+/- 
and SAP-/- C57BL/6 mice at 12 months of age is summarised in table 3.2.
Comparison of autoimmunity in male and female mice
Several autoantibodies were more frequent and occurred at higher titre in female 
mice than in males, across all SAP genotypes. No autoantibody occurred 
significantly more frequently or in significantly higher titre in males compared to 
females.
AUTOIMMUNITY HISTOLOGY
N Anti-nuclear
Number (%) +ve Median titre 
(range)
Anti-double 
stranded DNA
Number (%) +ve
Anti-histone
Median (range)
Anti-chromatin
Median (range)
Anti-single stranded 
DNA
Median (range)
Glomerulonephritis
Number (%) +ve
Splenic abnormality
Number (%) +ve
Female
WT 50 20 (40) 0 (0-1/1280) 3(6) 11.3(2-48) 3.0(0-240) 1.1(0-10) 8(16) 15(31)
SAP+/- 53 34 (64) 0 (0-1/1280) 14 (26) 15.1 (2-153) 11.9(0-98) 2.7 (0-24) 23 (43) 29(58)
SAP-/- 51 45(88) 1/640 (0-1/2560) 33 (65) 16.7(2-192) 36.5 (0-365) 3.8 (0-25.8) 38(75) 30 (63)
P=0.001 P=0.0001 P=0.001 P=0.1 P=0.0001 P=0.0001 PC0.0001 P=0.002*
Male
WT 50 11 (22) 0 (0-1/640) 6(12) 7.9 (2-24) 2.5 (0-49) 0 (0-7) 0(0) 9(20)
SAP+/- 49 24 (49) 0 (0-1/1280) 9(18) 8.2(2-81) 4.5 (0-49) 2.6 (0-24) 10(20) 19(39)
SAP-/- 48 47 (98) 1/640 (0-1/2560) 19 (40) 13.5(2-36) 38.8(0-169) 2.4 (0-22) 13 (28) 22 (49)
P=0.001 P=0.001 P=0.003 P=0.009 P=0.0001 P=0.003 P=0.001* P=0.007*
P values obtained by Chi-squared test, Fisher’s exact test or Mann-whitney U test as appropriate. * - Significance of wild-type versus SAP-/- only
Table 3.2 Summary of autoimmunity and glomerulonephritis in SAP+/+, SAP+/- and SAP-/- C57BL/6 mice at 12 months 
of age
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Among wild-type mice, there was a higher frequency (P <0.01, Chi-squared test) 
and titre (P = 0.04, Mann-Whitney U test) of ANAs at 12 months of age in female 
mice than males, and significantly higher titres in females compared to males of 
anti-histone antibodies (P = 0.007, Mann-Whitney U test). However, there was no 
significant difference in frequency or titre of ANAs between male and female 
SAP+/- mice or male and female SAP-/- mice.
Significantly more female than male SAP-/- mice had anti-dsDNA antibodies (65% 
vs 40%, P = 0.01, Chi-squared), and titres of anti-ssDNA antibodies were higher in 
SAP-/- females than males (P = 0.02, Mann-Whitney U test). Similarly, titres of 
anti-histone (P = 0.0001) and anti-chromatin (P < 0.003) antibodies were higher in 
SAP+/- females than males.
Importantly, there was considerably more frequent (P < 0.007, Chi-squared or 
Fisher’s exact test) and severe glomerulonephritis (P < 0.04, Mann-Whitney U test) 
among female mice than males, across all genotypes. Among SAP-/- mice, 
glomerulonephritis occurred in 75% females compared to 28% males, and was 
markedly more severe in females (P< 0.0001, Mann-Whitney U test). Among 
SAP+/- mice, glomerulonephritis was present in 43% of females, in whom it was 
more severe (P < 0.002), compared to 20% of males. No male wild-type mouse had 
glomerulonephritis, but it was present in 16% of wild-type females. These sex 
differences are reminiscent of the 9:1 female predominance in human SLE, which is 
characterised by ANAs and immune-complex glomerulonephritis.
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The frequency of abnormal splenic histology was significantly higher in female 
SAP+/- mice (P = 0.01, Fisher’s exact test), and female SAP-/- mice (P = 0.05) than 
males of the same genotype.
ABSENCE OF SPONTANEOUS AUTOIMMUNITY IN 
PURE-LINE 129/SV SAP DEFICIENT MICE
The deleted SAP gene was backcrossed for 6 generations onto the inbred 129/Sv 
mouse strain by Dr M Botto, Department of Rheumatology, Imperial College School 
of Medicine to produce “pure-line” 129/Sv SAP deficient mice. A cohort of 51 
“knockout” SAP deficient (SAP-/-) mice, 27 males (52.9%) and 24 females (47.1%) 
were followed for 18 months, all housed under identical conditions.
During the course of follow up, 2 female mice were found dead at 14 and 17 months 
of age and 3 males were found dead at 14, 16 and 17 months of age, respectively. 
One female mouse was killed at 14 months due to an eye infection.
All available mice were bled from the tail vein at 6 and 12 months of age, and killed 
by bleed out from the axillary artery at 18 months, before harvesting the kidneys in 
each case.
Serological Analysis
Serum obtained at 6, 12 and 18 months of age was tested for the presence of 
anti-nuclear antibodies (ANAs). Samples were screened at a dilution of 1/80 and
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titrated to end-point. At 6 months of age, ANAs were absent in all 129/Sv SAP 
deficient mice (0/51) and at 12 months of age ANAs were found at a titre of 1/80 in 
only 2 female SAP-/- mice and no males. At 18 months of age, ANAs were present 
in 6 of 21 (28.6%) female SAP-/- mice, at a titre of 1/80 in 3 cases and 1/160 in 3 
cases, and in 7 of 26 (26.9%) males, at a titre of 1/80 in 4 cases, 1/160 in 2 and 1/320 
in the remaining case. ANA staining was always homogeneous
The remaining serological analyses were carried out only on serum obtained at 18 
months of age.
Anti-dsDNA antibodies were analysed as before, and samples were screened at a 
dilution of 1/20 and titrated to end point. Titres of 1/20 or above were considered 
positive. Antibodies to dsDNA were present in 1 of 21 (4.8%) female mice and 2 of 
26 (7.7%) males, all at a titre of 1/20. Anti-chromatin and anti-ssDNA antibody 
assays were performed by immunoradiometric assay (IRMA) as before, and samples 
were considered positive when > 3 S.D. above the lower limit of detection. 
Antibodies against chromatin were present in 0 of 21 female mice (0%) and 2 of 26 
(7.7%) males. Anti-ssDNA antibodies were present in 1 of 21 (4.8%) females and 3 
of 21 (14.3%) male mice.
Histology
Renal histology was examined in all available mice. Coded sections of renal tissue 
were examined by Professor HT Cook, Department of Histopathology,
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Hammersmith Hospital, for the presence of glomerulonephritis as described in 
Materials and Methods. At 18 months of age, glomerulonephritis by light 
microscopy was present in 26.3% of female SAP-/- mice, including two in which it 
was severe, and in 1 (4.3%) male mouse, in which it was moderate.
Attempted Induction o f  Anti-chromatin Autoimmunity in 129/Sv 
M ice
In order to test whether immunisation with exogenous chromatin would induce 
anti-nuclear autoimmunity in the 129/Sv mouse strain, and if so, whether this was 
enhanced by SAP deficiency, a cohort of 10-week old 129/Sv SAP-/- mice and age 
matched wild-type controls were immunised with avian chromatin.
Groups comprising 20 male and 16 female SAP-/- mice and 23 male and 18 female 
wild-type mice were given 100 pg per mouse of chicken erythrocyte chromatin 
suspended in complete Freund’s adjuvant sub-cutaneously on dayO and boosted 
with the same dose suspended in incomplete Freund’s adjuvant on day +32. All 
mice were bled on day -1, +14, +28, +41 and +56.
All sera were screened for the presence of ANAs at a dilution of 1/80. No ANAs 
were detectable prior to chromatin administration and ANAs were not detected at 
any time point following chromatin administration in any mouse.
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SPONTANEOUS AUTOIMMUNITY IN HUMAN SAP 
TRANSGENIC MICE
C57BL/6 mice, transgenic for the human SAP gene, were produced by Maeda’s 
group in Japan [105], from whom they were obtained. These mice were crossed 
with our SAP-/- C57BL/6 mice by Dr MBotto, Department of Rheumatology, 
Imperial College School of Medicine, to produce mouse SAP-/-, human SAP 
transgenic pure-line C57BL/6 mice (SAP-/-, hSAP Tg). All offspring of SAP-/-, 
hSAP Tg mice were tested by PCR for the presence of the human SAP transgene by 
Dr DR Booth, and expression and concentration of human SAP were confirmed in 
individual experiments by rocket electroimmunoassay.
A cohort of 35 C57BL/6 SAP deficient mice, 16 males (45.7%) and 19 females 
(54.3%) were followed for 12 months, all housed under identical conditions. 
Thirteen (37.2%) of the mice were negative for the human SAP transgene 
(effectively SAP-/- mice), of which 7 were female and 6 were male; 22 (62.8%) 
were positive for the human SAP transgene (SAP-/-, hSAP Tg), of which 12 were 
female and 10 were male. Baseline concentration of human SAP was significantly 
higher in SAP-/-, hSAP Tg female mice (median = 93 pg/ml; range = 62-126) than 
in males (median = 23 pg/ml; range = 22-62) (P = 0.0001, Mann-Whitney U test).
At six months of age, there was no significant difference in presence or titre of 
ANAs in either sex, between SAP-/- and SAP-/-, hSAP Tg mice. Similarly, despite 
the expected increase in ANA titres with age in all mice, there was no difference at
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Figure 3.11 Comparison of spontaneous antinuclear autoimmunity 
between SAP deficient C57BL/6 mice, positive and negative for the 
human SAP transgene. Females are shown on the left (A, C) and males 
on the right (B, D). There was no significant difference in presence or 
titre of antinuclear antibodies at 6 months (A, B) or 12 months of age (C, 
D) between those mice expressing and those not expressing human SAP 
(Mann-Whitney U test, P>0.05 for all analyses). ANA titres were 
consistent with those previously shown in this chapter for SAP-/- mice 
(figure 3.3).
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12 months of age between those mice expressing and those not expressing human 
SAP (P > 0.05 between all groups, Mann-Whitney U test) (figure 3.11).
The presence and titre of anti-dsDNA antibodies were not significantly different in 
either sex at 6 or 12 months of age, between those mice expressing human SAP and 
those without the human SAP transgene (P > 0.05 between all groups, 
Mann-Whitney U test) (figure 3.12).
The titre of anti-chromatin and anti-ssDNA antibodies was not significantly different 
at 6 months, between SAP-/- and SAP-/-, hSAP Tg mice of either sex (P > 0.05 
between all groups, Mann-Whitney U test) (figure 3.13).
Renal histology was obtained at 12 months in all mice and coded slides were viewed 
by Professor HT Cook, Department of Histopathology, Hammersmith Hospital, for 
the presence of glomerulonephritis as described in Materials and Methods. There 
was no difference in frequency (P > 0.2, Fisher’s exact test) or severity (P > 0.2, 
Mann-Whitney U test) of glomerulonephritis between SAP-/- and SAP-/-, hSAP Tg 
mice of either sex (figure 3.14).
Since the number of mice in this experiment were relatively small, analysis was also 
performed after grouping males and females together. At 6 months of age, there was 
no difference in frequency or titre of ANAs, anti-dsDNA, anti-chromatin or 
anti-ssDNA antibodies between SAP-/- and SAP-/-, hS AP Tg mice. At 12 months
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Figure 3.12 Comparison of anti-dsDNA antibodies between SAP deficient 
mice , positive and negative for the human SAP transgene. Females are 
shown on the left (A, C) and males on the right (B, D). There was no 
significant difference in presence or titre of anti-dsDNA antibodies at 6 
months (A, B) or 12 months of age (C, D) between those mice expressing 
and those not expressing human SAP (Mann-Whitney U test, P>0.05).
135
A)
70-,
5  50-| 
>»||  
as
c  aro
§  30-
i^
 20 -
B)
25.0-| 
22.5
20.0-
|  ™
15.0-1I 12.5-
£  10.0-  
V
1  7.5-
SAP-/- SAP-/-, hSAP Tg
Genotype
SAP-/- SAP-/-, hSAP Tg
Genotype
C)
SAPV- SAP-/-, hSAP Tg
Genotype
D)
33 55
<
Z  4 -
I 3'
2 -
1-
SAP-I- SAP-/-, hSAP Tg
Genotype
Figure 3.13 Comparison of anti-chromatin (A, B) and anti-ssDNA (C, D) 
antibody titres at 6 months of age between SAP-/- and SAP-/-, hSAP Tg mice. 
Females are on the left (A, C) and males are on the right (B, D). There was no 
significant difference in antibody titres between the genotypes (Mann-Whitney 
U test, P>0.05).
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Figure 3.14 Comparison of presence and severity of 
glomerulonephritis between SAP-/- and SAP-/-, hSAP Tg females (A) 
and males (B) at 12 months of age. There was no difference between 
the genotypes (Fisher's exact and Mann-Whitney U tests, P>0.05).
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of age, there was no difference in frequency or titre of anti-dsDNA antibodies, no 
difference in frequency of ANAs, and no difference in frequency or severity of 
glomerulonephritis between SAP-/- and SAP-/-, hSAP Tg mice. However, there 
were significantly lower ANA titres at 12 months of age in SAP-/-, hSAP Tg mice 
than SAP-/- mice (P < 0.02, Mann-Whitney U test).
Expression of human SAP in the C57BL/6 human SAP transgenic mice was noted 
by Maeda’s group to reduce basal expression of native mouse SAP [105]. We 
confirmed this finding by electroimmunoassay for mouse and human SAP in a 
cohort of 23 pure-line C57BL/6 mice housed under identical conditions. Twelve of 
the 23 mice were shown to have the human SAP transgene, with a median human 
SAP concentration of 68 pg/ml (range: 31 to 140) and a median mouse SAP 
concentration of 0 pg/ml (range: 0-53). Among 11 littermate control mice in which 
the human SAP gene was absent, the median mouse SAP concentration was 
13.5 pg/ml.
Since absence of mouse SAP in our C57BL/6 SAP deficient mice was associated 
with the autoimmune phenotype described earlier in this chapter, and since the 
phenotype was not abrogated by the expression of human SAP in these SAP 
deficient mice, we examined whether suppression of mouse SAP expression in 
human SAP transgenic C57BL/6 mice, might be sufficient to induce autoimmunity. 
The cohort of 23 mice were bled at 6 to 8 months of age with a view to bleeding out
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and obtaining renal histology at 12 months of age. All sera from the 6 to 8 month 
bleed were tested for the presence of ANAs.
ANAs were present in 1 of 7 female human SAP transgenic mice at 6 months of age 
and in 1 of 7 female mice in which the human SAP transgene was absent. There 
were no ANAs among 9 males, of which 5 expressed human SAP.
SUMMARY
Previous in vitro and in vivo studies had suggested that the pentraxins and, in 
particular SAP, may have a role in handling chromatin in order to prevent 
autoimmunisation. The present results suggest an important role for SAP in the 
handling of nuclear antigens in vivo. The inbred C57BL/6 mouse strain has a 
predisposition to development of autoimmunity; however, deletion of the mouse 
serum amyloid P component gene in this strain led to a highly significant increase in 
spontaneous autoantibody production with a global increase in anti-nuclear 
antibodies. The anti-nuclear autoimmunity was associated with development of 
immune complex glomerulonephritis, particularly in female mice, reminiscent of the 
9:1 female predominance in the human equivalent, systemic lupus erythematosus. 
In addition, deletion of the SAP gene was associated with abnormal splenic 
histology with an increase in “lymphocyte score” as defined by red pulp 
lymphocytosis and white pulp volume and coalescence. Interestingly, the 
glomerulonephritis was clinically mild, despite often being histologically severe, and
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was not associated with proteinuria or reduced creatinine clearance. SAP-/- mice 
survived normally to the age of 12 months.
However, the data presented here also highlights several important issues. Total 
SAP deficiency in the 129/Sv mouse strain was insufficient to induce spontaneous 
autoimmunity; indeed this could not be induced in 129/sv SAP deficient mice, even 
by administration of exogenous chromatin suspended in complete Freund’s adjuvant. 
These data highlight the genetic complexity of autoimmunity, and in particular, 
systemic lupus erythematosus. Work in mouse models of human SLE have shown 
that susceptibility to development of the “full-blown” SLE phenotype is dependent 
upon complex genetic interactions involving several susceptibility loci.
A number of linkage studies have mapped genetic loci that influence the 
development and expression of SLE in both humans and mice. Genomic segments 
on murine chromosomes 1 (<Slel), 4 (Sle2) and 7 (Sle3) are associated with disease 
susceptibility in multiple strain combinations, suggesting a strong influence on 
autoimmunity by genes within them, and the human syntenic equivalent of mouse 
Slel, lq21-44, has also been shown to confer strong disease susceptibility. 
Subsequent analyses of congenic mouse strains have provided a detailed 
characterisation of the component autoimmune phenotype produced by each of these 
susceptibility loci. Slel in particular, but also Sle3, mediate the loss of immune 
tolerance to chromatin and lead to the appearance of high titres of antinuclear 
autoantibodies (ANAs) and initiation of autoimmunity. Slel in isolation however,
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does not cause the development of severe lupus nephritis, which appears to be 
mediated, in particular, by Sle3 [216-218].
The SAP gene is located within the Slel locus and the phenotype of our SAP 
deficient C57BL/6 mice was entirely consistent with the expected component SLE 
phenotype, with predominant loss of immune tolerance to chromatin and high titre 
ANAs, but relatively little severe lupus nephritis and normal survival to 12 months 
of age.
The DNA construct which resulted in deletion of the entire SAP gene was 
introduced into 129/Sv mouse embryonic stem (ES) cells, and cells lacking the SAP 
gene were injected into C57/BL6 blastocysts. By definition therefore, all our SAP 
deficient mice, including so-called “pure-line” C57BL/6 SAP-/- mice, were 
homozygous for the gene targeted 129/Sv allele on chromosome 1. One cannot 
exclude entirely the possibility, albeit remote, that the observed phenotype in our 
C57BL/6 mice was caused, not by deletion of the SAP gene that was targeted, but by 
an unknown 129/Sv gene on chromosome 1 linked to the SAP null allele. Another 
theoretical possibility would have been disruption of a nearby gene, as well as that 
encoding SAP during production of the DNA construct; however the complete SAP 
coding region that we selectively deleted definitely contained no other gene.
In order to exclude the possibility that the phenotype in our C57BL/6 SAP-/- mice 
was due to the interaction between a 129/Sv gene other than SAP and the remaining
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C57BL/6 genome, we followed several lines of investigation. Firstly, we 
determined the spontaneous phenotype in pure-line 129/Sv SAP-/- mice. They did 
not develop significant autoimmunity by 12 months. However, the 129/Sv strain are 
non-predisposed to autoimmunity and thus its absence in SAP-/- mice does not 
preclude important involvement of the SAP gene. Secondly, we determined the 
spontaneous phenotype in C57BL/6 SAP-/- mice expressing human SAP. Human 
SAP did not abrogate the autoimmune phenotype seen in SAP deficient C57BL/6 
mice. However, it would be surprising if human and mouse SAP functioned 
identically in the mouse, particularly given their different binding affinities in vitro, 
and therefore, the persistence of autoimmunity in human SAP transgenic mice 
lacking mouse SAP, does not exclude mouse SAP as the cause of the observed 
phenotype. Thirdly, we determined the spontaneous phenotype of human SAP 
transgenic C57BL/6 mice, in which mouse SAP expression is reduced. These mice 
did not have evidence of spontaneous autoimmunity at 6 months of age. However, 
the dynamics of human and mouse SAP expression is entirely unknown in this 
strain, and needs to be determined before any firm conclusions can be drawn.
We are currently in collaboration with Dr EK Wakeland, who has introduced extra 
copies of the mouse SAP gene into wild-type C57BL/6 mice. We plan to cross mice 
in which the extra SAP gene is expressed with our SAP-/- C57BL/6 mice and see 
whether the autoimmune phenotype is abrogated, which would definitively exclude 
any cause other than SAP deficiency for the autoimmunity.
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Despite the remote possibility that the observed phenotype in SAP deficient mice is 
SAP-independent, we believe this to be unlikely; SAP is the major DNA and 
chromatin binding protein of the plasma, and its participation in the in vivo handling 
of such potentially autoantigenic epitopes, seems highly likely. The remainder of 
this work attempts to elucidate the mechanisms by which SAP may prevent 
autoimmunity.
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Chapter 4 -  Clearance And Degradation Of 
Chromatin And Nucleosomes
INTRODUCTION
There is strong evidence that the autoantibody response in systemic lupus 
erythematosus (SLE), the prototypic immune complex-mediated autoimmune 
disease, is driven by immunisation with self antigen [261-267]. The study of the 
clearance and processing of immunogens is therefore, central to understanding the 
pathogenesis of the disease.
Studies of clearance of autoantigens have focused primarily on the clearance of 
DNA from the circulation [337-341]. However, native DNA is poorly immunogenic 
[268] and evidence suggests that DNA is a target antigen rather than the primary 
immunogen in SLE. Autoreactive T cells from SLE patients recognise cationic 
DNA-binding proteins, and nucleosome-primed T cells, which predict the 
development of lupus nephritis, emerge spontaneously in lupus-prone mice before 
the serologic manifestations of autoimmunity. These findings suggested that 
DNA-protein complexes are the major immunogen in SLE [269-272], a hypothesis 
further strengthened by Datta et al, who found that immunisation of pre-autoimmune 
lupus mice with pure mononucleosomes accelerated development of severe lupus 
nephritis [273]. Burlingame et al demonstrated that early autoantibodies in 
lupus-prone mice recognised discontinuous epitopes on native chromatin and the
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(H2A-H2B)-DNA subnucleosome and that as the immune response progressed, 
native DNA and other chromatin constituents generally became antigenic [274]. 
The same group compared the antigenicity of whole chromatin, DNA, denatured 
individual histones, and histone-histone and histone-DNA subnucleosome 
complexes and found that sera from patients with SLE reacted most frequently with 
whole chromatin, and that adsorption with chromatin removed the majority of 
reactivity with subnucleosome complexes and native DNA [275].
Studies of DNA in the circulation have revealed a size distribution consistent with 
the size of the nucleosome, and nucleosomes are the form in which DNA is released 
from cells dying by apoptosis [342]. There have been few reports concerning 
clearance or site of organ localisation of native long chromatin and nucleosome core 
particles from the circulation. Du Clos’ group reported a half-life of 6.5 minutes for 
core particle clearance from the circulation [320]. Burlingame eta l radiolabelled 
Hl-stripped chromatin and nucleosome core particles with [125I]Na, injected them 
intravenously and measured plasma clearance. In addition, they determined organ 
localisation 60 minutes following injection. However, tracer studies with proteins 
directly labelled by oxidative iodination are poorly informative about sites of 
clearance and catabolism because proteolysis is usually extremely rapid and the 
released iodotyrosine rapidly leaves the catabolising cell and is excreted in the urine. 
The amount of label associated with a particular tissue at any one time after 
injection, whether as catabolic products or intact protein, therefore, does not 
necessarily bear any relationship to the amount of protein catabolised by that tissue.
The “trapped catabolism” method depends on a common and straightforward 
principle. The subject protein is covalently linked to a tracer ligand, which is not 
itself degraded but is left behind in the catabolising cell upon degradation of the 
protein. The tracer ligand is therefore a cumulative marker of the amount of 
degradation that occurs in those cells. The method of choice for most applications 
of the trapped catabolism method is the tyramine cellobiose technique that was first 
described by Pittman et al [334]. Tyramine, the radioiodine acceptor, is linked to 
cellobiose, a non-hydrolysable reducing disaccharide, by reductive animation. The 
resulting tyramine-cellobiose (TC) adduct is then attached to the protein using 
cyanuric chloride. The method has been validated in several biological studies 
[334,343], but has not previously been used to determine catabolism of nucleosomes 
or chromatin.
Serum amyloid P component (SAP) is the major calcium-dependent DNA and 
chromatin binding protein of the plasma. SAP was shown in our laboratory to 
specifically displace HI histone and solubilise native long chromatin [61]. In 
addition, SAP binds to apoptotic cells and it was suggested that its major 
physiological role might be to enhance non-immunogenic clearance of nuclear 
material, including chromatin, which is released from such cells. Our discovery of a 
spontaneous lupus-like phenotype in SAP deficient C57BL/6 mice with highly 
significant antinuclear autoimmunity, further suggested that the physiological role of 
SAP might be to enhance non-immunogenic clearance of nuclear material. Indeed, 
studies performed in our laboratory comparing whole body clearance of
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radiolabelled chicken erythrocyte chromatin between [129/Sv x C57BL/6]F2 SAP-/- 
and wild-type mice, revealed more rapid whole body clearance of radioactivity in 
female SAP deficient animals [232].
The studies presented in this chapter examine the handling of exogenously 
administered chromatin and nucleosomes by mice in vivo, and attempt, in particular, 
to determine the effect of SAP on their turnover. The rate of clearance of long 
chromatin was initially determined by whole body clearance of radioactivity; 
however, the technique was refined and subsequent studies compared clearance from 
the plasma of native long chromatin and nucleosomes in SAP-/- and wild-type 
C57BL/6 mice. Further studies using the “trapped catabolism method” determined 
the relative contribution by different organs to catabolism of nucleosomes, and 
specific cell types within the major catabolising organs were identified by dipping 
film autoradiography. Differences in the in vivo handling of chromatin and 
nucleosomes between SAP-/- and wild-type C57BL/6 mice were sought.
WHOLE BODY CLEARANCE OF LONG CHROMATIN
Following intra-peritoneal injection of directly-labelled long chromatin, there was no 
significant difference between wild-type, SAP-/- and SAP-/-, hSAP Tg mice in rates 
of whole body clearance of radioactivity (figure 4.1). This result contrasted data 
published from our laboratory, in which SAP-/- (129/Sv x C57BL/6)F2 mice were 
found to clear long chromatin more rapidly than their wild-type counterparts [232]. 
In view of the possible inaccuracies associated with whole body clearance (due to
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Figure 4.1 Whole body clearance of chromatin in wild-type C57BI/6, 
SAP-/- C57BL76 and SAP-/- C57BL/6 mice transgenic for human SAP 
(SAP-/-, hSAP Tg). There was no significant difference in the percentage 
of total chromatin cleared between the three genotypes after 4 hours.
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bladder voiding and contamination of the fur with tracer) and our inconsistent 
results, all subsequent studies of clearance were designed to specifically examine 
clearance of chromatin and nucleosomes from the plasma after intra-venous 
administration, as described in Materials and Methods.
PLASMA CLEARANCE OF LONG CHROMATIN
Preliminary studies of plasma clearance of directly radioiodinated chromatin were 
performed in 4 wild-type C57BL/6 female mice and results are shown in figure 4.2.
In two separate experiments, clearance of long chromatin from the plasma was 
significantly more rapid in wild-type mice than in SAP-/- mice. In both 
experiments, at the 15 min time point, a significantly higher proportion of the 
injected chromatin had been cleared from the plasma in wild-type mice than SAP-/- 
mice, as shown in figure 4.3 (P < 0.004 and P < 0.05, Mann-Whitney U test). The 
rate of clearance of chromatin did not significantly differ between each experiment 
(P > 0.5, Mann-Whitney U test and Kruskal-Wallis test), and was therefore, 
independent of chromatin dose. For this reason, and since the experiments were 
identical in every respect other than chromatin dose injected, it was considered 
reasonable to pool the data from both experiments, which resulted in a highly 
significant difference between genotypes in the rate of plasma chromatin clearance 
at both 15 min (P< 0.001, Mann-Whitney U test and Kruskal-Wallis test) and 
30 min (P < 0.02, Mann-Whitney U test and Kruskal-Wallis test).
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Figure 4.2 Clearance from the blood of long chicken erythrocyte 
chromatin in 4 wild-type C57BL/6 mice. Mean percentage counts at each 
timepoint represents the mean (+/-SD) counts per gram of blood from 4 
animals expressed as a percentage of the counts per gram at 2 minutes 
after injection.
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Figure 4.3 Clearance from the plasma of long chromatin from two separate 
experiments, A) and B). Both experiments show that at 15 minutes, wild-type 
mice had cleared a significantly higher proportion of the injected long 
chromatin compared to SAP-/- mice (At 15 minutes A; P<0.004 B; P<0.05, 
Mann Whitney U test).
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PLASMA CLEARANCE OF NUCLEOSOMES
Nucleosomes were obtained from long chromatin. The size distribution of DNA 
fragments and the presence of all histone components (including HI histone) in the 
final material were determined by DNA extraction followed by agarose gel 
electrophoresis and SDS-PAGE followed by staining with silver nitrate, respectively 
(figure 4.4). Together, these confirmed the predominance of intact 
mononucleosomes in the final material, which were directly radioiodinated as 
described in Materials and Methods. Following radioiodination, TCA precipitability 
of the labelled material was 91%.
Preliminary experiments were undertaken in order to roughly determine the rate of 
clearance of mononucleosomes from the blood, so that relevant time points could be 
selected for comparison of rates of clearance in SAP-/- and wild-type C57BL/6 
mice. Results are shown in figure 4.5.
Plasma clearance of nucleosomes, shown in figure 4.6, was significantly faster in 
wild-type than SAP-/- C57BL/6 mice (P<0.04 and P<0.03 at 15 and 30 min 
respectively, Mann-Whitney U test).
In order to prove that the reduced rate of plasma clearance of nucleosomes observed 
in SAP-/- mice was caused specifically by SAP deficiency, we repeated the 
clearance experiments comparing 4 groups of mice. Using five weight-matched 6-8 
week old female mice per group, the groups were as follows: wild-type, SAP-/-,
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Figure 4.4 A) Agarose gel electrophoresis confirming the 
predominance of DNA fragments of between 100 and 200 base pairs in 
length, consistent with mononuceosomes. M is a 1 kilobase marker, 
lane 1 is chromatin that has been subjected to further digestion with 
micrococcal nuclease, and lane 2 is the calcium precipitated sample 
material. B) SDS-PAGE stained with silver nitrate confirming the 
presence of all histone components in the nucleosome preparation. 
Nucleosome core partricles (lanes 1-4) and long chromatin (lanes 5-8) 
were each loaded at 4 doses; 0.3 pg (lanes 4, 8), 0.9 pg (lanes 3, 7), 
1.8 pg (lanes 2, 6) and 3.4 pg (lanes 1, 5). Histone H1 and H5 (thin 
arrow) were apparent in lanes 1 and 5, the four core histones (thick 
arrow) in lanes 3 and 7.
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Figure 4.5 Clearance from the blood of mononucleosomes in 4 
wild-type C57BL/6 mice. Mean percentage counts at each timepoint 
represents the mean (+/-SD) counts per gram of blood from 4 animals 
expressed as a percentage of the counts per gram 2 minutes after 
injection.
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Figure 4.6 Comparison of plasma clearance of nucleosomes in SAP-/- 
and wild-type (WT) C57BL76 mice. Clearance of nucleosomes from the 
plasma occurred significantly more rapidly in wild-type mice than in 
SAP-/- mice (P<0.04 and P<0.03 at 15 and 30 minute timepoints, 
respectively; Mann-Whitney U test).
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SAP-/- after administration of mouse SAP, and SAP-/- after administration of human 
SAP.
Rates of nucleosome clearance from 2 consecutive experiments are shown in 
figure 4.7. In sharp contrast with previous results, rates of nucleosome clearance 
from the plasma in these experiments were not significantly different between 
wild-type and SAP-/- C57BL/6 mice. Interestingly, the nucleosomes injected in the 
latter two experiments were obtained by calcium precipitation of a different batch of 
long chromatin and subsequent DNA extraction and agarose gel electrophoresis of 
the chromatin revealed significant degradation of the starting material compared 
with that used as starting material for previous experiments (figure 4.8). 
Unfortunately, time did not permit preparation of a new batch of chicken erythrocyte 
chromatin for further investigation of plasma nucleosome turnover.
ORGAN LOCALISATION OF CATABOLISM OF 
NUCLEOSOMES
Confirmation of successful radioiodination of the tyramine cellobiose (TC)-labelled 
and native nucleosomes was obtained by autoradiography of the SDS-PAGE gel 
(figure 4.9).
In order for the “trapped catabolism” method to be considered biologically 
applicable, the tyramine-cellobiose (TC) labelled tracer must be metabolically 
indistinguishable from the tracer protein, at least through the step of irreversible
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Figure 4.7 Two separate experiments, A) and B), showing rates of 
plasma clearance of mononucleosomes in 4 groups of C57BL/6 
mice; wild-type, SAP-/-, SAP-/- into which human SAP had been 
injected and SAP-/- into which mouse SAP had been injected. There 
was no significant difference in clearance rates between any group 
of mice in either experiment.
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Figure 4.8 DNA extraction and agarose gel electrophoresis 
of two separate batches of chromatin. M is a 1 kilobase 
marker. Lane 1 is the batch of chromatin used for all previous 
experiments and lanes 2 and 3 are the degraded chromatin 
from which the nucleosomes for the experiment presented in 
figure 4.7 were prepared by calcium precipitation.
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Figure 4.9 Autoradiography of SDS-PAGE confirming 
successful radioiodination of native (lanes 1-3) and tyramine 
cellobiose-labelled (lanes 7-9) nucleosom es. In the upper 
panel, SDS-PAGE stained with silver nitrate confirming the 
Dresence of the different histone components, including 
listones H1 and H5, in the nucleosome preparations. In the 
ower panel, autoradiography of the SDS-PAGE gel confirming 
successful radioiodination of both native and TC-labelled 
nucleosome components, with no radioactivity associated with 
unlabelled nucleosom es in lanes 4, 5, and o. Three different 
volumes of each nucleosome preparation were loaded onto 
the gel.
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removal from the plasma. The most sensitive single index of this is comparison of 
in vivo plasma decay kinetics between the TC-labelled and native proteins. 
Figure 4.10 displays the identity between plasma decay kinetics of TC-labelled and 
directly radioiodinated nucleosomes, thereby validating as physiological, the use of 
the TC-labelled nucleosome preparation for examination of sites of catabolism of 
nucleosomes.
Twenty-four hours after injection, nucleosome clearance from the plasma was 
complete. The liver was the main site of catabolism of nucleosomes, followed by 
the kidneys accounting for 65.1% (+/-8.0) and 14.1% (+/-1.7), respectively. 
Retrieval from the carcass was 16.5% (+/- 9.8%) and from the spleen and intestine 
were 0.9% (+/-0.3) and 0.7% (+/-0.1) respectively. The remaining organs each 
accounted for catabolism of <0.5% of injected nucleosomes. There was no 
significant difference in overall contribution to catabolism by any organ between 
SAP-/- and wild-type mice. These results are shown in figure 4.11.
Since the presence of SAP enhanced rapid clearance of nucleosomes from the 
plasma with a significant difference in the percentage of an injected dose cleared by 
15 min, organ localisation of nucleosomes was compared at this time point between 
SAP-/- and wild-type C57BL/6 mice. In two separate experiments, the proportion of 
nucleosomes catabolised by the spleen at this time point was significantly higher in 
SAP-/- than wild-type mice (P < 0.003, Mann-Whitney U test) (table 4.1). Although
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Figure 4.10 Comparison of in vivo plasma decay kinetics between
directly radioiodinated and 125l-tyramine-cellobiose (TC) labelled 
nucleosomes. There was no difference in clearance kinetics, thereby
validating as physiological, the use of 125l-tyramine-cellobiose labelled 
nucleosomes for determination of organ localisation of nucleosome 
catabolism.
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Figure 4.11 Comparison of organ localisation of catabolism of nucleosomes 
between SAP deficient and wild-type C57BL/6 mice. The major sites of 
catabolism of nucleosomes were the liver and kidneys. There was no 
difference between genotypes in the organs in which nucleosomes were 
catabolised.
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the contribution to catabolism by the spleen was comparatively small, it was nearly 
twice as great in SAP-/- than wild-type mice.
Dipping film autoradiography was carried out on selected sections of liver, kidney 
and spleen from 3 wild-type and 3 SAP-/- mice, as described in Materials and 
Methods. Catabolism took place in the hepatocytes and Kupffer’s cells of the liver 
(figure 4.12a), in the red pulp of the spleen (figure 4.12b) and in the parenchymal 
cells of the kidney (figure 4.12c). There was no discernible difference between 
SAP-/- and WT mice in the cellular localisation of nucleosome catabolism.
SUMMARY
Understanding the clearance and processing of native long chromatin and 
nucleosomes, believed to be the principal immunogens in SLE [269-274], is central 
to understanding the pathogenesis of the disease.
The clearance and processing of nuclear constituents such as nucleosomes and 
chromatin has not been studied in detail. The “trapped catabolism method,” in 
which tracer is trapped in the cells in which the bound protein is catabolised, has not 
previously been used for determining the site of nucleosome catabolism. Using this 
method we have identified hepatocytes and Kupffer’s cells in the liver and renal 
parenchymal cells as the major sites of nucleosome catabolism, accounting for 
approximately 97.5% of the total.
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A)
Liver Spleen Kidneys 
Mean percentage (+/- SD)
Carcass
Wild-type 38.8 (7.8) 0.6 (0.2) 6.4 (1.2) 46.4 (7.8)
SAP-/- 32.7(11.7) 1.0 (0.3) 7.2 (1.4) 45.2 (7.4)
P value >0.05 < 0.003 >0.05 0.05
B)
Liver Spleen Kidneys 
Mean percentage (+/- SD)
Carcass
Wild-type 42.9 (3.1) 0.6 (0.1) 7.2 (0.7) 40.2 (3.6)
SAP-/- 40.3 (5.3) 1.0 (0.3) 7.4 (1.0) 42.7 (4.1)
P value >0.05 < 0.001 >0.05 >0.05
Table 4.1 Organ contribution to catabolism of nucleosomes within 15 
minutes of intravenous injection. In both experiments A) and B), a 
significantly higher proportion of the nucleosomes were catabolised in the 
spleens of SAP-/- mice compared to wild-type mice at this timepoint 
(P < 0.003 and P <  0.001, respectively, Mann-Whitney U test). There 
was no other difference between genotypes.
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Figure 4.12A) Splenic histology and dipping film autoradiography from three 
mice. The upper panel is from a wild-type mouse into which unlabelled 
nucleosomes were injected. The middle and lower panels are from SAP-/- 
and wild-type mice respectively, into which 125l-tyramine-cellobiose labelled 
nucleosomes were injected. Radioactivity is seen in the red pulp in the wild- 
type and SAP-/- mice with no difference in cellular location (arrowed)
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Figure 4.12B) Liver histology and dipping film autoradiography from a wild-type 
mouse injected with unlabelled nucleosomes (top panel) as a negative control. 
125l-tyramine-cellobiose labelled nucleosomes were injected into an SAP-/- mouse 
(middle panel) and a wild-type mouse (lower panel). Radioactivity was identified 
in Kuppfer’s cells and in hepatocytes (arrowed) with no difference in distribution 
between SAP-/- and wild-type mice
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Figure 4.12C) Renal histology and dipping film autoradiography from a 
wild-type mouse injected with unlabelled nucleosomes (top panel) as a 
negative control. 1251-tyramine-cellobiose labelled nucleosomes were 
injected into an SAP-/- mouse (middle panel) and a wild-type mouse 
(lower panel). Radioactivity was identified in parenchymal cells of the 
kidney (arrowed) with no difference in distribution between SAP-/- and 
wild-type mice
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The discovery that SAP is the main DNA, histone and chromatin binding protein of 
the plasma [61], in conjunction with the spontaneous SLE-like phenotype in SAP-/- 
C57BL/6 mice reported here, suggested that SAP might have an important role in 
the in vivo handling of nucleosomes and/or long chromatin. In order to investigate 
this possibility, we compared sites of catabolism of nucleosomes and plasma decay 
kinetics of injected avian chromatin and nucleosomes between SAP-/- and wild-type 
C57BL/6 mice.
Although the overall contribution to catabolism of nucleosomes by the spleen was 
comparatively small, within 15 min of injection it was nearly twice as great in 
SAP-/- mice compared to that in wild-type mice (P < 0.003, Mann-Whitney U test). 
Interestingly however, by 24 h there was no difference between genotypes in 
proportion of nucleosomes catabolised by the spleen. Previous studies in mice have 
suggested that approximately 0.5% of an injected antigen is processed by the spleen 
[344,345]. However, the time course of such processing is unknown. It is possible 
that in the absence of SAP, rapid uptake and processing of nucleosomes by the 
spleen resulting in a transiently high concentration of antigen is sufficient to initiate 
immunogenic rather than tolerogenic processing.
The present work demonstrates that absence of SAP significantly delayed clearance 
of both long chromatin and nucleosomes from the plasma. This was unexpected 
since previous experiments from our laboratory, using whole body counting of 
radioactivity, had shown accelerated clearance of long chromatin in SAP-/- mice
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compared to wild-type animals, with significantly increased whole-body counts in 
wild-type mice 4 h after injection. However, whole body counting of radioactivity 
and plasma clearance examine different physiological processes; furthermore whole 
body counting is susceptible to inaccuracies due to variable bladder voiding and 
variable contamination of the fur with excreted tracer.
That SAP accelerates clearance from the plasma but decelerates whole body 
clearance of long chromatin, is far from inconceivable. The fast removal of 
chromatin from the plasma in the presence of SAP may reflect binding of the SAP 
portion of the SAP-chromatin complex to sites of clearance, thereby enhancing 
uptake of chromatin from the plasma into relevant organs. The presence of a 
specific receptor for chromatin on hepatocytes or Kupffer’s cells has not been 
demonstrated. One might speculate that upon uptake of SAP-coated chromatin into 
the catabolising organ, SAP, which is itself known to be highly resistant to 
proteolysis [68,204], slows catabolism of the bound chromatin, thereby delaying 
whole body clearance.
The mechanisms by which persistence of chromatin and nucleosomes in the 
circulation initiate or influence development of autoimmunity are unknown at 
present. The possibility that the delayed plasma clearance of chromatin and 
nucleosomes in SAP-/- mice in itself represents uptake by circulating antigen 
presenting cells was excluded by the fact that counting was performed on TCA 
precipitates of plasma. One might expect that any persistence in the circulation of
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SAP deficient mice might increase the chance of initiating an autoimmune response. 
Alternatively however, the binding of SAP to long chromatin and nucleosomes may 
prevent initiation of autoimmunity not only by increasing the speed of their removal 
from the circulation, but by shielding the bound nuclear constituents from the 
immune system, analogous to the role of SAP in host defence, in which certain 
bacteria appear to have adapted to bind SAP, thereby preventing their recognition 
[69].
This work demonstrates also the difficulty of working with chromatin and 
nucleosomes. The chicken erythrocyte chromatin was prepared and stored in several 
batches as described in Materials and Methods. Nucleosomes were prepared using 
chromatin as the starting material by exactly the same method prior to each group of 
experiments. However, comparison of different batches of chromatin by agarose gel 
electrophoresis showed that there was significant degradation of the starting material 
over time. Since long chromatin consists of a series of tightly packed nucleosomes 
which in turn, consist of histones associated with DNA, it is almost impossible to 
determine whether the material with which one is working is behaving 
physiologically.
SAP therefore, appears to influence both the rate of plasma clearance of nuclear 
constituents, and the time course of their splenic uptake and catabolism. However, 
the detailed mechanisms by which events in the circulation, into which nucleosomes
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are released by cell apoptosis, and events in the spleen, in which nucleosomes are 
processed and degraded, initiate systemic autoimmunity remain to be elucidated.
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Chapter 5 - Pentraxins And Apoptosis
INTRODUCTION
There is much evidence that the autoimmune response in SLE is driven by antigen 
and that the initial immunogen consists of DNA-protein complexes. There is also 
evidence that anti-DNA antibodies cross react with small nuclear ribonuclear 
proteins (snRNPs) and that these may be potential immunogens [346]. Apoptotic 
cells have emerged in recent years as likely sources of these autoantigens which are 
ubiquitous and abundant intracellular components of all healthy tissues in the body.
Cell death is a key feature of growth, development and repair and normally occurs 
by the mechanism of apoptosis, or programmed cell death. Under normal 
circumstances, apoptotic cells are efficiently phagocytosed by other cells by means 
of a variety of specific receptors [276,347-349]. Such rapid clearance of apoptotic 
cells is believed to be important in inhibiting inflammation and autoimmune 
responses against intracellular antigens [322,350].
Recognition of the possible source of the autoantigens of SLE first came with the 
observation by Casciola-Rosen et al that many of the most characteristic 
“intracellular” autoantigens of SLE were present in surface blebs on cells 
undergoing apoptosis [277]. This led to the hypothesis that it might be apoptotic
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cells and bodies that are the source of the autoantigens that drive the autoimmune 
response in SLE.
This hypothesis is supported by considerable experimental evidence. Several of the 
mouse models of SLE result from mutated genes encoding proteins which regulate 
development of apoptosis [238,239]. For example, the presence of the Ipr gene, 
which encodes a mutated fas  gene, dramatically enhances susceptibility to lupus in 
the MRL strain of mouse [238]. Intravenous administration into normal mice of 
syngeneic apoptotic thymocytes was shown by Elkon’s group to induce 
autoantibody production [278]. Furthermore, defective in vivo clearance of injected 
apoptotic thymocytes has been demonstrated in lupus-prone Clq-deficient mice 
[279]. Among humans with SLE, both increased lymphocyte apoptosis [280] and, 
more recently defective clearance of apoptotic cells [281,351] have been proposed to 
be important events in the aetiopathogenesis of the disease.
One possible reason for enhancement of the immunogenicity of various potential 
autoantigens in SLE, is that during apoptosis they become modified [282]. In 
particular, apoptosis induced by the action of granzyme B was shown to modify 
many of the targets of systemic immune responses [283], and it is proposed that 
apoptosis might thus render cryptic epitopes immunodominant and lead to 
immunogenic presentation of epitopes to which the immune system has not achieved 
tolerance [284].
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Although CRP was shown to bind to nuclei and chromatin in vitro [296,297], Pepys’ 
group demonstrated that SAP and CRP bind to different nuclear structures in vivo. 
SAP is the major calcium-dependent specific DNA binding protein in the serum under 
physiological conditions [60-62] and CRP binds to nuclei via snRNPs [62]. 
Experiments using sera from various animals (mouse, rat, guinea pig, cow and plaice) 
all demonstrated specific calcium-dependent binding of SAP to DNA. Isolated purified 
human SAP also showed major calcium-dependent binding to native long chromatin, 
HI-stripped chromatin and native DNA at physiological ionic strength, and to 
nucleosomes in solution. Binding of SAP to chromatin was specifically shown to 
displace HI-type histones and solubilise long chromatin [61]. SAP was also shown to 
bind to dermal keratin bodies, that is, apoptotic cells, in normal skin [300] and to 
chromatin released from necrotic cells in vivo [299].
Since intravenous administration of syngeneic apoptotic cells had been shown to 
induce antinuclear autoantibody production in normal mice [278], we wondered 
whether SAP deficiency, which spontaneously leads to ANA production, 
glomerulonephritis and an enhanced immune response to chromatin, might enhance the 
immunogenicity of apoptotic cells. The studies presented here examine the possible 
role of pentraxins in handling apoptotic cells. The binding of SAP to apoptotic cells 
was confirmed and CRP binding to apoptotic cells was demonstrated. The immune 
response to injection of syngeneic apoptotic thymocytes was compared in SAP-/- and 
wild-type mice in vivo, and a possible effect of SAP on macrophage ingestion of 
apoptotic lymphocytes was sought both in vitro and in vivo.
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BINDING OF PENTRAXINS TO APOPTOTIC CELLS 
Binding o f  SAP to Apoptotic Jurkhat Cells
All cells were stained with the DAPI counterstain. Approximately 80% of cells that 
had been exposed to UV irradiation were apoptotic according to the TUNEL assay after 
6h. SAP bound to the surface of apoptotic Jurkhat cells, as determined by 
colocalisation of staining with anti-human SAP and TUNEL staining (figure 5.1 A). 
Cells that had not been exposed to UV irradiation showed < 5% staining by TUNEL 
assay and SAP did not bind to TUNEL-negative cells. Binding of SAP was completely 
calcium dependent, indicating that specific recognition by SAP of particular cell 
surface ligands was involved. The specificity of the RITC-anti-human SAP antibody 
for SAP was confirmed by complete abolition of staining after pre-absorption of the 
antibody with immobilised pure SAP (figure 5. IB).
Binding o f  CRP to Apoptotic Jurkhat Cells
Approximately 88% of Jurkhat cells that were incubated with a monoclonal anti-Fas 
antibody were FITC-annexin V positive after 6 h. Exclusion of trypan blue confirmed 
viability in over 95% of cells at this time point. CRP bound to approximately 45% of 
cells that had been incubated with the anti-Fas monoclonal antibody (Figure 5.2). 
There was no binding of CRP to the “non-apoptotic” cell population that had not been 
incubated with the anti-Fas monoclonal antibody. Binding of CRP was completely 
calcium dependent, indicating that specific recognition by CRP of particular cell 
surface ligands was involved. The specificity of the FITC-anti-human CRP antibody
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Figure 5.1 A Binding of SAP to apoptotic Jurkhat cells viewed by 
confocal microscopy. The DAPI counterstain (upper panel) shows 
all cells, the green fluorescence (middle panel) show cells which 
are apoptotic by TUNEL staining and the red fluorescence (lower 
panel) shows anti-SAP staining. SAP bound to the surface of 
apoptotic cells but not to non-apoptotic cells.
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Figure 5.1B Binding of SAP to apoptotic cells - control samples. The 
upper panels confirm specificity of SAP binding and show TUNEL staining 
(left) and absence of staining with anti-SAP (right) after incubation of cells 
with SAP in the presence of 10 mM EDTA. The lower panels confirm 
specificity of the anti-SAP antibody for SAP and show TUNEL staining (left) 
and absence of staining with anti-SAP after solid phase pre-absorption of 
the antibody with pure antigen.
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Figure 5.2 Binding of CRP to apoptotic Jurkhat cells shown by flow cytometry. A-B) Apoptosis induction A) Absence of 
apoptosis (as defined by annexin V binding) among cells incubated in the absence of anti-Fas monoclonal antibody B) 
Presence of apoptosis (defined by annexin V binding) in 88% of Jurkhat cells after incubation for 6 hours in the presence of 
anti-Fas monoclonal antibody. C-G) Binding of CRP to Jurkhat cells C) Absence of CRP binding to non-apoptotic Jurkhat cells 
D) Binding of CRP to 45% of all cells 6 hours after induction of apoptosis. E) Absence of CRP binding to apoptotic Jurkhat 
cells after incubation with CRP in the presence of EDTA, confirming calcium dependence of CRP binding F) Absence of 
fluorescence after incubation of apoptotic Jurkhat cells with CRP and staining with fluorochrome labelled antibody, from which 
the anti-CRP had been specifically removed by prior incubation with pure CRP, confirming specificity of the fluorescent 
antibody for CRP.
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for CRP was confirmed by complete abolition of staining after pre-absorption of the 
antibody with immobilised pure CRP, as shown by flow cytometric analysis in 
figure 5.2.
Competition between SAP and CRP for Apoptotic Cell Binding
Apoptosis occurred in 89% of all cells after 6 h of incubation with anti-Fas antibody 
and SAP binding was detected on 76-82% of all cells. There was no reduction of SAP 
binding in the presence of high concentrations of CRP. Cells incubated with CRP 
alone did not stain with anti-SAP (figure 5.3).
After 6 h of incubation with anti-Fas antibody, 92% of cells were apoptotic as defined 
by annexin V binding and CRP binding was detected on 38-52% of all cells. There 
was no reduction of CRP binding in the presence of high concentrations of SAP. Cells 
incubated with SAP alone did not stain with anti-CRP. These experiments demonstrate 
that there is no competition between SAP and CRP for binding to ligands on the 
surface of apoptotic cells, and presumably the two pentraxins recognize different 
molecules in this situation, just as they do in intact nuclei [62].
IMMUNE RESPONSE TO ADMINISTRATION OF SYNGENEIC 
APOPTOTIC THYMOCYTES 
Comparison between SAP-/- and Wild-type C57BL/6 Mice
ANAs were not detected prior to the first injection of apoptotic cells in any C57BL/6 
mice regardless of sex or SAP genotype. On day 14 (2 weeks after the first injection of
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Figure 5.3 Binding of SAP to the surface of apoptotic Jurkhat cells in the 
presence of increasing concentrations of CRP. A-B) Induction of 90% 
Jurkhat cell apoptosis by incubation with anti-Fas monoclonal antibody for 
6 hrs C) Absence of SAP binding to apoptotic Jurkhat cells after incubation 
with CRP alone D-H) SAP binding to apoptotic Jurkhat cells after 
incubation with D) SAP alone E) SAP and 1 mg/l CRP F) SAP and 10 mg/l 
CRP G) SAP and 100 mg/l CRP H) SAP and 1000 mg/l CRP
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apoptotic cells), ANAs were present in 0/20 female wild-type mice compared to 7/26 
female SAP-/- mice (P < 0.02, Fisher’s exact test), with titres of 1/80 in 5 animals, and 
1/160 and 1/320 in the other two. ANAs were present in 0/10 male wild-type mice 
compared to 2/9 male SAP-/- mice (P > 0.05, Fisher’s exact test), with titres of 1/80.
On day 28, ANAs were present in 1/20 female (at a titre of 1/80) and 0/10 male 
wild-type mice compared to 18/26 female and 3/9 male SAP-/- mice 
(females: P < 0.0001; males: P > 0.05, Fisher’s exact test). The median ANA titre in 
female SAP-/- mice was 1/80 (range; 0-1/1280). On day 28, antibodies against 
dsDNA, ssDNA and chromatin were determined in all mice and results are shown in 
table 5.1. Anti-ssDNA antibodies were present in 16/26 SAP-/- females compared to 
5/20 wild-type females (P < 0.02, Fisher’s exact test) and anti-chromatin antibodies 
were present in significantly more female SAP-/- (20/26) than female wild-type (9/20) 
mice at this time point (P<0.04, Fisher’s exact test). There were no significant 
differences in autoantibody titre between male mice of the two genotypes.
On day 42, ANAs were present in 1/20 female (titre of 1/80) and 0/10 male wild-type 
mice compared to 25/26 female and 3/9 male SAP-/- mice (females: P <  0.0001, 
Fisher’s exact test). Interestingly, there was a rise in ANA titres between days 28 and 
42 in 14 female and 1 male SAP-/- mice, ANA titres remained unchanged in 8 female 
and 6 male SAP-/- mice and fell from day 28 to day 42 in 4 female and 2 male SAP-/- 
mice. The median ANA titre in female SAP-/- mice on day 42 was 1/160, compared to
Number Anti-nuclear antibody
Number (%) +ve
Anti-double 
stranded DNA
Number (%) +ve
Anti-chromatin
Number (%) +ve
Anti-single 
stranded DNA
Number (%) +ve
Glomerulonephritis
Number (%) +ve
Female Wild-type 20 1(5) 4(20) 9(45) 5(25) 0(0)
SAP-/- 26 18 (69) 9(35) 20 (77) 16 (62) 9(36)
P < 0.0001 P = 0.33 P < 0.04 P < 0.02 P < 0.003
Male Wild-type 10 0(0) 2(20) 6(60) 2(20) 0(0)
SAP-/- 9 3(33) 4(44) 4(44) 2(22) 0(0)
P = 0.09 P = 0.35 P = 0.36 P= 1.0 P =  1.0
P values obtained by Chi-squared or Fisher’s exact test as appropriate
Table 5.1 Comparison of autoimmunity and glomerulonephritis between wild-type and SAP-/- C57BI/6 mice following 
intravenous administration of 1 x 107 apoptotic syngeneic thymocytes weekly, for 4 weeks. Autoimmunity is compared on 
day 28 (4 weeks after 1st intravenous injection of apoptotic thymocytes) and glomerulonephritis was determined on day 
56.
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1/80 on day 28. The median ANA titres were negative in male SAP-/- mice on both 
day 28 and day 42.
Glomerulonephritis was present in 9/26 (35%) female and 0/9 male SAP-/- mice and 
but was absent in all wild-type mice (females: P < 0.003, Fisher’s exact test) 56 days 
after the first injection. Glomerulonephritis was grade I in 5 mice and grade II and III 
in 2 cases each.
Comparison between Wild-type, SAP-/- and SAP-/-, hSAP Transgenic 
C57BL/6 Mice
ANAs were not detected prior to the first injection of apoptotic cells in any mouse 
regardless of genotype. On day 14 (2 weeks after the first injection of apoptotic cells), 
ANAs were present in 0/10 wild-type mice compared to 7/16 SAP-/- mice and 4/16 
SAP-/-, hSAP Tg mice (P < 0.03, SAP-/- vs wild-type; P > 0.05 wild-type vs 
SAP-/-, hSAP Tg, Fisher’s exact test).
Presence of autoantibodies on day 28 are shown in table 5.2. The median ANA titre in 
SAP-/- and SAP-/-, hSAP Tg mice at this time point was 1/80 (range; 0-1/1280).
On day 42, ANAs were present in 0/10 wild-type mice, 16/16 SAP-/- mice and 11/16 
SAP-/-, hSAP Tg mice (P< 0.0001, wild-type vs SAP-/-; P <  0.0008, wild-type vs 
SAP-/-, hSAP Tg; P > 0.05 SAP-/- vs SAP-/-, hSAP Tg, Fisher’s exact test). There 
was a rise in ANA titres between days 28 and 42 in 8 SAP-/- mice and 7 
SAP-/-, hSAP Tg mice, ANA titres remained unchanged in 6 SAP-/- mice and 8
N Anti-nuclear
antibody
Number (%) +ve
Anti-double 
stranded DNA
Number (%) +ve
Anti-chromatin
Number (%) +ve
Anti-single 
stranded DNA
Number (%) +ve
GN
Number (%) +ve
Wild-type 10 0(0) 0(0) 2(20) 3(30) 0(0)
SAP-/- 16 12 (75) 2(12) 11 (69) 13 (81) 8(50)
SAP-/- hSAP Tg 16 11 (69) 1(6) 8(50) 12 (75) 13(81)
P value (SAP-/- vs wild-type) 0.0002 0.5 0.04 0.02 0.009
P value (SAP-/-, hSAP Tg vs wild-type) 0.0008 1.0 0.2 0.04 0.0001
P value (SAP-/- vs SAP-/-, hSAP Tg) 1.0 1.0 0.47 1.0 0.13
P values obtained by Chi-squared or Fisher’s exact test as appropriate
Table 5.2 Comparison of autoimmunity and glomerulonephritis between wild-type, SAP-/- and SAP-/-, hSAP transgenic 
C57BI/6 female mice following intravenous administration of 1 x 107 apoptotic syngeneic thymocytes weekly, for 4 weeks. 
Autoimmunity was compared on day 28 (4 weeks after 1st intravenous injection of apoptotic thymocytes) and 
glomerulonephritis was determined on day 56. There was no significant difference in autoimmunity or glomerulonephritis 
between SAP-/- and SAP-/-, hSAP Tg mice. However, there was significantly more autoimmunity and glomerulonephritis 
in SAP-/- and SAP-/-, hSAP Tg mice than in wild-type mice.
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SAP-/-, hSAP Tg mice and ANAs fell from day 28 to day 42 in 2 SAP-/- mice and 1 
SAP-/-, hSAP Tg mouse. The median ANA titre increased in SAP-/- mice from 1/80 to 
1/320 between days 28 and 42, and in SAP-/-, hSAP Tg mice from 1/80 to 1/160.
There was no significant difference between presence or severity of glomerulonephritis 
in SAP-/- and SAP-/-, hSAP Tg mice (table 5.2).
Comparison between SAP-/- and Wild-type 129/Sv Mice
ANAs were not detected prior to the first injection of apoptotic cells in any mouse 
regardless of sex or SAP genotype. Similarly, ANAs were absent in all mice on days 
14, 28 and 42. There was no glomerulonephritis in any mouse on day 56.
MACROPHAGE INGESTION OF APOPTOTIC THYMOCYTES IN 
VIVO 
Comparison between SAP-/- and Wild-type C57BL/6 Mice
Thirty min after intraperitoneal injection of apoptotic thymocytes, approximately 30% 
of peritoneal macrophages were ingesting a thymocyte. At this time point, there was 
no significant difference in percentage of macrophages ingesting apoptotic thymocytes 
between wild-type and SAP-/- C57BL/6 mice (figure 5.4, table 5.3). Ingestion by 
macrophages was unaffected by whether the thymocytes were obtained from SAP-/- or 
wild-type mice.
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Figure 5.4 Ingestion of apoptotic mouse thymocytes by macrophages 
in vivo. Thirty minutes after intraperitoneal injection, small, darkly 
stained apoptotic thymocytes (arrowed) can be seen within the 
cytoplasm of certain peritoneal macrophages.
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A)
Experiment
1 2 3
Genotype injected
Mean (SD) Mean (SD) Mean (SD)
Wild-type 38(9) 20 (9) 22(11)
SAP-/- 35(15) 22 (6) 30 (6)
P > 0.05, T-test
B)
Experiment
1 2 3
Genotype injected
Mean (SD) Mean (SD) Mean (SD)
Wild-type 28 (14) 28 (5) 37 (10)
SAP-/- 30(9) 36(6) 29 (14)
P > 0.05, T-test
Table 5.3 Percentage of SAP-/- and wild-type peritoneal macrophages 
ingesting apoptotic thymocytes. Each result is the mean and standard 
deviation from 6 mice. A) Comparison between SAP-/- and wild-type 
mice after injection of apoptotic thymocytes obtained from wild-type mice 
in three identically performed experiments. B) Comparison between 
SAP-/- and wild-type mice after injection of apoptotic thymocytes obtained 
from SAP-/- mice in three identically performed experiments. There was 
no difference between SAP-/- and wild-type animals in the percentage of 
macrophages ingesting apoptotic cells.
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MACROPHAGE INGESTION OF APOPTOTIC HUMAN 
LYMPHOCYTES IN VITRO
Binding of SAP to the surface of apoptotic Jurkhat cells was confirmed prior to 
incubation with macrophages. SAP binding was absent after incubation of Jurkhat 
cells with SAP in the presence of EDTA.
Less than 4% percent of macrophages to which Jurkhat cells had not been added 
showed binding and/or ingestion of an apoptotic cell. Incubation of non-apoptotic 
Jurkhat cells with macrophages for 1 h resulted in binding and/or ingestion by 55% of 
macrophages. Presence of SAP on the surface of apoptotic Jurkhat cells was not found 
to significantly affect binding and/or ingestion by primary human macrophages 
(table 5.4). At least one SAP-coated apoptotic Jurkhat cell was bound and/or ingested 
by 88%, 75% and 61% of macrophages in three separate experiments, compared to 
77%, 85% and 65% of macrophages respectively, which had bound and/or ingested a 
non SAP-coated apoptotic Jurkhat cell (P > 0.05, T-test).
SUMMARY
Previous studies have shown the binding of SAP to dermal keratin bodies in vivo, that 
is, apoptotic cells in human skin [300]. The studies presented here confirm the binding 
of SAP to the surface of apoptotic Jurkhat cells, and reveal that CRP, the classical acute 
phase reactant in humans, also binds to the surface of apoptotic cells in vitro. During
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Incubated with Macrophages
1
Experiment
2 3
Apoptotic Jurkhat cells + SAP 88 75 61
Apoptotic Jurkhat cells - SAP 77 85 65
DMEM medium alone 3.5 4 3.5
SAP vs no SAP; P > 0.05, T-test
Table 5.4 Percentage of macrophages which had bound and/or ingested 
at least one apoptotic Jurkhat cell after incubation for 1 hour at 37°C. 
Comparison was between apoptotic Jurkhat cells coated with SAP on 
their surface ( + SAP) and Jurkhat cells on the surface of which there was 
no SAP (- SAP, by incubation in the presence of EDTA). Results from 
three identical experiments are shown. The presence of SAP on the 
surface of apoptotic Jurkhat cells did not significantly affect macrophage 
binding and/or ingestion at this timepoint. Incubation of macrophages 
with DMEM medium alone resulted in < 4% showing binding and/or 
ingestion of an apoptotic cell.
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the course of these studies, Hack and colleagues reported calcium-dependent binding of 
SAP to apoptotic cells that was independent of binding to chromatin [352]. They 
postulated that the binding of SAP to apoptotic cells might activate complement. 
Similarly, Elkon and colleagues reported the calcium-dependent binding of CRP to the 
surface of apoptotic cells during this time [353], and showed that CRP binding 
enhanced opsonisation and phagocytosis of apoptotic cells by macrophages. We were 
interested to determine whether there is competition between the pentraxin proteins, 
SAP and CRP, for ligands on the surface of apoptotic cells and have robustly 
demonstrated that this is not the case.
We were able to show that total SAP deficiency in the C57BL/6 mouse enhanced the 
immunogenicity of injected syngeneic apoptotic thymocytes, and was associated with 
significant glomerulonephritis after thymocyte injection in female mice. Furthermore, 
the autoimmunity associated with injecting apoptotic cells persisted and tended to 
increase in SAP-/- mice (until they were killed, 8 weeks after the first injection) but 
was usually transient, as reported by Elkon’s group [278], in wild-type mice. ANAs 
were not induced by injection of syngeneic apoptotic thymocytes into SAP-/- 129/Sv 
mice, further corroborating our findings of absent spontaneous autoimmunity in SAP 
deficient mice of this strain. Similarly, the induction of comparable autoimmunity 
between SAP-/- and SAP-/-, hSAP Tg C57BL/6 mice following injection of syngeneic 
apoptotic thymocytes, which differed significantly from that induced in their wild-type 
counterparts, support our findings of spontaneous autoimmunity in SAP-/-, hSAP Tg 
C57BL/6 mice.
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The present studies of macrophage ingestion of apoptotic cells, performed in vivo using 
thymocytes injected intraperitoneally and in vitro using a human system, failed to show 
any influence of SAP on macrophage binding and/or ingestion. However, in these 
preliminary studies the dynamic process of binding and/or ingestion of apoptotic cells 
by macrophages was only determined at a single time point in both models. 
Conflicting observations of increased macrophage ingestion of apoptotic Jurkhat cells 
in the presence of SAP have recently been reported by Bijl et al, using an almost 
identical experimental protocol [354]. However such findings of opsonisation by SAP 
contrast sharply with previous work from this laboratory showing that SAP is a potent 
anti-opsonin for bacteria being phagocytosed by neutrophils [69]. Further work is 
clearly necessary to resolve these issues.
Current evidence suggests that the process of macrophage ingestion of cells dying by 
apoptosis normally induces expression of anti-inflammatory cytokines [322,350,355]; 
in contrast, cells dying by necrosis are thought to induce pro-inflammatory cytokines 
which may promote maturation of dendritic cells and lead to efficient antigen 
presentation and an immune response [322,350,355]. Apoptotic cells are believed to be 
the source of the immunogens in SLE, and the pentraxin proteins, which are known to 
bind to these immunogens [60,61], have been shown here to bind to their surface. SAP 
deficiency in the C57BL/6 mouse was shown to enhance the immunogenicity of 
administered apoptotic mouse thymocytes, and pentraxins in general may play an 
important role in regulating apoptotic cell immunogenicity in vivo. Although we were 
unable to demonstrate any direct influence of SAP on macrophage ingestion of
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apoptotic cells, these were only preliminary studies and further investigation of the 
mechanisms by which pentraxins affect apoptotic cell immunogenicity are warranted.
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Chapter 6 -  General Conclusions
ROLE OF SAP IN MOUSE ANTINUCLEAR AUTOIMMUNITY
Despite the high degree of evolutionary conservation of the pentraxin proteins SAP 
and CRP, implying physiological roles with significant survival value, their 
functions remain unknown.
The creation of SAP knockout mice enabled the participation of SAP in amyloid 
pathogenesis to be directly demonstrated [208] and SAP has thus become a 
legitimate target for therapy in systemic amyloidosis. Indeed, an SAP inhibitor 
developed in collaboration with F Hoffmann-La Roche Ltd is currently undergoing 
therapeutic trials in patients with amyloidosis [212]. Although SAP knockout mice 
appeared initially to develop and breed normally, a cohort of [129/Sv x C57BL/6]F2 
mice were noted to spontaneously develop a phenotype resembling human SLE with 
antinuclear autoimmunity and glomerulonephritis [232]. The binding of pentraxins 
to nuclear constituents had previously been demonstrated [60-62,299], and it had 
been postulated some years earlier that pentraxins might have a role in handling 
chromatin in order to prevent autoimmunisation.
The studies presented here of the spontaneous lupus-like phenotype in pure-line 
C57BL/6 SAP-/- mice suggest that mouse SAP has an important physiological role, 
inhibiting the formation of pathogenic autoantibodies against chromatin and DNA.
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The dependence of autoimmunity upon mouse strain and its absence in a cohort of 
inbred 129/Sv SAP-/- mice, highlights the genetic complexity of the lupus diathesis, 
but corroborates work in mouse models of human SLE in which the “full-blown” 
SLE phenotype has been shown to depend upon complex genetic interactions 
between several disease susceptibility loci [215].
Following our observations of spontaneous autoimmunity in C57BL/6 SAP-/- mice 
we were unable to completely exclude the remote possibility that the phenotype was 
caused, not by deletion of the SAP gene itself, but by an unknown 129/Sv gene on 
chromosome 1 linked to the SAP null allele conferring lupus susceptibility when 
expressed in the C57BL/6 background. In order to address this issue, SAP-/- 
C57BL/6 mice transgenic for human SAP were developed. Mice expressing the 
human SAP transgene were compared to their littermate controls in whom the 
human SAP transgene was not expressed. Interestingly, and perhaps contrary to our 
initial expectations, the spontaneous autoimmune phenotype was not abrogated by 
expression of human SAP. On reflection however, it would be surprising if human 
and mouse SAP functioned identically in the mouse particularly given their different 
binding affinities in vitro [63], and the persistence of autoimmunity in human SAP 
transgenic mice lacking mouse SAP does not exclude mouse SAP deficiency as the 
cause of the lupus phenotype.
In order to definitively answer the question of whether deficiency of mouse SAP in 
C57BL/6 mice is responsible for the lupus-like phenotype, we are currently
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investigating transgenic reconstitution of SAP-/- mice with mouse SAP. In a 
collaborative project with Dr EK Wakeland from the University of Texas, USA, he 
has introduced extra copies of the mouse SAP gene into a cohort of wild-type 
C57BL/6 mice and we plan to cross these with our SAP-/- C57BL/6 mice and 
determine whether expression of mouse SAP (from a chromosome other than 
chromosome 1) on the C57BL/6 SAP-/- background abrogates the autoimmune 
phenotype.
APOPTOTIC CELLS, AUTOIMMUNITY AND PENTRAXINS
Apoptosis, a term coined by Currie and colleagues in 1972 [356] describes a 
common type of programmed cell death and is an essential part of life for any 
multicellular organism. Indeed, the way in which most cells die is conserved from 
worm to mammal [357,358].
Apoptotic cells were first proposed to be the source of immunogens in SLE 
following the observation by Casciola-Rosen and colleagues that the most 
characteristic “intracellular” autoantigens were present in blebs on the apoptotic cell 
surface [277]. Some years later, the hypothesis that apoptotic cells are the source of 
the immunogens in SLE is now supported by considerable experimental evidence 
[238,239,278,280,281]. However, the exact relationship between nuclear 
constituents, autoimmunity and apoptotic cells remains unknown.
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Certain groups focused on modification of the targets of systemic immune responses 
during apoptosis thus revealing so called “cryptic epitopes” to which the immune 
system had not previously achieved tolerance. Many antigens targeted by 
autoantibodies in systemic autoimmune disease undergo structural modifications 
during apoptosis including proteolysis and hyperphosphorylation [348,359]. The 
activation of caspases is the central effector mechanism in apoptosis [360]. The 
observation that PARP [361] and Ul-70 kD [362], two SLE-associated protein 
autoantigens, were cleaved by caspases during apoptosis led several groups to use 
ANAs in the systematic identification of other autoantigens cleaved during the cell 
death process. Casciola-Rosen and colleagues and Casiano and colleagues 
separately identified subsets of intracellular autoantigens that were cleaved during 
apoptosis [348,359,363]. Notably however, many autoantigens frequently targeted 
by autoantibodies in systemic autoimmune diseases remain intact during apoptosis 
[348,359,364]. Progression from apoptosis to secondary necrosis was associated 
with additional proteolysis of specific intracellular autoantigens that are cleaved 
during apoptosis [365]. These results suggest that in the absence of phagocytosis 
progression of cell apoptosis to secondary necrosis involves additional degradation 
of specific autoantigens, with potential immunostimulatory consequences. 
However, there is scant evidence that exposure of the immune system to modified 
forms of apoptotic self-antigens are sufficient to elicit autoantibodies. Under what 
circumstances then, does apoptotic cell material provoke immune responses? Sauter 
and colleagues suggested that uptake of apoptotic material by dendritic cells may 
lead to an immune response only if followed by a maturation signal provided under a
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pro-inflammatory context [366]. According to this notion, apoptosis associated with 
normal cellular turnover induces dendritic cells or other phagocytic cells to produce 
anti-inflammatory molecules and cross present apoptotic cell antigens to the immune 
system, leading to induction of peripheral tolerance. Induction of peripheral 
tolerance arises due to the fact that in the absence of pro-inflammatory signals, 
immature dendritic cells and other professional phagocytes display low levels of 
MHC class I, class II and costimulatory molecules thus inducing self tolerance rather 
than initiating immune responses [367]. Evidence for this hypothesis has come from 
a number of studies in which pro-inflammatory conditions, such as an infection, 
were associated with dendritic cell maturation, up-regulation of MHC molecules and 
co-stimulatory signals, presentation of self-peptides derived from dying cells (as 
well as foreign peptides from the infectious agent) and efficient activation of 
autoantigen-specific T and B cells [368-370].
Our discovery of enhanced immunogenicity of intravenously administered syngeneic 
apoptotic thymocytes into SAP-/- C57BL/6 mice compared to their wild-type 
counterparts, suggested a role for mouse SAP in handling apoptotic cells in vivo. 
Confirmation that the pentraxins, SAP and CRP, bind to the surface of apoptotic 
cells suggests that the mechanism by which SAP inhibits autoimmunity in the mouse 
is either by affecting uptake of or response to apoptotic cells by macrophages or 
other phagocytic cells thus influencing apoptotic cell immunogenicity, or by binding 
and regulating the clearance and/or degradation of chromatin and nucleosomes 
released from dying cells in vivo, or both.
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The final phase of apoptosis, the programme of cell deletion in vivo, is swift and safe 
phagocytosis of intact unwanted cells. Although ignored for many years, the 
removal of apoptotic cells by macrophages is now thought to define the meaning of 
cell death in higher organisms and critically regulate immune responses [371], Cells 
undergoing apoptosis can display a number of “eat-me” signals. Some, such as 
exposure on the outer membrane leaflet of phosphatidylserine, which is usually 
restricted to the inner membrane leaflet, are relatively well characterised [335]. 
Others are more poorly defined, such as sites that bind adhesive bridging molecules 
present in extracellular fluid. These include Clq [279,331], 02 glycoprotein I 
(fcGPI) [372] and thrombospondin [373]. A role for C lq in vivo was confirmed by 
studies demonstrating defective clearance of apoptotic cells in deletion-mutant mice 
[279,331]. It is interesting that a cohort of C lq deficient [129/Sv x C57BL/6]F2 
mice were discovered to develop a spontaneous lupus-like phenotype [331] similar 
to that reported from our laboratory in SAP deficient [129/Sv x C57BL/6]F2 animals 
[232], but that C lq deficiency on a pure C57BL/6 background was insufficient to 
cause the lupus phenotype (verbal communication, M Botto), markedly contrasting 
with the autoimmunity presented here in SAP deficient pure-line C57BL/6 mice.
The potential bridging role of the abundant P2 GPI was demonstrated by Schroit and 
colleagues in studies in which macrophages were found to bind P2 GPI only after it 
was complexed with phosphatidylserine (PS) [372]. Chemical modification of 
cysteines abolished p2 GPI-dependent PS uptake by inhibiting the binding of 
PS-P2 GPI complex to macrophages. Antibodies to P2 GPI inhibited binding of the
198
complex to macrophages indicating that recognition was mediated by P2 GPI and not 
by the lipid. Furthermore, antibodies to putative macrophage PS receptors such as 
CD36, CD68 and CD 14 did not inhibit uptake of the PS-P2 GPI complex by 
macrophages [372]. However, there is evidence that phagocyte scavenger receptors 
such as CD68 recognise apoptotic cell surface sites that can be masked by antibodies 
against oxidised low density lipoproteins (LDL) [374]. Interestingly, and of 
relevance to the work presented in this thesis, Chang and colleagues recently 
reported that CRP binds to both apoptotic cells and oxidised LDL through 
recognition of a common ligand [375].
Although we are aware of a number of mammalian phagocyte receptors that mediate 
the engulfment of dying cells, we do not yet know what contribution is made to the 
clearance task by each molecule. There is evidence that macrophages might “tether” 
dying cells by using phagocyte surface CD 14 or P2 integrins before engaging 
receptors that drive phagocytosis. The relative importance of the dynamic 
reorganisation of the phagocyte membrane which is dependent on lipid fluxes 
similar to those occurring in apoptotic cells themselves also needs clarification. Our 
current understanding of the molecular mechanisms mediating apoptotic cell 
clearance thus remains poor. The apparent redundancy of many of the mechanisms 
mentioned is consistent with the importance for health of safely clearing apoptotic 
cells but might equally reflect the exquisite control of phagocyte responses which 
may modulate inflammation. The potential significance programmed into these 
molecular mechanisms was suggested by a seminal in vitro experiment.
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Macrophages are crucial for both clearance of apoptotic cells generated in injured 
tissue and for host defence against infection by bacteria or protozoa. Normally the 
ingestion of particles of similar size to these invaders triggers macrophages to 
secrete molecular mediators capable of initiating protective but potentially injurious 
inflammatory responses. The ingestion of large numbers of apoptotic cells failed to 
elicit this macrophage release of pro-inflammatory mediators. If, however, 
experimental conditions were deliberately changed so that recognition mechanisms 
for “quiet clearance” were replaced by bridging immunoglobulin and macrophage 
Fc receptors, macrophages released pro-inflammatory mediators [376].
Although inflammatory responses are vital for host defence against infection, when 
persistent they underlie important diseases such as rheumatoid arthritis. Dangerous 
immune cells can be quietly cleared from inflamed sites by undergoing apoptosis 
and being engulfed by macrophages promoting the resolution of acute inflammation 
[373]. Indeed, uptake of apoptotic cells actively suppresses the secretion from 
activated macrophages of inflammatory mediators such as tumour necrosis factor-a 
(TNF-a) [322,350]. How is anti-inflammatory meaning conferred on phagocytic 
clearance of apoptotic cells? “Resetting” of activated macrophages can be 
mimicked by the ligation of macrophage receptors mediating the engulfinent of 
apoptotic cells, notably CD36 and its bridging ligand thrombospondin [350]. 
Indeed, receptor-triggered release of the anti-inflammatory and immunosuppressive 
cytokine transforming growth factor pi (TGF-pi) by macrophages ingesting 
apoptotic cells might be crucial in mediating the suppression of macrophage-directed
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inflammation [322,350,377]. Macrophages are nevertheless activated to secrete 
pro-inflammatory mediators by the ingestion of white blood cells undergoing 
secondary necrosis after apoptosis, but not by intact apoptotic cells [378]. 
Therefore, whether clearance has an anti- or pro-inflammatory meaning might be 
determined by the state of the dying cell, the phagocyte receptors engaged and the 
downstream signalling pathways activated.
The anti-inflammatory action of phagocyte clearance of apoptotic cells might also be 
perturbed in disease processes. For example, anti-phospholipid antibodies that 
recognise and bind to PS exposed by apoptotic cells can be found in patients with 
SLE. Such autoantibodies can coat apoptotic cells so that they are bound by 
macrophage Fc receptors with resultant promotion of TNF-a release rather than its 
suppression [379].
Studies presented in this work compared macrophage uptake of apoptotic cells in the 
presence and absence of SAP and were performed in a mouse model in vivo and in a 
human system in vitro. Although these were only preliminary studies, we were 
unable to determine any influence of SAP on macrophage ingestion of apoptotic 
cells in either system. These results conflict with the observations of Bijl and 
colleagues who, using an almost identical experimental protocol, recently reported 
increased macrophage ingestion of apoptotic Jurkhat cells in the presence of SAP 
[354]. Bijl’s findings also conflict with previous work from our laboratory which
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showed SAP to be a potent anti-opsonin. However, these in vitro experiments were 
in the context of neutrophil phagocytosis of bacteria [69].
Our studies do not exclude the possibility that SAP may influence macrophage 
ingestion of apoptotic cells and hence their immunogenicity in a more subtle, but 
nevertheless important manner. Indeed, binding of CRP to apoptotic cells in vitro 
was shown by Elkon and colleagues to amplify classical pathway activation of 
complement on the surface of the dying cell but paradoxically attenuate deposition 
of the membrane attack complex (MAC) and inhibit cell lysis [353]. However, CRP 
enhanced opsonisation of apoptotic cells by macrophages associated with expression 
of the anti-inflammatory cytokine transforming growth factor P (TGF-P). Evidence 
exists therefore, that coating of apoptotic cells by CRP promotes an 
anti-inflammatory cytokine profile from ingesting macrophages. The absence of 
pentraxin proteins bound to the surface of apoptotic cells might thus lead to release 
of pro-inflammatory cytokine mediators from ingesting macrophages, similar to 
those expressed following ingestion of necrotic cells.
NUCLEOSOMES, AUTOIMMUNITY AND PENTRAXINS
The plasma of patients with SLE contains increased levels of nucleosomal-like DNA 
that closely resemble the characteristic oligonucleosomal ladder generated during 
apoptosis [324]. This observation directly implicated apoptosis as the possible 
source of immunostimulatory nucleosomes and was consistent with studies pointing 
to nucleosomes as the in vivo immunogens driving the anti-DNA and anti-histone
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immune responses in SLE [269-272]. This notion was further strengthened by 
reports that spontaneous apoptosis of cultured mouse lymphocytes was associated 
with the release of immunostimulatory nucleosomes [380-382]. In agreement with 
these studies, apoptosis of lymphocytes from SLE patients in vitro was shown to be 
accompanied by the release of nucleosomes into the extracellular milieu [280]. 
Furthermore, in vivo studies showed that serum nucleosomal DNA naturally occurs 
in autoimmune mice and correlates with apoptosis in the thymus [383]. In SLE 
patients, the plasma levels of nucleosomes were shown to correlate with serum 
antinucleosome antibody titres [324].
Serum amyloid P component (SAP) is the major calcium-dependent DNA and 
chromatin binding protein of the plasma [60]. SAP was shown some time ago in our 
laboratory to specifically displace HI histone and solubilise native long chromatin 
and it was suggested that its major physiological role might be to enhance 
non-immunogenic clearance of nuclear material, including chromatin, which is 
released from such cells [61].
Studies presented in this work comparing plasma clearance of intravenously 
administered nucleosomes and chromatin in the presence and absence of SAP, 
consistently showed that the presence of SAP enhanced their rate of clearance. 
Furthermore, studies using the trapped catabolism method, showed robustly and for 
the first time that nucleosome catabolism occurs largely in the liver and kidneys, but 
that in the absence of SAP, early uptake of nucleosomes into the spleen is increased.
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Thus, SAP leads to rapid removal of nucleosomes and chromatin from the plasma 
and may have a pivotal role in preventing dose-related immunogenic processing of 
nuclear constituents in the spleen.
SUMMARY
The studies presented in this thesis suggest that deficiency of the plasma pentraxin 
proteins SAP and CRP contribute to the lupus diathesis. The finding of striking 
spontaneous antinuclear autoimmunity in SAP deficient pure-line C57BL/6 mice 
coupled with the confirmation of binding of SAP and CRP to apoptotic cells and the 
previously reported binding of SAP to chromatin and DNA suggest a physiological 
role for pentraxins in handling of chromatin in vivo.
Current evidence strongly implicates defective apoptotic cell processing and 
clearance in the development of systemic autoimmunity. Binding of CRP to the 
apoptotic cell was recently shown to amplify complement classical pathway 
activation on its surface but protected the dying cell from assembly of the terminal 
complement components and lysis. CRP also enhanced opsonisation of apoptotic 
cells by phagocytes and was associated with expression of anti-inflammatory 
cytokines. Studies of SAP binding to apoptotic cells in vitro and in vivo were not 
shown in this work to influence macrophage uptake of apoptotic cells, although 
recently published work conflicts with our findings and suggests that binding of 
SAP, like CRP, results in opsonisation of apoptotic cells. There is considerable 
experimental evidence that defective apoptotic cell clearance is associated with
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increased immunogenicity and this may be due to loss of membrane integrity, and 
exposure of increasingly degraded autoantigens with consequent presentation of 
cryptic epitopes as uncleared apoptotic cells progress to secondary necrosis. In 
addition, the milieu in which phagocytic cells engulf apoptotic cells appears to play 
a pivotal role in control of immune responses. In the presence of pro-inflammatory 
conditions such as an infection, dendritic cells and professional phagocytes receive a 
maturation signal and efficient activation of autoantigen-specific T and B cells 
ensues. In contrast, apoptosis associated with normal cellular turnover induces 
engulfment by immature dendritic cells and phagocytes which produce 
anti-inflammatory molecules leading to induction of peripheral tolerance.
It is likely that the loss of membrane integrity associated with progression of cells 
from early apoptosis to secondary necrosis is associated with increasing release into 
the circulation of nuclear material contained within apoptotic cell surface blebs such 
as nucleosome core particles and DNA. It is known that the plasma of patients with 
the prototypic systemic autoimmune disease SLE contains increased levels of 
nucleosomal-like DNA that closely resembles the characteristic oligonucleosomal 
ladder generated during apoptosis. SAP is the single plasma protein that shows 
calcium dependent binding to nucleosomal DNA and chromatin and in vivo 
experiments presented in this thesis suggest that an alternative mechanism whereby 
plasma pentraxins, in particular SAP, may influence immunogenicity of 
nucleosomes is by binding to them and enhancing their rate of clearance from the 
plasma. Furthermore, in vivo studies consistently demonstrated that SAP deficiency
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was associated with increased early uptake of nucleosomes and chromatin into the 
spleen. It is attractive to postulate that SAP deficiency, perhaps in the setting of 
dysregulated apoptosis, might lead to presentation of a critical mass of nucleosomal 
autoantigens to the immune cells of the spleen thereby enhancing antigen-specific T 
cell activation.
Despite being unable, at present, to completely exclude the remote possibility that 
the lupus-like phenotype in SAP-/- C57BL/6 mice is SAP independent, we believe 
this to be unlikely. SAP is the only major calcium dependent DNA and chromatin 
binding protein of the plasma and we have shown in this work that its binding to 
chromatin and nucleosomes affects their rate of plasma clearance and site of 
catabolism. Consistent with this notion, work published from other groups within 
the last few years has suggested that the interaction between pentraxins and 
apoptotic cells has immunomodulatory consequences.
Finally, no deficiency state or polymorphism at the amino acid level has been 
identified in the human SAP or CRP genes. A CRP intron polymorphism however, 
has been shown to influence basal levels of CRP [384] and a CRP promoter 
polymorphism has been shown to be associated with type II diabetes mellitus 
susceptibility in Pima Indians [385]. There is considerable evidence that basal CRP 
concentration is important in cardiovascular disease risk [172,386,387]. A deficient 
CRP response to autologous tissue damage in patients with SLE and the finding of a 
lupus-like phenotype in SAP deficient mice raise the possibility that CRP responder
206
status or basal CRP and/or SAP concentration may contribute to the genetic 
predisposition to human SLE. Further work is required to determine whether 
patients with SLE and their relatives have defects in the structure, regulation, 
metabolism or function of SAP and/or CRP. Similarly, further work is required to 
definitively answer whether plasma pentraxins, when they bind to apoptotic cells 
and their immunogenic contents, opsonise or behave as anti-opsonins and determine 
the exact downstream immunomodulatory effects.
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Appendix 1 -  Proposals For Future 
Research
MOUSE STUDIES
Our observations of spontaneous antinuclear autoimmunity in pure line C57BL/6 
SAP-/- mice coupled with extensive in vitro evidence of SAP binding to apoptotic 
cells, chromatin, histones and DNA provide strong evidence that SAP deficiency is 
responsible for the autoimmune phenotype. However, we are unable from these 
studies alone to categorically rule out the remote possibility that the observed 
autoimmune phenotype is not due to SAP deficiency itself but instead due to the 
interaction between an unknown 129/Sv gene on chromosome 1 linked to the SAP 
null allele and the remainder of the C57BL/6 genome.
Studies to address this critical issue are already underway. The aim is to introduce 
extra copies of the mouse SAP gene into a cohort of wild-type C57BL/6 mice. Mice 
into which the extra SAP gene has been successfully introduced and is expressed 
will then be crossed with our SAP-/- C57BL/6 mice. We will then be able to 
determine whether expression of mouse SAP (from a chromosome other than 
chromosome 1) is sufficient to abrogate the autoimmune phenotype in our C57BL/6 
SAP-/- mice.
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APOPTOTIC CELLS, AUTOIMMUNITY AND PENTRAXINS
Several publications during the last few years have corroborated the findings 
presented in this thesis of in vitro binding of the pentraxins, SAP and CRP, to 
apoptotic cells. Although binding of CRP has been shown to opsonise apoptotic 
cells and enhance macrophage uptake in vitro, further studies are required to confirm 
these findings. Similarly, further in vitro studies are required to determine the 
immunomodulatory effects of SAP binding to apoptotic cells both in terms of 
macrophage uptake, where our results conflict with the findings of others, and in 
terms of macrophage cytokine profiles where, thus far, no work has been published.
In this work, we were unable to detect any effect of SAP on macrophage uptake of 
apoptotic mouse thymocytes in vivo. However, further work of a similar nature is 
required in which both uptake by stimulated and unstimulated macrophages and 
their immunologic consequences is examined at different time points. The 
considerable challenge to any investigator attempting to determine such effects is 
how to examine in vitro what is essentially a dynamic process in vivo.
NUCLEOSOMES, AUTOIMMUNITY AND PENTRAXINS
Using the trapped catabolism method we were able to determine that the liver and 
kidneys are the major sites of nucleosome catabolism. SAP was also shown to 
accelerate clearance of nucleosomes and chromatin from the plasma and divert 
nucleosome uptake away from the spleen. Further experiments are required to
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determine the downstream effects of SAP deficiency in terms of antigen processing. 
It would be particularly interesting to compare intravenous injection of an 
autologous lupus antigen in the presence and absence of SAP and determine whether 
SAP deficiency resulted in an increase in the antigen-specific splenic T cell 
repertoire or enhanced activation of antigen-specific T cells in the spleen.
One of the experimental difficulties encountered during our in vivo nucleosome 
clearance experiments was the degradation over time of the starting material. 
Unfortunately, further experiments of this nature are likely to be hampered by the 
batch to batch variation of nucleosome preparations which is extremely difficult to 
overcome.
HUMAN STUDIES
The deficient CRP response to autologous tissue damage during SLE flares and the 
key role of pentraxins in animal models of lupus suggest that SAP and/or CRP may 
be important candidate genes in SLE. Moreover linkage analysis has demonstrated 
important SLE susceptibility loci on chromosome 1 and the pentraxin genes are 
within certain of these candidate linkage regions. Further family studies will 
continue to narrow the respective disease susceptibility regions and should 
eventually point to relatively few candidate genes contained within each locus.
Although recently established, the genetic component to baseline CRP concentration 
is not fully understood. Whether there is a genetic component to CRP
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responsiveness remains unknown. If these genetic components are clearly defined in 
the near future as seems likely, it will be interesting to determine whether they 
behave as SLE susceptibility factors. Similar studies may reveal a genetic 
component to baseline SAP concentration which may uncover a hitherto unknown 
relationship with susceptibility to SLE.
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